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Abstract           
Colorectal cancer (CRC) is the fourth most common cancer in the UK and the second highest 
cause of cancer deaths. It is a complex disease with multiple environmental and genetic 
factors. Some risk genes have a low frequency of the risk allele in the population, but have a 
high effect, and have been well studied. Others are more common but have a much smaller 
effect; many of these are still being identified and characterised. 
The 11q23.1 locus was linked to CRC risk by a genome-wide association study, via the single 
nucleotide polymorphism rs3802842. Subsequent expression analysis on human colonic 
tissue revealed the risk allele of rs3802842 is correlated with lower expression of three 
adjacent genes: C11orf53, C11orf92 and C11orf93. C11orf53 and C11orf93 are protein 
coding, while C11orf92 is non-coding. All three are of unknown function. This locus is not 
associated with risk of cancer in any other tissue, but has been linked to colitis-associated-
CRC in mice. 
To investigate these genes and their role in CRC, I have examined their localisation in 
intestinal tissue in humans and mice. I have created a knockout mouse model to study the 
effects of the loss of the genes on development and CRC induction, and used ex-vivo systems 
for further functional assays. 
The three genes have distinct transcript patterns along the length of the intestines, which are 
consistent between humans and mice. These patterns do not indicate they are specific to 
either stem cells or differentiated cells, although all genes show higher expression in the base 
of the crypt than the top. There are several significant differences in transcript level and 
distribution in the intestinal tissue of an established mouse CRC-susceptible background 
(ApcMin/+) compared to wild type tissue. Previous work by Claire Smillie and evidence that I 
have gathered using protein localisation indicate that at least one of the genes in this locus 
may play a role in the endoplasmic reticulum. 
The knockout mouse model created carries a 20kb deletion, spanning the last two thirds of 
C11orf53, all of C11orf92, and the first third of C11orf93. C11orf-/- occur at lower frequency 
than expected, and show around 50% survival in the week following weaning. Tissue staining 
in the intestines shows reduced staining of mucins secreted by goblet cells in C11orf-/- mice 
compared to C11orf+/+ mice. Global transcript expression analysis on intestinal tissue shows 
many immune system-related genes have altered expression between the genotypes, while 
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blood panels show that C11orf-/- mice have low red and white blood cells. However, no 
obvious CRC phenotype has been observed in aged mice, or when crossed onto the ApcMin/+ 
susceptible background, or via chemical induction. 
Ex-vivo analysis of the knockout mice has utilised the culture of cell lines and intestinal 
organoids. Cell lines showed no differences in cell proliferation or migration between the 
genotypes. However C11orf-/- organoids did have reduced budding compared to C11orf+/+ 
organoids, a phenotype that is linked to defective intestinal homeostasis. 
In summary, I have created a mouse model deleting the 11q23.1 CRC risk locus. Deletion of 
these genes has not caused CRC to develop, but there is evidence of alteration in the 
intestinal, immune and blood systems, and the model should greatly aid in further 
understanding the functional role of these genes and their precise role in CRC risk. I 
hypothesise that the genes play a role in the endoplasmic reticulum, and disruption of these 





Lay Summary          
Colorectal cancer (CRC) has a major health impact in the UK, where it is the fourth most 
common cancer and the second highest cause of cancer death. As with other cancers, there 
are many different factors involved in whether someone develops CRC. Some of these are 
related to a person’s lifestyle, and some are genetic. Much work has been done in identifying 
and studying these genetic factors, to understand as much as possible about this disease. 
A large-scale study of people with and without CRC found a particular region on chromosome 
11, containing three genes, that is linked to CRC risk. People with the risk version of this 
region have lower activity of the three genes located there, called C11orf53, C11orf92 and 
C11orf93, but the function of these genes is currently unknown, so we do not know how they 
are involved in CRC development. 
To investigate the C11orf genes and their role in CRC, I looked at the location of their product 
in intestinal tissue, which shows they are located in specific areas of the intestine, which can 
help us further our understanding of their cellular function. I also saw intriguing differences 
in the expression of these genes in the intestines of healthy mice compared with a type of 
mouse known to be susceptible to CRC (ApcMin/+). 
As stated above the C11orf genes are expressed in mice, hence I made mice that are 
completely lacking the region to see what the effect of deleting the genes would be. The mice 
null for the three genes have altered immune system activity, and low levels of both red and 
white blood cells. They have a disruption in the cells that produce mucus lining their 
intestines. They also have difficulties in surviving weaning, with only around half making past 
this point. However, they do not currently show any development of CRC, even when old or 
given chemicals which can cause CRC. When we took intestinal tissue from the mutant mice 
and produced mini-guts, we saw that there was a difference to mini-guts produced from 
normal mice, similar to other known genetic disruptions in the intestine. 
There is still a lot of work to be done to understand what these genes do and how they are 
involved in CRC, but my work confirms that they have a cellular role in the function of the 
intestines and suggests they are involved in the immune system. Hopefully, this new 
information and the avenues it leads to will ultimately enable an improvement in prevention 
of the disease and indeed impact on public health.  
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Chapter 1: Introduction        
1.1 Colorectal cancer 
1.1.1 Colorectal tumours 
Colorectal cancer (CRC) is a term for cancers of the large intestine, spanning the appendix to 
the rectum (figure 1.1). The colon is divided into right and left, which have different 
embryonic origin. The right colon, comprising appendix, caecum, ascending colon, hepatic 
flexure and proximal two-thirds of the transverse colon, is derived from the embryonic 
midgut, while the left colon, comprising distal third of the transverse colon, splenic flexure, 
descending colon, sigmoid colon, rectosigmoid junction, rectum and anus, is derived from 
the embryonic hindgut (Glebov et al., 2003). The right and left colon can show distinct 
patterns of gene expression. 
The intestines comprises four layers: innermost mucosa, submucosa, muscularis propria and 
outermost serosa (Treuting and Dintzis, 2012; Treuting et al., 2012; Young et al., 2006) (figure 
1.2). The mucosa itself has three layers: innermost simple columnar epithelium, lamina 
propria (connective tissue) and muscularis mucosae (thin smooth muscle). In both small and 
large intestine, the epithelium has crypt structures. The small intestine also has villi to 
increase surface area for nutrient absorption, while the large intestine has many secretory 
cells producing mucus to aid movement of faecal matter as water is absorbed. The 
submucosa contains blood vessels, lymphatic vessels and nerve. The muscularis has two 
layers of muscle, the inner layer being in rings perpendicular to the long axis of the intestine 
and the outer layer being longitudinal. The serosa is connective tissue. 
Over 90% of colorectal carcinomas are adenocarcinomas, due to the high concentration of 
glands found in the tissue (Cancer Research UK, 2016). The typical progression of colorectal 
cancer is from aberrant crypt focus, to adenomatous polyp, to adenocarcinoma (Hamilton et 
al., 2000). The earliest sign of neoplasia in the intestines is aberrant crypt foci (ACF), which 
are characterised by dysplastic or hyperplastic crypts (Nucci et al., 1997). ACF can develop 
into polyps, which project out from the mucosa. Hyperplastic polyps, while showing 
accelerated cell proliferation, are not considered to have the same risk of malignancy as 
neoplastic polyps, in which the cells have begun to lose differentiation. Neoplastic polyps 
that originate from glandular tissue are known as adenomatous polyps, or adenomas, and 
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are typically removed upon detection due to their high risk of progressing to adenocarcinoma 
(Atkin and Saunders, 2002). The defining feature of an adenocarcinoma is invasion beyond 
the muscularis mucosae into the submucosa. 
There are three systems for describing the stage of a CRC: tumour, node, metastasis (TNM) 
staging, number staging and Dukes’ staging, in addition to the grade of the tumour (Cancer 
Research UK, 2016; Hamilton et al., 2000). The TNM system is most commonly used in the 
UK and is the most descriptive. TNM staging assigns a number to the growth of the tumour 
(T), the extent of lymph node infiltration (N) and whether or not metastasis has occurred (M). 
T1 cancers have invaded the submucosa, T2 cancers have reached the muscularis propria, T3 
cancers have reached the serosa, and T4 cancers have grown beyond the serosa to invade 
other organs or structures (figure 1.3). Tis, or carcinoma in situ, refers to growths that have 
not penetrated beyond the mucosa. N0 cancers have not spread to any lymph nodes, N1 
cancers have spread cancer cells to 1-3 nearby lymph nodes, and N2 cancers have cancer 
cells present in at least four lymph nodes. M0 cancers have not spread to any distant organs 
but M1 cancers have distant metastasis. 
The Dukes’ system has only four broad categories. Stage A cancers are only in the submucosa 
or muscularis of the colon, stage B cancers are in the serosa or beyond but have not spread, 
stage C cancers have reached the lymph nodes and stage D cancers have metastasised. The 
number system applies the same categories as the Dukes’ system, but they are 1-4 rather 
than A-D. Additionally, stage 2 is divided into 2A and 2B, depending on whether the cancer 
has grown up to or beyond the serosa, and stage 3 is divided into 3A, 3B and 3C, depending 
on how far into the colon the tumour has grown and how many lymph nodes contain cancer 
cells. A comparison of how each system would categorise a given cancer is given in table 1.1. 
Cancers may be given a grade along with the stage. Rather than describe the extent of the 
tumour growth, the grade refers to the appearance of the individual cells. Grade 1 tumours 
contain cells that are still largely differentiated, grade 2 tumour cells are moderately 
differentiated, grade 3 tumour cells are poorly differentiated, and grade 4 tumours are 





Figure 1.1: Annotated human large intestine. The appendix to the proximal two thirds of the 
transverse colon is collectively the right colon, and is derived from the embryonic midgut. 
The distal third of the transverse colon to the anus is collectively the left colon, and is derived 




Figure 1.2: Haematoxylin and eosin stained tissue sections of human colon, taken at (a) 12.5x, 
showing the entire cross-section with mucosa, submucosa, muscularis propria and serosa 
layers, and (b) 150x, showing the epithelium, lamina propria and muscularis mucosae layers 




Figure 1.3: Cross section of 
the colon showing tissue 
layers and tumour stages, 
with tumours numbered 








Description TNM Number Dukes’ 
Tumour in situ present in the mucosa only Tis   
Tumour is in the submucosa only T1 N0 M0 
1 A 
Tumour has reached the muscularis propria T2 N0 M0 
Tumour has reached the serosa T3 N0 M0 2A 
B 
Tumour has grown beyond the serosa but has not 
spread to lymph nodes or distant organs 
T4 N0 M0 2B 
Tumour is in the submucosa and has spread to 1-3 
lymph nodes but no distant organs 
T1 N1 M0 
3A 
C 
Tumour has reached the muscularis and has spread to 
1-3 lymph nodes but no distant organs 
T2 N1 M0 
Tumour has reached the serosa and has spread to 1-3 
lymph nodes but no distant organs 
T3 N1 M0 
3B 
Tumour has grown beyond the serosa and has spread 
to 1-3 lymph nodes but no distant organs 
T4 N1 M0 
Tumour is any size and has spread to at least four 
lymph nodes but no distant organs 
T* N2 M0 3C 
Tumour is any size with any degree of lymph node 
spreading and has metastasised to distant organs 
T* N* M1 4 D 
Table 1.1: Comparison of the TMN, numbers and Dukes’ systems of categorising CRC stage, 
with a description of the cancer at each stage.   
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1.1.2 Incidence, treatment and mortality 
In the UK, CRC is the fourth most common cancer, with 41804 new cases in 2015, amounting 
to 12% of all new cancer cases that year (Cancer Research UK, 2016). The more common 
cancers are breast cancer, prostate cancer and lung cancer. Due to the sex differences in the 
incidence of breast and prostate cancers, CRC is the third most common cancer in both men 
and women when the sexes are considered separately. Cancers of the right colon are more 
common in women than in men, and left colon cancers are more common in men than in 
women. 
Treatment for CRC varies with the stage at which it is diagnosed. Surgery to remove the 
growth is the primary treatment for CRC and can be local excision, resection with 
anastomosis, resection with colostomy, or total colectomy, depending on how extensive the 
cancer is and how much of the colon must be removed; this should be accompanied by 
lymphadenectomy (Cunningham et al., 2010). The colon is highly sensitive to radiation and 
so radiotherapy is not routinely used in the treatment of colonic cancer, but neoadjuvant or 
adjuvant radiotherapy is used to treat rectal cancer (Häfner and Debus, 2016). 
Chemotherapy drugs used to treat CRC include fluorouracil (5-FU), a thymidylate synthase 
inhibitor that blocks thymidine synthesis, leading to thymineless death in rapidly dividing 
cells (Longley et al., 2003); capecitabine, which is metabolised to 5-FU (Walko and Lindley, 
2005); and oxaliplatin, a planar platinum-based drug which reacts with deoxyribonucleic acid 
(DNA) bases to create intra- and interstrand crosslinks, causing inhibition of DNA replication 
and transcription (Graham et al., 2004). 
There were 16384 deaths due to CRC in the UK in 2016, which was 10% of all cancer deaths 
that year (Cancer Research UK, 2016). It is the second highest cause of cancer death in the 
UK, behind lung cancer, although in men alone there are more deaths from prostate cancer 
than CRC, and more deaths from breast cancer than CRC in women alone. England and Wales 
have 57% 10-year survival, 59% five-year survival and 76% one-year survival. Men have 
higher survival than women. When CRC is diagnosed at the earliest stage, over 90% of 
patients survive beyond five years, but when it is diagnosed at the latest stage, the five-year 
survival is below 10%. 
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Incidence in the UK has been stable overall over the last decade, with a 4% decrease in men 
and 2% increase in women (Cancer Research UK, 2016). Mortality has decreased 17% in men 
over the same period and 12% in women, giving 14% reduction in mortality overall. 
 
1.1.3 Genetic changes in colorectal cancers 
Colorectal cancers can be divided into subtypes, depending on the genomic instability 
present: those with chromosomal instability (CIN), those with microsatellite instability (MSI), 
and those with CpG island methylator phenotype (CIMP). These pathways are not mutually 
exclusive and a tumour can have characteristics of more than one. 65-85% of sporadic 
colorectal cancers exhibit CIN, characterised by increased rates of gain or loss of 
chromosome regions or whole chromosomes, leading to aneuploidy and high loss of 
heterozygosity (Pino and Chung, 2014). MSI is detected in around 12% of sporadic CRC cases 
and is a hallmark of deficiencies in DNA mismatch repair (MMR) machinery, such as MLH1 
and PMS2 (Boland and Goel, 2010). CIMP is characterised by hypermethylation of promoter 
CpG islands, resulting in the inactivation of multiple tumour suppressor genes, and is present 
in around 20% of sporadic CRC cases (Mojarad et al., 2013). Sporadic tumours with MSI also 
have CIMP, as CIMP provides the mechanism for inactivating the MMR genes; cancers 
associated with a hereditary MMR defect such as Lynch syndrome have MSI without CIMP 
(Jass, 2007). 
The Wnt signalling pathway is disrupted in over 90% of sporadic colorectal cancers (Cancer 
Genome Atlas, 2012). The canonical Wnt signalling pathway is an important regulator of cell 
proliferation, differentiation, adhesion and migration, and so plays key roles in 
embryogenesis and adult homeostasis (Logan and Nusse, 2004; MacDonald et al., 2009). It is 
particularly important in tissues with high cell turnover, such as the epithelium of the 
intestines. Binding of secreted Wnt to its Frizzled (FZD) receptor causes inhibition of the β-
catenin degradation complex of adenomatous polyposis coli protein (APC), glycogen 
synthase kinase 3 (GSK3), casein kinase 1 (CK1) and axin, allowing β-catenin to accumulate 
and translocate into the nucleus where it binds TCF/LEF transcription factors and stimulates 
expression of Wnt-responsive genes (Behrens et al., 1998; Gregorieff and Clevers, 2005; 
Molenaar et al., 1996; Schatoff et al., 2017) (figure 1.4). 
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The most common mutation in the Wnt signalling pathway is biallelic inactivation of APC, 
member of the β-catenin destruction complex; APC mutations are seen in over 80% of 
sporadic colorectal cancers, and are one of the earliest identified mutations in the CRC 
pathway (Cancer Genome Atlas, 2012; Powell et al., 1992). The APC gene is on chromosome 
arm 5q, which has high rates of loss through CIN (Al-Sohaily et al., 2012). Other frequent 
mutations found in colorectal cancers that affect the Wnt signalling pathway include 
activating mutations in β-catenin gene CTNNB1, upregulation of the Wnt receptor FZD, and 
inactivation of DKK-1, which encodes the DICKKOPF-1 competing ligand for the LPR6 Wnt 
receptor (González-Sancho et al., 2005; Morin et al., 1997; Terasaki et al., 2002). 
The RAS/MAPK pathway is a cell-signalling pathway which communicates extracellular 
signals from the cell membrane to the nucleus, in particular regulating cell proliferation by 
transducing signals from growth factors and proto-oncogenes (Fang and Richardson, 2005; 
Zhang et al., 2002). Around 60% of sporadic colorectal cancers have mutations in the 
RAS/MAPK pathway, with 55% having mutually exclusive activating mutations in either KRAS, 
NRAS or BRAF (Cancer Genome Atlas, 2012). Extracellular signals promote guanosine 
diphosphate binding to Ras proteins, including K-ras and N-ras, leading to activation of Raf 
proteins such as B-raf, and triggering a kinase cascade culminating in the phosphorylation of 
transcription factors (Fang and Richardson, 2005; Zhang et al., 2002). 
TP53, encoding the tumour suppressor p53, is mutated in around 60% of sporadic 
adenocarcinomas, but not in adenomas, meaning TP53 mutations occur relatively late in 
colorectal tumourigenesis (Vogelstein et al., 1988). p53 has multiple roles in preserving 
genome integrity including arresting the cell cycle at the G1 checkpoint, activating genes 
encoding DNA repair machinery, and triggering apoptosis in cells with excessively damaged 
DNA or that are at risk of aberrant mitosis (Kastenhuber and Lowe, 2017). It is therefore a 
highly important tumour suppressor gene and is the most widely mutated gene in cancer 
(Kandoth et al., 2013). 
The transforming growth factor (TGF) β pathway plays roles in a variety of cell processes, 
including proliferation, apoptosis, stem cell renewal, differentiation and adult tissue 
homeostasis (Shi and Massagué, 2003; Weiss and Attisano, 2013). The TGF-β superfamily of 
secreted signalling ligands includes the bone morphogenetic protein (BMP), Nodal, Activin 
and growth and differentiation factor (GDF) families. TGF-β ligands bind to receptor 
serine/threonine kinases at the cell surface and the signal is transduced to the nucleus via 
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Smad proteins. Many components of the TGF-β signalling pathway are found to be mutated 
in CRC, including TGFBR1, ACVR2A, SMAD3 and SMAD4 (Cancer Genome Atlas, 2012). 
Recently, analysis of gene expression in a large dataset of over 4000 patients was used to 
define four consensus molecular subtypes (CMS) of CRC (Guinney et al., 2015). CMS1, or MSI 
immune, represents 14% of tumours and is defined as being MSI, CIMP-high and 
hypermutated, with BRAF mutations, and immune infiltration and activation. CMS2, called 
the canonical subgroup, comprises 37% of tumours and is CIN-high with WNT and MYC 
activation. 13% of tumours are CMS3, or metabolic, meaning they are mixed MSI status, CIN-
high and CIMP-low, with KRAS mutations and metabolic deregulations. CMS4, or 
mesenchymal, represents 23% of tumours and is CIN-high, with stromal infiltration, TGF-β 
activation and angiogenesis. The remaining 13% show a mixture of features, and may be a 
transitional phenotype, or may represent intratumour heterogeneity. These subtypes, which 
were identified from patient samples, have been shown to also be present in in vitro and in 
vivo CRC models (Linnekamp et al., 2018). The use of CMS offers the potential for improved 





Figure 1.4: Schematic of basic canonical Wnt signalling. When Wnt signalling is inactive, GSK3, 
in complex with APC/AXIN/CK1, phosphorylates cytoplasmic β-catenin and so targets it for 
degradation. When Wnt signalling is activated, secreted Wnt binds to the transmembrane 
receptors Frizzled and LRP5/6. GSK3 is then phosphorylated, inhibiting its own activity. β-
catenin accumulates in the cytoplasm and is transported into the nucleus, where it binds to 




1.1.4 Genetic risk factors for CRC 
The known genetic factors which contribute to CRC susceptibility can be broadly split into 
two groups: high penetrance, low frequency mutations, which are only present in a small 
percentage of the population but which confer a greatly increased risk of CRC development; 
and low penetrance, high frequency variants, which are more common but carry a lower 
associated risk (Peters et al., 2015) (figure 1.5). High penetrance mutations manifest in 
hereditary syndromes and so have largely been identified via studies of affected families. The 
three most common hereditary syndromes are familial adenomatous polyposis, Lynch 
syndrome and MUTYH associated polyposis. 
Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome characterised by 
the development of hundreds of adenomatous polyps, mostly in the left colon, which are 
detectable between ages 10 and 20 (Galiatsatos and Foulkes, 2006; Talbot et al., 2000). These 
adenomas have a high tendency to progress to adenocarcinomas, giving almost 100% 
incidence of CRC by age 40. Around 1% of all CRC cases is due to FAP. FAP is caused by an 
inherited inactivating mutation in one copy of APC, the gene so frequently mutated at the 
initiation of sporadic CRC. There are many different mutations observed in APC, with the site 
of the mutation correlating with the severity of FAP (Nieuwenhuis and Vasen, 2007), such as 
mutations before codon 157 or after codon 1595 (of a total 2843 codons) being associated 
with attenuated FAP (A-FAP). A-FAP adenomas typically number below 100 and are more 
proximal than in classic FAP, and CRC onset in A-FAP occurs on average 15 years later than 
classic FAP (Galiatsatos and Foulkes, 2006). 
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer, is an autosomal 
dominant syndrome that accounts for around 3% of CRC cases, with the mean age of cancer 
diagnosis being 45 (Lynch et al., 2009; Peltomaki et al., 2000). The majority of adenomas 
develop in the right colon and show accelerated carcinogenesis, progressing from adenoma 
to adenocarcinoma more rapidly than non-Lynch syndrome cancers (Rijcken et al., 2002). 
Lynch syndrome is caused by germline mutations in MMR genes, with MLH1, MSH2, MSH6, 
PMS2, PMS1 and MLH3 all being linked to Lynch syndrome heritability, although MLH1, MSH2 
and MSH6 account for over 95% of known mutations associated with Lynch syndrome (Lynch 
et al., 2009; Peltomäki, 2005). Lynch syndrome tumours are therefore defined by high MSI, 
resulting from the defective DNA repair machinery. 
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MUTYH associated polyposis (MAP) is an autosomal recessive syndrome, caused by a biallelic 
mutation in the MUTYH gene (Farrington et al., 2005; Mork and Vilar, 2016; Poulsen and 
Bisgaard, 2008). It has variable presentation, ranging from no polyps to polyp numbers 
almost equal to classic FAP. MUTYH is a DNA glycosylase involved in base excision repair for 
oxidative damage, and mutation of MUTYH results in G:C > A:T transitions. MAP tumours 
have high incidence of such transitions occurring within the APC gene (Sieber et al., 2003). 
In contrast to high penetrance mutations, low penetrance variants do not typically have a 
strong enough effect to create a clear familial syndrome and so contribute to “sporadic” risk, 
although they can influence a family history of CRC. These variants are identified via genome 
wide association studies (GWAS). Identified variants of this type include CTNNB1 and CDH1, 
both members of the Wnt signalling pathway; TGFB1, BMP2 and BMP4, members of the TGF-
β signalling pathway; and POLD3, a DNA polymerase with proofreading ability (Dunlop et al., 
2016; Peters et al., 2015). 
Due to their increased frequency, an individual may carry risk alleles for multiple low 
penetrance variants, the effects of which combine into their overall genetic risk (Dunlop et 
al., 2012). Common variants may also be present in a person carrying a high-effect mutation 
and so further modify their risk. As many low penetrance variants are overrepresented in 
adenomas as well as adenocarcinomas, it has been suggested that such variants affect CRC 
risk by modifying susceptibility to the precursor adenomas rather than the rate at which 
adenomas progress (Carvajal-Carmona et al., 2013).  
Theoretically there are also variants of intermediate effect and frequency, but as they do not 
have either the effect size to present in family studies, or the frequency to be detectable in 
GWAS, they have so far been very difficult to identify; this will likely change as the cost of 
genome sequencing continues to drop and GWAS can be carried out on large enough cohorts 
to provide the power to find these intermediate variants. 
Comparing the genes which are the cause of hereditary CRC syndromes, genes which have 
been identified as low penetrance CRC variants, and genes which frequently accumulate 
mutations during CRC development, there are many overlaps in the pathways implicated, 





Figure 1.5: Known CRC susceptibility loci arranged by risk allele frequency and effect size. 
High effect, low frequency variants cause strong hereditary syndromes and so have largely 
been identified by familial studies, while low effect, high frequency variants are typically 
identified by GWAS studies of sporadic cancers. The hypothesised “missing heritability” 
genes have too weak an effect to be detectable in familial studies, but are not common 
enough to be detectable in GWAS. The continued development of next generation 




1.1.5 Environmental risk factors for CRC 
1.1.5.1 Medical conditions 
Inflammatory bowel disease (IBD), mainly comprising Crohn’s disease and ulcerative colitis 
(UC), is characterised by chronic inflammation. The risk of CRC is 70% higher in the IBD 
population than the non-IBD population, with an individual’s risk increase correlating with 
duration of disease, extent of colitis and degree of inflammation (Canavan et al., 2006; 
Castaño-Milla et al., 2014; Lutgens et al., 2013). While IBD underlies only 1-2% of CRC cases, 
CRC is the cause of 15% of deaths in IBD patients (Munkholm, 2003), and IBD is the third 
highest risk factor for CRC, behind FAP and Lynch syndrome (Kulaylat and Dayton, 2010). 
Overall CIN and MSI occur at the same rate in colitis-associated CRC (CA-CRC) as in sporadic 
CRC, but the timing and frequency of specific mutations can show different patterns (Lakatos 
and Lakatos, 2008). Rather than being an initiating mutation as in sporadic CRC, APC 
mutations occur later in the progression of CA-CRC and so at a lower frequency (Aust et al., 
2002). Conversely, TP53 mutations occur at a higher rate in CA-CRC as they are earlier events 
than in sporadic CRC (Hussain et al., 2000). 
The pathogenesis of CA-CRC is complex and there are many mechanisms that contribute. 
Many mucosal inflammatory mediators are induced by the chronic inflammation that 
characterises IBD, including inflammatory cytokines, chemokines and cyclooxygenase (COX) 
enzymes, and some of these are linked to CRC. For example COX-2, which is induced by 
inflammatory stimuli including IFN-γ and TNF-α, is upregulated in colorectal cancers, and 
expression of COX-2 correlates with tumour stage and depth of invasion (Elzagheid et al., 
2013; Lim et al., 2010). Another pathway involved in the pathogenesis of CA-CRC is that of 
reactive oxygen and nitrogen species (RONs). These are produced in high amounts by 
inflammatory cells such as activated neutrophils and macrophages, leading to inflamed tissue 
having higher concentrations of RONs (Kimura et al., 1998; Rachmilewitz et al., 1995). Such 
species can cause denaturation of proteins and DNA alterations including base modifications, 
double base lesions and single- and double-strand breaks (Klaunig et al., 1998); and oxidative 
stress can also inactivate the MMR system (Chang et al., 2002). 
Diabetes mellitus (DM) is characterised by defects in insulin secretion and/or action; type 1 
DM has absolute insulin deficiency due to autoimmune destruction of insulin-secreting β-
cells in the pancreas, while type 2 DM has insulin resistance. Meta-analyses have linked type 
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2 DM only with CRC, with 22-30% increase in CRC risk in type 2 DM patients (Jiang et al., 2011; 
Larsson et al., 2005; Luo et al., 2012). There are many shared risk factors between CRC and 
type 2 DM, such as obesity, but other possible mechanisms for this link include 
hyperinsulinemia due to resistance, as levels of insulin and insulin-like growth factor 1 have 
been shown to correlate with the number and classification of colorectal adenomas (Schoen 
et al., 2005). 
 
1.1.5.2 Lifestyle factors 
It is estimated that 54% of UK CRC cases in 2015 were preventable (Cancer Research UK, 
2016). Key lifestyle factors that affect cancer risk include diet, physical activity, weight, 
alcohol consumption and tobacco smoking. 
High intake of both red and processed meat have been linked to increased CRC risk by 
multiple meta-analyses of human studies, showing that 100-120g red meat per day increases 
CRC risk 17-30%, and 25-50g of processed meat per day increases risk 9-50% (Aune et al., 
2013; Chan et al., 2011; Norat et al., 2002). It has also been shown that beef and blood 
sausage promote colon carcinogenesis in rats treated with a carcinogen (Pierre et al., 2004). 
In this study, a control group given no meat but supplemented with haem to match the beef 
diet haem content showed carcinogenesis equal to the beef diet. Haem, which is present in 
high concentrations in meat, stimulates production of N-nitroso compounds, leading to DNA 
damage (Joosen et al., 2009). 13% of UK CRC cases are due to processed meat consumption 
(Brown et al., 2018). In contrast, meta-analyses show high consumption of fibre reduces CRC 
risk, with a 10% reduction in CRC risk per 10g/day total dietary fibre and 20% risk reduction 
per 90g/day whole grains (Aune et al., 2011; Ben et al., 2014; Song et al., 2015). 28% of UK 
CRC cases are due to insufficient fibre consumption (Brown et al., 2018). 
CRC risk is increased with alcohol consumption. Risk increases 17% with daily consumption 
of 1.5-6 units of alcohol (12.5-50g), and is 33% higher in people who drink over 6 units per 
day, according to one meta-analysis (Bagnardi et al., 2015). Another meta-analysis found risk 
increases 7% with each additional unit of alcohol drunk per day (Fedirko et al., 2011). The 
first metabolite of alcohol, acetaldehyde, is carcinogenic and causes DNA damage including 
sister-chromatid exchange and intra-strand crosslinks (Matsuda et al., 1998; Obe et al., 
1986). 6% of UK CRC cases are due to alcohol consumption (Brown et al., 2018). 
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Physical inactivity increases colon cancer risk up to 24%, while sedentary behaviour increases 
colon cancer risk up to 27%; rectal cancer is not associated with physical activity, but 
sedentary behaviour increases rectal cancer risk up to 6% (Boyle et al., 2012; Cong et al., 
2014; Robsahm et al., 2013). Sedentary behaviour, defined as waking behaviour with low 
energy expenditure while sitting or lying down, is not interchangeable with physical 
inactivity, defined as performing insufficient moderate- and vigorous-intensity activity, hence 
the risk being conferred individually by each being different (van der Ploeg and Hillsdon, 
2017). Proposed mechanisms for the protective effect of physical activity on colorectal 
cancer include altered levels of hormones such as insulin and prostaglandins, increased 
immune function, and decreased gastrointestinal transit time (Friedenreich, 2011; 
McTiernan, 2008). 5% of UK CRC cases are due to too little physical activity (Brown et al., 
2018). 
Being overweight (body mass index (BMI) of 25-29.9) or obese (BMI of 30+) has been linked 
by meta-analyses to CRC risk, independent of diet and physical activity (Chen et al., 2015; 
Ning et al., 2010; Xue et al., 2017). Overweight men have 18% higher risk of colon cancer and 
6% higher risk of rectal cancer, while obese men have 48% higher risk of colon cancer and 
25% higher risk of rectal cancer. CRC risk in men increases 10% per 5 BMI units gained during 
adulthood. There is a 12% increase in risk of colon cancer in obese women and no association 
between rectal cancer and BMI in women, or between CRC and adult weight gain in women. 
Proposed mechanisms for the increased risk of CRC with increased weight include insulin 
resistance, chronic inflammation and altered adipokine secretion, with adipose tissue 
dysfunction as a key underlying cause (Van Kruijsdijk et al., 2009; Martinez-Useros and 
Garcia-Foncillas, 2016). 11% of UK CRC cases are due to overweight and obesity (Brown et 
al., 2018). 
People who are current or former smokers have 17-25% higher risk of CRC than people who 
have never smoked, with risk being higher in those who began smoking at a younger age and 
increasing 7-11% per 10 cigarettes smoked daily (Huxley et al., 2009; Liang et al., 2009; Tsoi 
et al., 2009). The association may be stronger for rectal cancer than colonic cancer. There are 
over 60 established carcinogens present in cigarette smoke, which act through a range of 
mechanisms (Alavanja et al., 2004). 7% of UK CRC cases are due to tobacco smoking (Brown 
et al., 2018).  
17 
 
1.2 The 11q23.1 locus 
1.2.1 Identification as a CRC risk locus 
The 11q23.1 locus was identified as a CRC risk locus in a 2008 GWAS (Tenesa et al., 2008). In 
phase 1 of this GWAS, 1012 early-onset Scottish CRC cases and 1012 controls were genotyped 
for 555510 single nucleotide polymorphisms (SNPs). The highest-ranked 15008 SNPS were 
taken into phase 2 and genotyped in 2057 Scottish CRC cases and 2111 controls. Finally, 
14500 CRC cases and 13294 controls from seven populations were genotyped for the five 
highest-ranked SNPs from phases 1 and 2, the populations being Scottish, English, German, 
Israeli, Spanish, Canadian and Japanese. 
In addition to replicating known risk loci at 8q24 and 18q21, this study identified a novel risk 
SNP, rs3802842, at locus 11q23.1, with odds ratio=1.1 and P=5.8E-10. rs3802842 has a minor 
allele frequency (MAF) of 0.29. The association between this SNP and CRC risk has been 
replicated in multiple populations, including Austrian, African American, Dutch, Japanese, 
Finnish and Chinese (Hofer et al., 2017; Kupfer et al., 2010; Middeldorp et al., 2009; Tanikawa 
et al., 2018; Tanskanen et al., 2018; Xiong et al., 2010). There are site-specific differences in 
the risk conferred by rs3802842, with the risk of rectal cancer being higher than colonic 
cancer. The extent of this difference varies between populations. 
rs3802842 lies within an intronic region and so is not a coding variant (figure 1.6). Expression 
analysis on colonic tissue and CRC cell lines has shown that rs3802842 genotype correlates 
with expression of three local genes, C11orf53, C11orf92 and C11orf93, with expression of all 
three genes decreasing with increased risk alleles of the SNP (Biancolella et al., 2014; Closa 
et al., 2014; Smillie, 2015) (figure 1.7). This relationship does not hold for the next nearest 
gene, POU2AF1. 
C11orf53 is a protein-coding gene on the forward strand with five exons. There are three 
known transcripts (table 1.2a). C11orf92, also called COLCA1, is believed to be a non-coding 
gene. It is on the reverse strand and has five exons, with five known transcripts (table 1.2b). 
C11orf93, also called COLCA2, is a protein-coding gene on the forward strand, which overlaps 
with C11orf92. There are nine exons and seven known transcripts (table 1.2c). In this thesis I 
will refer to these genes only by their C11orf name. 
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It has been proposed that the 11q23.1 locus acts as a CRC risk modifier in patients with Lynch 
syndrome as well as in the general population. This has been shown in a Lynch syndrome 
cohort with a mix of MLH1, MSH2 and MSH6 mutations (Wijnen et al., 2009) and the 
association with MLH1 has been replicated, although not the association with MSH2 or MSH6 
(Talseth-Palmer et al., 2010). The extent of this effect and its clinic usefulness has been 
disputed (Houlle et al., 2011; Win et al., 2013). A study looking specifically at PMS2-
associated Lynch syndrome did not find any risk modification from 11q23.1 (ten Broeke et 
al., 2017). It has also been shown that 11q23.1 does not modify the extent of polyposis in 




Figure 1.6: A schematic of the human locus 11q23.1, containing the genes C11orf53, C11orf92 (aka COLCA1) and C11orf93 (aka COLCA2), showing their 
exon structure and relative positions and sizes. Locations of key SNPs, including the original tagging SNP rs3802842 and probable causative SNP 




Figure 1.7: Correlation of expression of (a) C11orf53, (b) C11orf92, (c) C11orf93 and (d) 
POU2AF1 with increasing risk alleles of rs3802842. Expression data was generated using qRT-
PCR from 116 colorectal tissue samples. The association between rs3802842 genotype and 





Table 1.2: Details of the known transcripts of (a) C11orf53, (b) C11orf92 and (c) C11orf93. Data from Ensembl, July 2018.
1.2a) C11orf53 known transcripts 
Name Transcript ID Basepairs Protein Biotype CCDS UniProt RefSeq 
C11orf53-203 ENST00000637637.1 1049 236aa  Protein coding CCDS31674 Q8IXP5 
NM_198498  
NP_940900 
C11orf53-201 ENST00000280325.5 1208 286aa  Protein coding - A0A1C7CYV6 - 
C11orf53-202 ENST00000635886.1 545 110aa  Nonsense mediated decay - A0A1B0GU63 - 
1.2b) C11orf92 known transcripts 
Name Transcript ID Basepairs Protein Biotype CCDS UniProt RefSeq 
COLCA1-205 ENST00000620864.1 8098 No protein  Antisense - NM_001302644 COLCA1-205 
COLCA1-204 ENST00000540738.3 5537 No protein  Antisense - NM_001302646 COLCA1-204 
COLCA1-201 ENST00000355430.4 5442 No protein  Antisense - NM_207429 COLCA1-201 
COLCA1-203 ENST00000532918.4 5366 No protein  Antisense - NM_001302645 COLCA1-203 
COLCA1-202 ENST00000526150.1 391 No protein  Antisense - - COLCA1-202 
1.2c) C11orf93 known transcripts 
Name Transcript ID Basepairs Protein Biotype CCDS UniProt RefSeq 
COLCA2-201 ENST00000398035.6 1414 154aa  Protein coding CCDS44728 A8K830 
NM_001136105  
NP_001129577 
COLCA2-202 ENST00000526216.1 1332 154aa  Protein coding CCDS44728 A8K830 - 
COLCA2-205 ENST00000614153.4 1264 154aa  Protein coding CCDS44728 A8K830 
NM_001271457  
NP_001258386 
COLCA2-204 ENST00000610738.5 975 251aa  Protein coding CCDS73378 A8K830 
NM_001271458  
NP_001258387 
COLCA2-206 ENST00000638573.1 1080 286aa  Protein coding - A8K830 - 
COLCA2-203 ENST00000528846.5 823 106aa  Protein coding - A0A0A0MTE5 - 
COLCA2-207 ENST00000639470.1 1207 133aa  Nonsense mediated decay - A0A1W2PQW7 - 
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1.2.2 Functional understanding of 11q23.1 
The region has been fine-mapped to examine SNPs in the vicinity that were not included in 
the original analysis (Biancolella et al., 2014; Closa et al., 2014; Smillie, 2015). Three other 
nearby SNPs, rs7130173 (MAF=0.29), rs3087967 (MAF=0.27) and rs10891246 (MAF=0.27), 
have higher correlation with expression of C11orf53, C11orf92 and C11orf93 (figure 1.8). The 
relationship is in the same direction as rs3802842, with the minor allele being associated with 
lower expression. While rs3802842 is the tagging SNP, one of these other higher-ranked SNPs 
may be the causal SNP for the differential expression that is observed. These SNPs are also 
all non-coding (figure 1.6). 
While the association between CRC, rs3802842, and C11orf53, C11orf92 and C11orf93 has 
been widely replicated, understanding of the underlying mechanism is still greatly lacking; as 
the function of these genes is unknown, we cannot hypothesise how reduction of this 
function can lead to CRC development. 
Claire Smillie carried out functional analysis of the three genes, including tissue specific 
expression analysis using FANTOM5 data, which showed that C11orf53 is primarily expressed 
in colorectal tissue, while C11orf92 and C11orf93 have broader expression including male 
reproductive tissues, kidney and lung (Smillie, 2015). Preliminary localisation studies showed 
C11ORF53 may co-localise with the endoplasmic reticulum (ER) protein Sec61, and C11ORF93 
has a speckled appearance within the cell, possibly also within the ER. Claire Smillie also 
performed extensive gene ontology enrichment analysis on gene sets derived from 
correlative expression within normal colorectal tissue and global expression changes in cells 
during overexpression or small interfering ribonucleic acid (RNA) knockdown of the C11orf 
genes. Enriched terms indicated involvement in RNA metabolic processes, the cell cycle, 
vesicles, and organelle membranes. The ER was also frequently arising: ER membrane 
correlates to C11orf93 expression in colonic tissue, and ER membrane, ER components and 
ER stress response are enriched in genes altered by C11orf53 overexpression, C11orf53 
knockdown and C11orf92 knockdown. 
The ER and unfolded protein response (UPR) have been linked to CRC and intestinal 
homeostasis (Drake et al., 2015; Heijmans et al., 2013; Niederreiter et al., 2013). This is in 
part due to the role of the ER in the correct function of goblet cells, the secretory cells of the 
intestines that produce large amounts of mucus and so have extensive ER to ensure correct 
assembly of the secreted mucus components (Hasnain et al., 2013; Heazlewood et al., 2008; 
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Park et al., 2009; Zhao et al., 2010). Goblet cells are part of the intestinal immune system and 
mucus aids prevention of inflammation by minimising intestinal epithelium contact with 
rough material and microorganisms; disrupted mucus production is therefore associated 
with inflammation and colitis (Bergstrom et al., 2015; Johansson et al., 2014; Van der Sluis et 
al., 2006). As such, ER stress and UPR is also associated with colitis (Hino et al., 2014; Kaser 
et al., 2008; Shkoda et al., 2007; Zhang et al., 2015), which is a significant risk factor for CRC, 
as discussed above. 
An additional study shows that C11ORF93 is found in the cytoplasm of normal epithelial, 
immune and tumour cells within the colon, while C11ORF92 forms granules within many 
immune cell types including neutrophils and macrophages, and so concludes that these 
genes are involved in immune pathways (Peltekova et al., 2014). However, our tests of the 
antibodies used demonstrate a lack of the specificity desired for localisation studies, in 
addition to C11orf92 having no confirmed protein to detect immunologically. More work is 
therefore needed on the localisation of these gene products, utilising improved tools. 
Figure 1.8: Correlation of expression of C11orf92 with 167 SNPs from the 11q23.1 locus, using 
colonic gene expression in 117 people. Each dot represents one SNP, colour coded for r2 with 
tagging SNP rs3802842. rs7130173, rs3087967 and rs10891246 have higher correlation with 
C11orf92 expression than rs3802842. Image from Smillie, 2015.  
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1.2.3 Evolution and conservation in other species 
1.2.3.1 Evolution of the locus 
C11orf53 is the oldest of the three genes in the 11q23.1 locus, being present in almost all 
descendants of bony fish, but not cartilaginous fish, and so arising between 530 and 435.3 
million years ago (MYA) (figure 1.9). 
C11orf93 arose later, between 435.3 and 413.0 MYA, and is present only in the descendants 
of lobe-finned fish and not ray-finned fish (figure 1.9). As in humans, C11orf93 orthologues 
are adjacent to and in the same orientation as C11orf53 orthologues. 
C11orf92 is the youngest of the three genes, being present only in placental mammals and 
arising between 158.6 and 105.5 MYA (figure 1.9). While C11orf92 has no orthologues listed 
in genome browsers, examination of the equivalent locus (as defined by the presence of 
C11orf53 and C11orf93 orthologues) show an orthologous gene, between C11orf53 and 
C11orf93 and in the opposite orientation, in animals including armadillos, goats, dolphins, 
and various mouse and primate species. 
There are many placental mammals that do not contain a C11orf92 orthologue, such as pigs, 
rabbits, rats and gorillas. It is possible that the gene has been lost many times. However, due 
to the gene being possibly non-coding and quite small – only 342bp in orangutans – I believe 
it is also likely the orthologues of C11orf92 have simply not yet been annotated as genes in 
many species, particularly those that have been less intensively studied and still only have 
genome scaffolds rather than full genome sequences. This hypothesis opens the prospect 
that not only is the gene more frequent among placental mammals, but that it may in fact be 




Figure 1.9: Vertebrate phylogenetic 
tree, with presence of orthologues 
of C11orf53, C11or92 and C11orf93 
marked. Periods during which each 
gene originated are indicated, with 
the time of key branchpoints marked 
(data from Ensembl, July 2018). 
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1.2.3.2 Mouse orthologues 
The orthologous locus in Mus musculus is on chromosome 9 at position A5.3. As in the human 
locus, the C11orf92 orthologue is between the other two genes and in the reverse 
orientation, with some overlap between the 5’ end of C11orf92 and the 5’ end of C11orf93 
(figure 1.10). 
The mouse orthologue of C11orf53 is 1810046K07Rik. It is a protein coding gene with 6 exons 
and two known transcripts (table 1.3a). There is 82% identity of complementary DNA (cDNA) 
sequence and 80% identity of protein sequence between the human and mouse genes. 
The mouse orthologue of C11orf92 is 2010007H06Rik. Like C11orf92, it is believed to be non-
coding. There is 56% identity of cDNA sequence between human and mouse genes. There 
are two exons and two known transcripts (table 1.3b). 
The mouse orthologue of C11orf93 is Gm684, recently renamed Colca2. It has five exons and 
two known transcripts (table 1.3c). There is 73% cDNA sequence identity and 63% protein 
sequence identity between the human and mouse genes. 





Figure 1.10: A schematic of the mouse locus 9A5.3, containing 18100046K07Rik (orthologue of C11orf53), 2010007H06Rik (orthologue of 
C11orf92/COLCA1), and Colca2 (orthologue of C11orf93/COLCA2), showing their exon structure and relative positions and sizes. The position and 




1.3a) 1810046K07Rik transcripts 
Name Transcript ID bp Protein Biotype CCDS UniProt RefSeq 
1810046K07Rik-201 ENSMUST00000039959.10 1318 235aa  Protein coding CCDS52792 Q9D8Q6 
NM_027217  
NP_081493 
1810046K07Rik-202 ENSMUST00000181366.1 466 103aa  Protein coding - M0QWA8 - 
1.3b) 2010007H06Rik transcripts 
Name Transcript ID bp Protein Biotype CCDS UniProt RefSeq 
2010007H06Rik-202 ENSMUST00000186025.1 4934 No protein  Antisense - - - 
2010007H06Rik-201 ENSMUST00000050829.1 626 No protein  Antisense - - - 
1.3c) Colca2 transcripts 
Name Transcript ID bp Protein Biotype CCDS UniProt RefSeq 
Colca2-202 ENSMUST00000215038.1 1269 239aa  Protein coding CCDS57676 F8VPY8 - 
Colca2-201 ENSMUST00000114427.3 1263 239aa  Protein coding CCDS57676 F8VPY8 
NM_001195681  
NP_001182610 




The overarching aim of this project is to increase functional understanding of the 11q23.1 
locus and its role in CRC, with a view to aid any future development of improved prevention 
and treatment of CRC in people with the risk genotype. 
I will take two main approaches to this; the first, covered in chapters three and four, is to 
examine the localisation of the gene products. I will use immunological detection of the 
proteins in cell lines, via DDK-tagged overexpression proteins, to observe if the proteins are 
localising to specific subcellular compartments, in addition to working on generating a mouse 
line carrying endogenous fluorescent tags. I will also use in situ hybridisation to detect 
messenger RNA (mRNA) transcripts within human and mouse colonic tissue, to view the 
distribution of gene expression within the tissue context. 
The second approach, covered in chapters five and six, is to assess the effect of loss of these 
genes on biological systems. I will generate and characterise a knockout mouse model of the 
locus, including histological assessment of tissue, differential expression analysis and tumour 
induction studies. I will also generate ex vivo cell and organoid models, using material from 
the knockout mouse, for further quantitative experiments on features such as cell 
proliferation. 
Currently very little is known as to the function of C11orf53, C11orf92 and C11orf93, and so 
we cannot know their role in CRC development beyond the observation that reduced 
expression is associated with an increase in risk. While the time limits of this project will 
necessarily preclude in depth characterisation of these genes, I aim to begin to narrow down 




Chapter 2: Materials and Methods      
2.1 DNA Methods 
2.1.1 DNA extraction from mouse earclips 
Earclips were taken from mice at 14 days old by animal technicians and stored at -20°C until 
use. 
To each was added 100µl DirectEar PCR lysis buffer (Viagen, 402-E) and 4µl 10mg/ml 
proteinase K solution (Promega, MC5005). Samples were incubated at 55°C for 14 hours and 
85°C for 45 minutes. 300µl dH2O was then added to each tube and samples were mixed by 
vortexing. 
Samples were stored at -20°C. 
 
2.1.2 Polymerase chain reaction (PCR) 
DNA solutions extracted from earclips were then used in PCR reactions to genotype the 
animals. Primers were purchased from Sigma and IDT and were resuspended in dH2O. 
 
2.1.2.1 C11orf genotyping PCR 
Reaction mix 
5µl 2X DreamTaq PCR master mix (Thermo Fisher Scientific, K1081) 
0.25µl 20µM forward primer 
0.25µl 20µM reverse primer 
2µl DNA solution 
dH2O to total volume 10µl 
Thermocycler program 
 95°C for 4 minutes 
 32 cycles of: 95°C for 35 seconds     
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   55°C for 40 seconds 
   72°C for 1 minute 5 seconds 
 72°C for 10 minutes 
 Cooled to 10°C at 0.1°C/second 
PCR products were visualised under ultraviolet (UV) light on 1.5% agarose gel (Biogene, 300-
300) containing 1:10000 ethidium bromide (Thermo Fisher Scientific, 15585011), run at 
100V. 
 
2.1.2.2 ApcMin/+ genotyping PCR 
Reaction mix 
13µl 2X PCR master mix 
3µl 20µM MAPC MT primer 
3µl 20µM MAPC 15 primer 
0.5µl 20µM MAPC 9 primer 
3µl DNA solution 
dH2O to total volume 25µl 
Thermocycler program 
 94°C for 4 minutes 
 31 cycles of: 94°C for 1 minute 
   54°C for 2 minutes 
   72°C for 3 minutes 
 72°C for 10 minutes 
 Cooled to 10°C at 0.1°C/second 
PCR products were visualised under UV light on 2% agarose gel containing 1:10000 ethidium 
bromide, run at 100V. 
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2.1.2.3 Primer sequences 
Name Sequence 
M53 CRISPR check F TTAATGCTGACTGGGATACC 
M53 CRISPR check R GGAAATCCAGCTCAAAGATC 
M92 CRISPR check F AGATGCTCTATGTTAGTGCC 
M92 CRISPR check R CCTACCAAACAAAAGCCAAA 
M93 CRISPR check F ATGTGGCATTTAGATACTGG 
M93 CRISPR check R GGATCAAGGCTACGTATATG 
M53 tag check F TCAGTCCTACTCGCTGCATG 
M53 tag check R TGGCCTCCTTGTGAAGGTTG 
M93 tag check F GCTACTTCTGCCAACATTGG 
M93 tag check R CACAAGACCAAGTTTGAGGG 
Shr2 tag check F TGTTCGACATCCTGGCTACC 
Shr2 tag check R GTTGTTTAGCAAAGCCTGGC 
MAPC MT TGAGAAAGACAGAAGTTA 
MAPC 15 TTCCACTTTGGCATAAGGC 
MAPC 9 GCCATCCCTTCACGTTAG 
 
2.1.3 Gel purification 
Samples were run on agarose gel containing ethidium bromide and visualised using UV light. 
Bands were cut from the gel using a clean scalpel. DNA was purified from gel sections using 
QIAquick gel extraction kit (Qiagen, 28704), according to supplied kit instructions. 
 
2.1.4 Restriction digest 
Reaction mix 
200µl 10X appropriate endonuclease buffer 
0.75µl restriction endonuclease 




dH2O to total volume 20µl 
Incubated at 37°C for 70 minutes in water bath and visualised on 1.5% agarose gel run at 60V, 




 5µl each 100µM oligonucleotide 
 10µl dH2O 
Incubation 
 37°C for 30 minutes 
 95°C for 5 minutes 





 0.5µl cut vector 
1µl diluted annealed oligonucleotide 
2.5µl dH2O 
5µl 2X T4 ligase buffer (New England Biolabs, B0202S) 
1µl T4 DNA ligase (New England Biolabs, M0202S) 




2.2 RNA Methods 
2.2.1 RNA extraction from tissue 
Mouse tissue was harvested, washed in phosphate-buffered saline (PBS) (IGMM Technical 
Services), and stored in RNAlater (Thermo Fisher Scientific, AM7021) at 4°C overnight. Tissue 
was then chopped up and moved to fresh tube. 1ml Trizol (Thermo Fisher Scientific, 
15596026) and a 7mm ball bearing was added to each and the tissue homogenised in the 
TissueLyser using four 8 minute 50Hz cycles. Samples were left for 5 minutes at RT and moved 
to fresh tubes. 0.2ml chloroform was added and samples shaken for 15 seconds and left at 
RT for 10 minutes. 
Samples were centrifuged at 12000g for 15 minutes at RT. The colourless upper aqueous 
phase was moved to a new tube, the white solid and red lower aqueous phases were 
discarded. 0.5ml isopropanol was added and left for 10 minutes at RT. Samples were 
centrifuged at 12000g for 10 minutes at 4°C and the supernatant discarded. 
1ml 75% ethanol was added and samples were mixed by vortexing. Samples were centrifuged 
at 7500g for 5 minutes at 4°C, the supernatant discarded and the pellet air-dried. RNA was 
resuspended in 30µl dH2O at 57°C, quantified using the Nanodrop, and stored at -80°C. 
 
2.2.2 DNase treatment 
RNA was DNase treated prior to cDNA synthesis. DNase reaction mixture was prepared on 
ice: 
1µl DNase I (New England Biolabs, M0303S) 
1µl 10X DNase buffer (New England Biolabs, B0303S) 
1µg RNA 
dH2O to total volume 9µl 
Samples were incubated at 37°C for 30 minutes. 




2.2.3 cDNA synthesis 
cDNA synthesis reaction mix was added to each 10µl DNase-treated sample: 
4µl 5X M-MLV reverse transcriptase buffer (Invitrogen, 18057018) 
2µl random primer mix (Invitrogen, 48190011) 
2µl dNTP mix (10mM each) (Invitrogen,  18427088) 
1µl RNase inhibitor (Thermo Fisher Scientific, N8080119) 
1µl M-MLV reverse transcriptase (Invitrogen, 28025013) 
Samples were incubated at 37°C for 1 hour, followed by 95°C for 5 minutes. 
 
2.2.4 RNA synthesis 
RNA was synthesised using HiScribe T7 RNA synthesis kit (New England Biolabs, E2050S) and 
1µg of DNA template, according to supplied kit instructions. 
 
2.2.5 RNAscope on FFPE tissue 
2.2.5.1 RNAscope protocol 
RNAscope was performed on 5µm formalin-fixed paraffin-embedded (FFPE) tissue sections 
on superfrost plus slides. Slides were prepared and pretreated for RNAscope 2.5 assay with 
RNAscope Pretreatment Reagents (ACDBio, 322000 and 322500), according to ACDBio user 
manual number 322452, with the following modifications: following boiling in Target 
Retrieval Reagents, rather than a brief wash in 100% ethanol, mouse tissue slides were left 
in 100% ethanol for 5 minutes and human tissue slides were left in 100% ethanol for 10 
minutes (page 15); before addition of Protease Plus, slides were rehydrated by briefly dipping 
in PBS (page 15). 
Singleplex RNAscope was performed using the RNAscope 2.5 HD Red Detection kit (ACDBio, 
322360) and RNAscope Wash Buffer (ACDBio, 310091), according to ACDbio user manual 
322360-USM, with the following modification: slides were stained with 50% Gill’s 
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haematoxylin (Sigma-Aldrich, GHS132-1L ) for 20 seconds, rather than two minutes (page 
15). 
Duplex RNAscope was performed using the RNAscope 2.5 HD Chromogenic Duplex Detection 
kit (ACDBio, 322500) and RNAscope Wash Buffer (ACDBio, 310091), according to ACDBio user 
manual 322500-USM, with the following modification: slides were stained with 50% Gill’s 
haematoxylin for 20 seconds, rather than 30 seconds (page 20). 
2.2.5.2 RNAscope probes 
Gene Species Channel Catalogue number 
C11orf53 Human C1 460841 
C11orf53/1810046K07Rik Mouse C1 460861 
C11orf92/COLCA1 Human C1 447801 
C11orf92/2010007H06Rik Mouse C1 460911 
C11orf93/COLCA2 Human C1 460851 
C11orf93/Gm684 Mouse C1 460871 
Lgr5 Mouse C2 312171-C2 
PPIB (positive control) Human C1 313901 
Ppib (positive control) Mouse C1 313911 
Ppib (positive control) Mouse C2 313911-C2 





2.3.1 Guide RNA preparation 
Plasmid px458 was digested with restriction endonuclease BbsI (New England Biolabs, 
R0539S), as described above, using NEBuffer 2.1 (New England Biolabs, B7202S). 
Guide RNA (gRNA) sequences were purchased as single stranded DNA oligonucleotides, 
together with reverse complements. Oligonucleotides were annealed, as described above. 
Sequences were designed so that annealed oligonucleotide would have sticky ends 
complementary to those left when plasmid px458 was linearised; a 5’ G was added for T7 
RNA synthesis, with an additional 5’ G to reduce off-target effects. 
gRNA oligonucleotides were ligated into linearised px458, as described above, and the 
plasmids transformed into competent cells, as described below. Colonies were picked and 
used in minipreps to obtain a stock of plasmid, as described below. Plasmids were Sanger 
sequenced by IGMM Technical Services to ensure correct insertion of the gRNA sequence. 
gRNA template was then amplified from the px458 plasmids by PCR using T7 tagged forward 
primers and universal reverse primer. Product was gel purified, as described above, and 
subsequently used in re-PCR until the required concentration of 1µg in maximum 8µl. 
T7-tagged templates were used for in vitro RNA synthesis using T7 RNA polymerase, as 
described above. gRNAs were purified using RNeasy kit (Qiagen, 74104), according to 
supplied instructions. 
Name Sequence 
C11orf53 knockout gRNA sequence TATGGAAGTCGGAATCGGAC 
C11orf92 knockout gRNA sequence GCAGTGGAAACCTGGCCTAA 
C11orf93 knockout gRNA sequence AGGACTCGAAGATCTGGTCG 
C11orf53 mTFP1 tag gRNA sequence TGGGGCTCTTATGAGTGC 
C11orf93 EYFP tag gRNA sequence GTTTCTACTAACTATAGC 
Shroom2 mCherry tag gRNA sequence GCATTAATCTCCAGGGCT 
gRNA forward oligonucleotide CACCGG[guide sequence here] 
gRNA reverse oligonucleotide AAAC[reverse complement guide sequence]CC 
T7 tagged forward primer TGTAATACGACTCACTATAGGG[guide sequence] 
Universal reverse primer AAAAGCACCGACTCGGTGCC 
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2.3.2 CRISPR injection mix preparation 
RNA was all defrosted on ice. 
Individual components spun at 13200rpm for 30 minutes at 4°C and the supernatant moved 
to a fresh tube. 
Injection mix 
 50ng/µl Cas9 mRNA (Tebu Bio, L-6125-20) 
 25ng/µl each gRNA 
 150ng/µl each repair template 
 dH2O to total volume 50µl 
Mix was spun at 13200rpm for 30 minutes at 4°C and supernatant moved to a fresh tube. 




2.4 Bacterial Methods 
2.4.1 Transformation 
Competent cells were defrosted on ice. 2.5µl ligation mix was added to each tube and mixed 
by swirling. 
Cells were incubated 
 30 minutes on ice 
 42°C for 30 seconds using water bath 
 5 minutes on ice 
950µl SOC medium (Thermo Fisher Scientific, 15544034) was added to each tubes and 
incubated on shaker in 37°C incubator for 1 hour. 
Each culture was plated on two warm L-amp plates (IGMM Technical Services), one with 50µl 
and one with 200µl. Cultures were spread around whole plate using cell spreader. Plates 
were incubated at 37°C overnight and examined for colonies. 
 
2.4.2 Plasmid purification 
Colonies were picked into 5ml L-broth with ampicillin. Cultures were incubated on shaker in 
37°C incubator overnight. Plasmids were extracted from expanded colonies using the 
QIAprep Spin Miniprep kit (Qiagen, 27104), according to supplied kit instructions. 
 
2.4.3 Glycerol stocks 
Colonies were picked into 5ml L-broth with ampicillin, prepared by adding 2µl ampicillin stock 
to 1ml LB. Cultures were incubated on shaker in 37°C incubator overnight. 0.85ml of 5ml 
overnight cultures were added to 0.15ml glycerol (Invitrogen, 15514-011). Tubes were 




2.5 Protein Methods 
2.5.1 Protein extraction from cells 
Lysis buffer 
843µl RIPA buffer (Therma Fisher Scientific, 89900) 
40µl complete EDTA-free protease inhibitor cocktail (Roche, 11873580001) 
10µl pefablock (Roche, 11429868001) 
1µl pepstatin (Sigma-Aldrich, P5318) 
1µl Na3VO4 (Sigma-Aldrich, S6508-50G) 
5µl PMSF (Thermo Fisher Scientific, 36978) 
100µl phosSTOP (Roche, 4906845001) 
Cell pellets were either freshly harvested and kept on ice, or defrosted on ice. Cells were 
lysed with 200µl lysis buffer per pellet on ice for 30 minutes, vortexing every 10 minutes. 
Lysates were centrifuged at 13200rpm for 30 minutes at 4°C and the supernatant moved to 
fresh tubes. 
 
2.5.2 Protein quantification 
Protein concentration was quantified by Bradford reagent (BioRad, 5000006) in 96 well 
plates. Standard curve was established by adding 0-7µl of 1mg/ml BSA (Vector Laboratories, 
SP-5050) were added to wells, in triplicate. Additionally 1µl of each sample was added to 
wells, in triplicate. 200µl Bradford reagent was added to each well and mixed by pipetting. 
The plate was read using an optical plate reader at 595nm. Sample concentrations were 




2.5.3 Western blots 
2.5.3.1 Western blot solutions 
4X resolving buffer 
181.7g Tris base (Sigma, T6066) 
20ml 20% sodium dodecyl sulphate (SDS) (IGMM Technical Services) 
dH2O to total volume 1000ml 
pH 8.8 
10% resolving gel 
5ml 4X resolving buffer 
4ml 40% acrylamide (Sigma, A7168) 
9.8ml dH2O 
200µl 10% ammonium persulphate (APS) (Sigma-Aldrich, A3678) 
20µl TEMED (Thermo Fisher Scientific, 17919) 
4X stacking buffer 
12.14g Tris base 
4ml 20% SDS 
dH2O to total volume 200ml 
pH 6.8 
3% stacking gel 
1.25ml 4X stacking buffer 
0.375ml 40% acrylamide 
3.375ml dH2O 




10X running buffer 
30g Tris base 
144g glycine (Fisher Scientific, G/0800/60) 
50ml 20% SDS 
dH2O to total volume 1000ml 
50X wet transfer buffer 
14.5g Tris base 
72g glycine 
dH2O to total volume 500ml 
1X wet transfer buffer 
20ml 50X transfer buffer 
780ml dH2O 
200ml 100% methanol 
Loading buffer 
 1ml glycerol 
 500µl β-mercaptoethanol 
 2ml 10% SDS 
 1.25ml 1M Tris-HCl, pH 6.7 
 3ml 0.05% w/v bromophenol blue solution (Sigma-Aldrich, B0126) 
 
2.5.3.2 Western blot protocol 
7.2ml of 10% resolving gel added to 1.5mm mould, with 1ml dH2O gently layered on top. 





 Required volume of protein 
 4µl loading buffer 
 dH2O to total volume 20µl 
Samples boiled at 100°C for 5 minutes in heating block and loaded into gel inside tank full of 
1X running buffer. Gel was run at 100V for approximately 2.5 hours, until dye front had reach 
bottom of gel. 
Polyvinylidene fluoride (PVDF) membrane (Amersham, 10600023) was soaked in 100% 
methanol until saturated. PVDF membrane, filter paper, sponges and gel soaked in 1X wet 
transfer buffer until saturated. Membrane and gel were layered inside filter paper and 
sponges in plastic holder and inserted into tank full of 1X wet transfer buffer. Transfer was 
run at 100V for 90 minutes at 4°C, with stir bar inside tank. 
Membrane was washed in 1% PBS-tween (Sigma, P2287) (PBST) and blocked in 5% milk in 1% 
PBST for 1 hour at RT. Membrane was incubated with primary antibody in 3ml of 5% milk in 
1% PBST overnight at 4°C on roller; antibody concentration is antibody dependent. 
Membrane was washed 3 x 5 minutes in 1% PBST at RT. Membrane was incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibody diluted 1:2000 in 5% milk in 
1% PBST for 1 hour at RT. 
Membrane was washed 3 x 5 minutes in 1% PBST. Enhanced chemiluminescence (ECL) 
solutions 1 and 2 (Thermo Fisher Scientific, 32106) were mixed 1:1 and pipetted onto 
membrane, incubated for 1 minute at RT, and blotted off. Western blot was developed using 
light-reactive film (Amersham, 28906837). 
To re-probe a membrane, membrane was washed 3 x 1 hour in 1% PBST before re-blocking. 





2.5.3.3 Western blot antibodies 
Antibody Manufacturer Dilution 
Anti-C11ORF53 (rabbit) Sigma, SAB1103541 1:1000 
Anti-C11ORF93 (goat) Santa Cruz, Sc-245159 1:200 
Anti-DDK (mouse) OriGene, TA50011-100 1:1000 
Anti-β-actin, HRP-conjugated Santa Cruz, Sc-47778 hrp 1:50000 
Anti-rabbit, HRP-conjugated Promega, W4011 1:2000 
Anti-goat, HRP-conjugated Promega, V8051 1:2000 
Anti-mouse, HRP-conjugated Promega, W4021 1:2000 
 
2.5.4 Immunofluorescence on cultured cells 
2.5.4.1 Immunofluorescence protocol 
Cells were grown on glass coverslips in six-well plates to 90% confluency. Cells were washed 
in PBs and fixed in 3ml per well of ice-cold 1:1 acetone:methanol at -20°C for 30 minutes. 
Fixed cells were washed 2 x 5 minutes in PBS on shaker at RT. 1ml 10% donkey serum (Sigma-
Aldrich, D9663) in PBS was added per well and incubated for 1 hour at RT to block, followed 
by a brief PBS wash. 
200µl of primary antibody solution, diluted according to individual antibody specifications in 
10% donkey serum in PBS, was pipetted onto each coverslip and incubated for 1 hour at RT. 
Cells were washed 3 x 5 minutes in 1% PBST. 
200µl of Alexa Fluor secondary antibody solution, diluted 1:1000 in 1.5% donkey serum in 1% 
PBST, was pipetted onto each coverslip and incubated for 20 minutes at RT in the dark. Cells 
were washed 2 x 5 minutes in 1% PBST. 
Coverslips were mounted on superfrost plus slides using Vectashield mounting medium 
containing DAPI (Vector Laboratories, H-1200), and sealed around the edges with nail 




2.5.4.2 Immunofluorescence antibodies 
Antibody Manufacturer Dilution 
Anti-C11ORF53 (rabbit) Sigma, SAB1103541 1:300 
Anti-C11ORF93 (goat) Santa Cruz, Sc-245159 1:300 
Anti-DDK (mouse) Origene, TA50011-100 1:1000 
Anti-calnexin (rabbit) Cell Signalling, C5C9 #2679 1:150 
Anti-calnexin (mouse) BD Bioscience, 610524 1:400 
Anti-γ-tubulin (mouse) Sigma, T5326 1:1000 
Anti-mouse Alexa Fluor 488 (goat) Life Technologies 1:1000 
Anti-rabbit Alexa Fluor 488 (goat) Life Technologies 1:1000 
Anti-goat Alexa Fluor 488 (donkey) Life Technologies 1:1000 
Anti-mouse Alexa Fluor 594 (goat) Life Technologies 1:1000 
Anti-rabbit Alexa Fluor 594 (goat) Life Technologies 1:1000 
 
2.5.5 Immunohistochemistry on FFPE tissue 
2.5.5.1 Immunohistochemistry protocol 
Immunohistochemistry was performed on sections of FFPE tissue by Vidya Rajasekaran, 
Calum Robertson and Marion Bacou. 
Slides were rehydrated by incubation in xylene for 15 minutes and decreasing concentrations 
of ethanol (100%, 90%, 70%) for 10 minutes each at RT. Slides were dipped in dH2O and 
blocked using 3% H2O2 solution for 20 minutes at RT. Slides were washed with 0.1% PBST for 
5 minutes at RT. 
Antigen retrieval was carried out suing 1X citrate buffer (Thermo Scientific, AP-9003-500) 
with 0.1% tween. Solution was heated to boiling point before slides were added. Slides were 
boiled in solution for 10 minutes. Slides were cooled at RT for 30-45 minutes and washed in 
0.1% PBST for 5 minutes at RT. Slides were permeabilised with 0.5% Triton-X100 (Sigma-
Aldrich, X100-500ML) in PBS for 20 minutes at RT and washed in 0.1% PBST for 2X 5 minutes 
at RT. 
Slides were blocked with 5% donkey serum in PBST for 1 hour at RT. Primary antibodies were 
added to slides in blocking buffer and incubated for 2 hours at RT or overnight at 4°C. Slides 
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were washed in 0.1% PBST for 3X 5 minutes at RT. Secondary antibodies were added in 
blocking buffer and incubated for 2 hours at RT or overnight at 4°C. Slides were washed in 
0.1% PBST for 5X 5 minutes at RT. 
Signal was detected using by incubation with 3,3’-diaminobenzine (DAB) (Vector 
Laboratories, SK-4100) for 10 minutes at RT. Slides were washed in dH2O for 5 minutes at RT 
and counterstained in Harris haematoxylin (Sigma-Aldrich, HHS32) for 30 seconds. Slides 
were washed under tap water for 5 minutes and dehydrated in increasing concentrations of 
ethanol (70%, 90% and 100%) for 15 minutes each and xylene for 20 minutes at RT. Coverslips 
were applied with mounting medium. 
2.5.5.2 Immunohistochemistry antibodies 
Antibody Manufacturer Dilution 
Anti-Ki-67 (rabbit) Abcam, ab15580 1:300 
Anti-β-catenin (mouse) BD Biosciences, 610153 1:100 
Anti-cytokeratin-7 (rabbit) Abcam, ab181598 1:500 
Anti-Clca1 (rabbit) Abcam, ab180851 1:300 
Anti-rabbit, HRP-conjugated Sigma, A9169 1:200 
Anti-mouse, HRP-conjugated Sigma, A9044 1:200 
 
2.5.5.3 Other tissue staining 
Haematoxylin and eosin (H&E) staining, Periodic Acid Schiff (PAS) staining and Alcian Blue 




2.6 Cell culture methods 
2.6.1 Human cancer cell lines 
2.6.1.1 Cell culture 
Cells were cultured in DMEM (Gibco, 41965-039), supplemented with 10% fetal calf serum 
(FCS, IGMM Technical Services) and 1% penicillin-streptomycin (IGMM Technical Services). 
Cells were grown in T25 flasks in 5ml medium or T75 flasks in 12ml medium, with filter caps. 
Flasks were kept in incubators at 37°C and 5% CO2. Cells were passaged at 90% confluency, 
2-3 times per week. 
To passage, medium was removed and cells were washed with warm PBS. Cells were 
detached from flasks by adding 2.0g/l warm trypsin solution (0.5ml for T25 flasks and 2ml for 
T75 flasks) and incubating at 37°C for 2-3 minutes. Following incubation, 2-4ml of warm 
DMEM was added to flasks and detachment of cells was ensured through pipette-washing 
and mechanical shock. Cells were pelleted by centrifugation at 3000rpm for 4 minutes. Cells 
were washed in warm PBS, re-pelleted, and resuspended in warm DMEM. Cell suspension 
was split into new flasks at 1:3. 
If required, cells were counted using a Coulter counter. 100µl of cell suspension was diluted 
to 10ml in isotone. Particles were counted between 10µm and 30µm. 
 
2.6.1.2 Transfection 
Lipofectamine solution for one well of a six-well plate was made by adding 10µl of 
lipofectamine (Invitrogen, 11668-019) was added to 306.25µl Opti-MEM reduced serum 
medium (Gibco, 11058021), scaled up for required number of wells. Solution was incubated 
for 5 minutes at RT. 
Plasmid solution for one well of a six well plate was made by adding 4µg of plasmid to 312.5µl 
Opti-MEM reduced serum medium, scaled up for required number of wells. Lipofectamine 
and plasmid solutions were mixed 1:1 and incubated for 30 minutes at RT. 
Cells were washed with warm PBS and given 1.9ml DMEM supplemented with 10% FCS. 600µl 
of the transfection mix was gently added dropwise to each well. Non-transfected controls 
were given lipofectamine without plasmid.  
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2.6.2 Primary Mouse Fibroblasts 
2.6.2.1 Fibroblast extraction 
Complete medium was RPMI-1640 medium (Gibco, 21875-034) supplemented with: 
10% FCS 
1% penicillin-streptomycin 
100µM asparagine (Sigma-Aldrich, A4159) 
2mM glutamine (IGMM Technical Services) 
50µM 2-mercaptoethanol 
Pronase solution 
10mg pronase protease (Merck Millipore, 53702) 
494µl dH2O 
5µl 1M Tris pH8 (IGMM Technical Services) 
1µl 0.5M ethylenediaminetetraacetic acid (EDTA) pH8  (IGMM Technical Services) 
Solution incubated at 37°C for 30 minutes. 
Collagenase-pronase solution 
10mg collagenase D (Roche, 11088866001) 
4ml complete medium 
250µl pronase solution 
Solution filtered through 0.22µm syringe filter. 
1cm radius ear tissue was collected immediately post-mortem and stored in complete 
medium for transport from animal unit to tissue culture hood. Tissue was incubated in 70% 
ethanol at RT for 5 minutes and air-dried. Ear pieces were transferred to 10cm dishes 
containing 10ml of complete medium, and cut into pieces under 3mm radius. Tissue pieces 
were transferred into cryovials and collagenase-pronase solution was added to total volume 
of 1.8ml. Cryovials were incubated at 37°C for 90 minutes on a horizontal shaker at 200rpm. 
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Digested tissue was poured into 70µm cell strainers in 10cm dishes with 10ml fresh complete 
medium, and ground with syringe plungers for 5 minutes. The cell suspensions were moved 
into 50ml falcon tubes. Strainers and dishes were rinsed with further 10ml completed 
medium and this medium was also added to the falcon tubes. 
Cell suspensions were centrifuged at 600g for 7 minutes at 4°C. The supernatant was 
discarded and the pellets resuspended in 10ml complete medium. Centrifugation and 
resuspension were repeated once. The cells were plated in 10cm dishes with 10µl 
amphotericin B (Sigma-Aldrich, A2492) at 250µg/ml. The following day cells were washed 
with PBS and given fresh complete medium with amphotericin B. 
 
2.6.2.2 Fibroblast culture 
When confluent, cells were washed with warm PBS and trypsinised by adding 2ml 1X EDTA-
trypsin solution (Sigma-Aldrich, 59418C) and incubating at 37°C for 3 minutes. 6ml complete 
medium was added and cells suspensions centrifuged at 450g for 5 minutes at 4°C. Cell 
pellets were resuspended and plated at the desired density in complete medium. No 
amphotericin B was added after the first passage. When split 1:3 cells required passaging 




2.7 Cell Assays 
2.7.1 SRB proliferation assay 
Cells were seeded in 96-well plates in 200µl of medium per well, with one plate prepared per 
timepoint. Human SW480 colorectal cancer cells were seeded at 6000 cells per well and 
mouse primary fibroblasts were seeded at 1500 cells per well. In addition to seeded wells, 
wells of medium only were included to provide a blank. The outer ring of wells were filled 
with medium but were not included in calculations, instead providing an evaporation buffer. 
At each timepoint the appropriate plate was mixed by adding 100µl 50% (w/v) trichloroacetic 
acid solution (Sigma-Aldrich, T0699) to each well and incubated at 4°C for 1 hour. The plate 
was rinsed four times with tap water and dried upside down on paper towels overnight. 
When all plates were fixed 100µl 0.4% sulforhodamine B (SRB) solution (Sigma, S2902-100ml) 
was added to each well and incubated for 30 minutes at RT. Plates were washed with multiple 
brief 1% acetic acid washes until no stain was present in the wash. Plates were air dried 
overnight. 
200µl 10mM Tris solution was added per well and the stain resuspended by either use of a 
plate shaker at 450rpm or manual pipette mixing. The plates were read on a plate reader at 
565nm. The blank medium value was subtracted from the sample values. 
 
2.7.2 Scratch migration assay 
Cells were seeded in six-well plates in 10% FCS medium. When 90% confluent, the cells were 
washed with warm PBS and switched to 0.1% FCS medium. 24 hours later a scratch was made 
down the centre of each well with a P200 pipette tip and the cells washed and given fresh 
0.1% FCS medium. 
Brightfield images of the scratch were taken 1 hour, 24 hours and 48 hours post scratch. 
Marks drawn on the plate ensured the same region of the scratch was photographed at each 
timepoint. Closure of the scratch was measured using Selection and Measure tools in ImageJ 




2.7.3 Chamber insert migration assay 
Chamber inserts (ibidi, 80209) were adhered to the base of a 24 well plate. Cells were seeded 
at 49000 cells per chamber in 70µl of 10% FCS medium. At 90% confluence the cells were 
changed from 10% FCS medium to 0.1% FCS medium – cells were not washed with PBS due 
to the risk of dislodging the chambers. The following day the inserts were removed and the 
wells topped up with 300µl 0.1% FCS medium. 
Plates were set up for live imaging using the Santana microscope, with one Brightfield image 
taken every 30 minutes for 72 hours. Closure of the gap was measured using Selection and 
Measure tools in ImageJ to manually select the remaining gap and calculate it as a proportion 




2.8 Mouse methods 
2.8.1 Tissue collection and processing 
Mice were culled by cervical dislocation or CO2 asphyxiation. Animals were pinned on their 
back and the body opened on the ventral midline. Organs were removed and rinsed in PBS 
before being placed in 10% neutral buffered formalin (NBF) (Sigma, HT501128). In the case 
of stomach, caecum and intestines, organs were flushed with PBS to remove all digestive 
material before fixation. Intestines were rolled onto 2mm diameter bamboo skewers, so that 
the outer serosa was against the skewer and the inner mucosa was exposed to the NBF. 
Tissue was fixed at RT for 24 hours, washed in PBS for 5 minutes at RT, and stored in 70% 
ethanol at 4°C. Tissue was then processed and paraffin embedded by the University of 
Edinburgh Division of Pathology. 
 
2.8.2 Blood collection and processing 
Animals were culled by CO2 asphyxiation. Animals were pinned on their back and blood 
collected via cardiac puncture through the sternum, using a 30 gauge needle on a 1ml 
syringe. Blood was dispensed in 1.5ml tubes containing 10µl 0.5M EDTA anticoagulant per 
300µl blood. Blood was mixed with EDTA by shaking. Tubes were stored on ice and delivered 
to the University of Edinburgh Easter Bush Pathology lab for automated blood counts. 
 
2.8.3 1,2-Dimethylhydrazine injections 
Mice were weighed the morning of the injection and their dosage calculated at 40mg 1,2-
dimethylhydrazine (DMH)/kg body weight. DMH stock solution (Sigma, 40690) at 790mg/ml 
was diluted to 2mg/ml in 1mM EDTA-saline at pH 7.0. DMH was administered by 
subcutaneous injection. 
Mice were weighed once a day to monitor for weight loss and checked twice a day for signs 
of being unwell, including hunched gait, reduced motility, rectal prolapse or blood around 




2.9 Organoid culture 
Organoids were derived and cultured by Anna Maria Ochocka-Fox. Freshly harvested mouse 
intestines were flushed with cold PBS. Tissue was cut into 2-4mm pieces and washed with 
ice-cold PBS. Tissue fragments were incubated in either 3mM EDTA in PBS for the SI or 25mM 
EDTA in PBS for the LI, for 30 minutes at 4°C with gentle rocking. EDTA solution was removed 
and tissue resuspended in ice-cold PBS to release crypts. Tissue suspensions were passed 
through 70µm cell strainer to remove residual villous material. Tissue suspensions were then 
centrifuged at 300g for 5 minutes at 4°C to pellet crypts and allow removal of single cells. 
Pure crypts were added to warmed Matrigel (BD Bioscience, 356231) and plated in 24-well 
plates, with 2-4 small bubbles of Matrigel per well. 
Organoids were cultured in advanced DMEM/F-12 medium (Gibco, 12634-028), 
supplemented with: 
 2mM GlutaMax (Invitrogen, 25050-079) 
 10mM HEPES (Invitrogen, 15630-056) 
 100µg/ml penicillin/streptomycin (IGMM Technical Services) 
 N2 supplement (Invitrogen, 17502-048) 
 B27 supplement (Invitrogen, 12587-010) 
 1mM N-acetylcysteine (Sigma-Aldrich, A9165) 
 0.1% BSA (Sigma-Aldrich, A9647-100G) 
 10nM [Leu-15] gastrin I (Sigma-Aldrich, G9145) 
 10nM nicotinamide (Sigma-Aldrich, N0636) 
 500nM A83-01 (Tocris Bioscience, 2939) 
 10µM SB202190 (Sigma-Aldrich, S7067) 
 50ng/ml murine recombinant EGF (Invitrogen, PMG8043) 
 100ng/ml murine recombinant noggin (Peprotech, 250-38) 
 1µg/ml murine recombinant R-spondin1 (R&D, 3474-RS-050) 
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 100ng/ml muraine Wnt3A – LI only (R&D, 1324-WN-010) 
Medium was changed twice weekly. Organoids were photographed on day one, two, four 






Continuous data sets, such as RNAscope signal counts or intestinal polyp counts, were 
checked for normal distribution using the Shapiro-Wilks test. Comparisons between two data 
sets were then carried out using unpaired two-tailed student’s t test, if both groups were 
normally distributed, or by two-tailed Mann-Whitney U test if not. 





Chapter 3: Investigation of Gene Function through Protein 
Localisation          
3.1 Introduction 
The localisation of a protein both within individual cells and in the wider tissue context can 
give important hints as to function. There are many different cell types within the intestines, 
some of which are only found in certain regions of tissue, such as the stem cells being in the 
base of the crypt (Barker et al., 2007). By examining the expression patterns across tissue, 
and investigating possible co-expression with known cell-type markers, we can gain insight 
into the role of proteins of interest. 
Further to establishing which cells express a protein, we can also look in detail within the cell 
to try and identify which subcellular component or organelle the protein of interest 
associates with, and if this localisation changes under different conditions, such as β-
catenin’s movement between the cytoplasm and nucleus in colonic cancers (Kobayashi et al., 
2000). 
The localisation of C11ORF92 and C11ORF93 has been previously examined in colonic tissue 
via immunohistochemistry (Peltekova et al., 2014). This study found that C11ORF92 occurs 
in granular organelles in immune cells of the lamina propria, including neutrophils, 
macrophages and mast cells, while C11ORF93 is present in the cytoplasm of cells from 
multiple origins, such as epithelial, lymphoid and mesenchymal. However, in silico analysis 
suggests that C11orf92 is not protein coding (Smillie, 2015), which conflicts with an antibody-
based approach to its localisation. Additionally, the anti-C11ORF93 antibody used in this 
study shows multiple bands on Western blot testing, although the authors speculate this is 
due to additional isoforms (Peltekova et al., 2014). They did not examine C11ORF53. 
Western blot analysis by Claire Smillie on the available antibodies for C11ORF53, C11ORF92 
and C11ORF93 showed that none have the high specificity desired for localisation studies 
(Smillie, 2015). As an alternative to direct detection of the proteins, I carried out 
immunofluorescence using overexpression plasmids carrying DDK-tagged versions of 
C11ORF53 and C11ORF93, and attempted to establish a mouse line with endogenous 
fluorescent tags. Due to the data indicating C11orf92 does not produce a protein, it was not 
included in these experiments.  
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3.2 Use of antibodies to visualise protein localisation 
3.2.1 Methods 
3.2.1.1 Immunofluorescence 
I performed immunofluorescence on proliferating human cancer cell lines, cultured on glass 
coverslips in six-well plates. These cells were stained with primary antibodies to proteins of 
interest, followed by fluorescent secondary antibodies. The cells were also stained with DAPI 
to mark the nuclei and mounted. Slides were imaged using fluorescence microscopy. 
Claire Smillie has previously demonstrated that the available antibodies for C11ORF53 and 
C11ORF93 have issues of non-specific binding, visible as multiple extra bands on Western 
blots (Smillie, 2015). To confirm that the antibodies have the same lack of specificity when 
used for immunofluorescence as for Western blots, I used them to stain HCT116 and HT29 
colorectal cancer (CRC) cell lines (figure 3.1). HT29 cells have high expression of all three 
C11orf genes, while HCT116 cells do not have any expression detectable by quantitative real 
time PCR (qRT-PCR) (Smillie, 2015). Both the anti-C11ORF53 and anti-C11ORF93 antibodies 
show signal across the HCT116 cells which, given the qRT-PCR data, we must consider to be 
non-specific. There is stronger signal in the HT29 cells, but when the images from the two 
cells lines are compared it is difficult to determine what signal in the HT29 cells is specific 




Figure 3.1: Fluorescence images of fixed proliferating HCT116 and HT29 colorectal cancer 
cells, stained with DAPI and either (a) anti-C11ORF53 or (b) anti-C11ORF93, using Alexa Fluor 
488 secondary. HCT116 cells have no endogenous expression of either gene while HT29 cells 
have high levels of expression, as determined by qRT-PCR. As signal is visible in both cell lines, 
it therefore must be considered due to non-specific binding, and these antibodies are not 




3.2.1.2 Overexpression plasmids 
To circumvent the lack of high specificity antibodies to the proteins, I utilised Myc-DDK-
tagged overexpression plasmids. These plasmids, which were based on the pCMV6-entry 
vector, contained cDNA from either C11orf53 or C11orf93, with a Myc-DDK tag on the 3’ end 
(figure 3.2). The C11orf53 transcript used encodes the 236 amino acid protein. The C11orf93 
transcript used encodes the 154 amino acid protein; while there are other transcripts 
produced, at the time of purchase of these plasmids this was the only transcript available. 
Neither plasmid includes the 5’ or 3’ untranslated regions. The fusion genes had the CMV 
promoter, which gives strong constitutive expression in mammals, and the Kozak consensus 
sequence for transcription initiation. The plasmids also contained a neomycin resistance 
gene to allow selection. These plasmids were transfected into plated HeLa and SW480 cells; 
the empty pCMV6 plasmid was also used as a control. 
Protein lysates from transfected cells were used in Western blot analysis for C11ORF53, 
C11ORF93 and DDK, which shows the transfected plasmids were successful in producing 
overexpressed DDK-tagged proteins (figure 3.3). While there are many extra bands detected 
by the anti-C11ORF53 and anti-C11ORF93 antibodies, it is still possible to see one band of 
increased intensity in the corresponding overexpression lysate, matching the DDK bands. 
 
Figure 3.2: The pCMV6-Entry plasmid from OriGene transfected into cell lines for transient 
transfection. cDNA sequences of C11orf53 transcript ENST00000637637.1 and C11orf93 




Figure 3.3: Western blots of SW480 cell lysates following transfection with either empty 
plasmid, C11ORF53-DDK overexpression plasmid or C11ORF93-DDK overexpression plasmid. 
Membranes were probed for C11ORF53, C11ORF93 and DDK. Predicted sizes of proteins are 
29kDa for C11ORF53-DDK and 20.4kDa for C11ORF93-DDK, so the observed bands are bigger 
than expected; this was also observed by Claire Smillie. The C11ORF53-DDK plasmid gives 
higher overexpression than the C11ORF93-DDK plasmid, demonstrated by the different 





3.2.2.1 Co-localisation of tagged proteins 
I carried out immunofluorescence on SW480 and HeLa cells that had been transfected with 
the DDK-tagged overexpression plasmids. Cells were also stained with DAPI to identify the 
nuclei. SW480 is a CRC cell line with very little expression of the C11orf genes and is amenable 
to transfection. HeLa cells also have a low level of C11orf expression and are similarly 
receptive to transfection. This cell line is from a cervical cancer, rather than CRC, but was still 
included to compare if the proteins’ activity in colonic cells is conserved in cells of other 
tissues. The transfection efficiency was not 100%, as evidenced by not all cells being positive 
for DDK. This efficiency could be improved by optimising the protocol, but as I was achieving 
sufficient overexpression to both see it on the Western blot and in enough of the cells to 
assess the localisation, it seemed unnecessary to spend time on optimisation. 
As previous work suggested a link to the endoplasmic reticulum (ER) (Smillie, 2015), I co-
stained for the ER protein calnexin alongside DDK. Calnexin is a molecular chaperone which 
retains misfolded or incompletely folded proteins in the ER (Bergeron et al., 1994). As it is an 
integral ER membrane protein, it can be used to define the area of the ER membrane. 
C11ORF53-DDK co-localises with calnexin in both HeLa and SW480 cells (figure 3.4a), 
implying C11ORF53-DDK is also located within the on the ER membrane or within the ER. 
C11ORF93-DDK gives up to four punctate dots per cell of strong signal (figure 3.4b). These 
dots do appear within the bounds of the ER, as marked by calnexin, but as we are capturing 
3D cells in 2D images we cannot say if the protein is within the ER or associated with the 
membrane, or simply above or below the ER. I also stained for γ-tubulin, which plays a role 
in microtubule nucleation (Oakley et al., 2015), as it forms similar foci, but there was no co-




Figure 3.4a: Fluorescence images of proliferating SW480 and HeLa cells, transfected with pCMV6 plasmid containing C11ORF53-DDK. Cells were stained 
with DAPI, anti-calnexin using Alexa Fluor 594 secondary to mark the endoplasmic reticulum, and anti-DDK using Alexa Fluor 488 secondary to mark the 
transiently-overexpressed C11ORF53. The C11ORF53-DDK signal colocalises with calnexin, suggesting that C11ORF53-DDK is found throughout either 




Figure 3.4b: Fluorescence images of proliferating SW480 and HeLa cells, transfected with pCMV6 plasmid containing C11ORF93-DDK. Cells were stained 
with DAPI, anti-calnexin using Alexa Fluor 594 secondary to mark the endoplasmic reticulum, and anti-DDK using Alexa Fluor 488 secondary to mark the 
transiently-overexpressed C11ORF93. The C11ORF93-DDK forms punctate dots, indicated with arrows, that appear within the endoplasmic reticulum 
as marked by calnexin, suggesting that these small regions of C11ORF93-DDK are found either on the surface of or within the endoplasmic reticulum.  
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Figure 3.4c: Fluorescence images of proliferating SW480 cells, transfected with empty pCMV6 plasmid, as a control to the cells transfected with 
pCMV6 plasmid carrying C11orf53 and C11orf93. Cells were stained with DAPI and anti-DDK using Alexa Fluor 488 secondary. The absence of DDK 




Figure 3.5: Fluorescence images of proliferating SW480 cells, transfected with pCMV6 plasmid containing C11ORF93-DDK. Cells were stained with DAPI, 
anti-γ-tubulin using Alexa Fluor 594 secondary and anti-DDK using Alexa Fluor 488 to mark the transiently-overexpressed C11ORF93. γ-tubulin and 
C11ORF93-DDK foci indicated with arrows. As the γ-tubulin and C11ORF93-DDK foci do not colocalise, C11ORF93-DDK is not associated with γ-tubulin 
within the cells. 
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3.2.2.2 Proliferation assay on transfected cells 
In order to assess possible function of the proteins, I carried out a sulforhodamine B (SRB) 
proliferation assay on transfected cells to measure the effect of overexpression of the 
proteins. The assay was performed on SW480 cells that were either non-treated or had been 
transfected with the empty plasmid, C11ORF53-DDK overexpression plasmid or C11ORF93-
DDK overexpression plasmid. 
All cells transfected with a plasmid showed a substantially slower proliferation rate than non-
treated cells (which can be expected, as transfection and overexpression can be highly 
stressful for cells), but there were no observable differences between transfection with the 
three different plasmids (figure 3.6). This is consistent with data from Claire Smillie showing 
no significant difference in proliferation when CRC cell lines are treated with siRNA to knock 
down C11ORF53 or C11ORF93 (Smillie, 2015), and my own data showing no significant 
difference in proliferation in primary mouse cell lines which have had the three genes 




Figure 3.6: SRB proliferation assay on SW480 cells following transfection with either empty 
plasmid, C11ORF53-DDK overexpression plasmid or C11ORF93-DDK overexpression plasmid, 
with measurements taken 24, 48 and 72 hours post-transfection. Non-transfected cells also 
included for comparison. Results shown are the mean of three experiments, each containing 
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3.3 Generation of endogenously-tagged mouse lines 
3.3.1 Methods 
3.3.1.1 Choice of fluorescent tags 
To remove the various caveats of using overexpression plasmids and obtain results we could 
have more confidence in, I undertook to create endogenously tagged proteins. This would 
keep the tagged protein under endogenous regulation, and the complete transcript, 
including untranslated regions (UTRs), would be produced. We chose to use fluorescent tags 
as it would remove the need for antibodies for visualisation, although fluorescent tags are 
larger than some other tags such as DDK. 
Two different fluorescent proteins were chosen, to enable us to visualise them in the same 
sample; as we do not know how, or if, the proteins interact, this would allow observation of 
any patterns of co-expression in the same cell type or co-localisation to the same subcellular 
component. Following discussion with Ann Wheeler from the IGMM Advances Imaging 
Resource, the tags used were monomeric teal fluorescent protein 1 (mTFP1) for C11orf53 
and enhanced yellow fluorescent protein (EYFP) for C11orf93. The wavelengths of these two 
fluorescent proteins allows co-visualisation of the tagged proteins with DAPI to mark the 
nuclei, additional immunofluorescence using an Alexa Fluor 568 secondary antibody, and the 
RNAscope in situ hybridisation technique using Cyanine5 (figure 3.7). 
Rather than join the tags directly onto the protein, I included a short flexible linker peptide, 
(GGGGS)3. By allowing the two proteins some distance and independent movement, the 
linker improves folding and stability and so aids function of both the protein of interest and 




Figure 3.7: Excitation and emission spectra of the proposed 
fluorescent protein tags for C11ORF53 and C11ORF93, 
mTFP1 and EYFP. Use of these two proteins allows 
simultaneous visualisation of both tags alongside DAPI for 
nuclear staining, Alexa Fluor 568 fluorophore for 
immunofluorescence, and Cyanine5 fluorophore for 
RNAscope. Key to excitation and emission graph colours for 
each fluorochrome is shown on the left. Graph was 








3.3.1.2 CRISPR experiment design 
While adding fluorescent tags could have been performed in cell lines, we are interested in 
localisation within the tissue context as well as the cell context. We therefore began by 
creating a tagged mouse line, as we could subsequently generate primary cell lines from the 
mice if required. 
Due to the close proximity of C11orf53 and C11orf93, it would be unlikely that we would 
obtain both tags on the same chromosome copy from breeding together tags on different 
chromosome copies. Breeding could still produce mice carrying both tags heterozygously, 
but the expression of these genes is already low and I was concerned any co-expression/co-
localisation studies of the two proteins would be hampered if we could further only visualise 
half of the expressed protein. We therefore decided to target both genes in a single 
experiment to generate a compound tagged line. 
It has been shown that CRISPR/Cas9 can be used to insert a tag immediately before the stop 
codon of a protein (Li et al., 2014); I used this approach and prepared guide RNAs (gRNAs) 
and repair template DNA to inject with Cas9 mRNA into mouse embryos. The guides were 
designed to target Cas9 cleavage as close to the stop codon as was possible with the available 
protospacer adjacent motif (PAM) sites. An additional 5’ G was added to the sequence to 
reduce off-target effects (Cho et al., 2014). 
The repair templates consisted of the linker peptide and fluorescent tag sequences flanked 
by 150bp of sequence either side of the stop codon (figure 3.8a, 3.8b). This 150bp length was 
recommended for short targeted changes, such as changing a SNP from one allele to another; 
I did consider if the homology arms should increase in length if a larger sequence is being 
inserted, but there was no clear guidance in the literature and, as the tags are all around 
700bp, I was already concerned about the size of the repair template to be injected into the 
cells. The PAM sequence in the repair template was mutated to avoid Cas9 cleaving the 




Figure 3.8: Schematic of CRISPR approach to inserting fluorescent tags at the C-terminus of C11ORF53 and C11ORF93. (a) The unedited gene sequence 
within the chromosome. The Cas9 endonuclease was targeted to within 10bp of the stop codon. (b) The repair template injected into the nuclei of 
C57BL6/J mouse eggs by microinjection. The repair template consisted of the final 150bp of gene sequence before the stop codon, the linker peptide 
sequence, the fluorescent tag sequence, the stop codon, and the first 150bp of sequence following the stop codon. (c) The edited gene resulting from 
homologous recombination following Cas9 activity. The linker peptide and fluorescent tag have been inserted immediately before the stop codon, 
leaving all other gene sequence unchanged. Genotyping primers, positions marked with grey arrows (not to scale), were used to determine if integration 
of the repair template had successfully taken place. The inner pair of primers were used to confirm the new sequence was present in the genome by 
the presence or absence of a PCR product, while the outer pair of primers were used to confirm the insertion was in the desired location by the size of 
the PCR product. 
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.3.3.1.3 Genotyping of potentially tagged animals 
To identify animals with the fluorescent tag inserted, I designed primers within the tag 
sequences and 50bp either side of the homology arms (figure 3.8c). The inner primers 
validate that the fluorescent protein has integrated into the genome, as these sequences are 
not otherwise found in the mouse genome. The outer primers allow confirmation that the 
sequence has inserted in the correct place: the wild type product is approximately 400bp, 
but the presence of the tag gives and additional 700bp. Following amplification, sequencing 
can also ensure the insertion is in frame, so that the C-terminus of the protein and the 
fluorescent tag would be properly translated. 
 
3.3.2 Results 
3.3.2.1 Tagging C11orf53 and C11orf93 
The CRISPR mix was injected into the nuclei of C57BL/6J eggs by Jacek Mendrychowski from 
the CBS Transgenic Core. These eggs were fertilised and kept overnight in an incubator; 
embryos at the two-cell stage were then transferred into females. We had three injection 
sessions, as the first two did not produce pregnancies. 
Given this lack of pups, following the third session some embryos, both injected and non-
injected, were kept in the incubator rather than being transferred into a female, so that Jacek 
Mendrychowski could monitor their development. All non-injected embryos progressed 
correctly to the blastocyst stage, but none of the injected embryos did. Approximately half 
of them died, although they did not lyse, while the other half appeared alive and healthy but 
were stalled at the two-cell stage. However, this third session did result in a successful 
pregnancy that gave two pups. 
When the animals were genotyped, I saw only the 400bp wild type product using the primers 
outside the homology arms instead of the 1100bp product indicating the presence of the 
insertion. The primers within the tags gave no products. The additional check of mixing the 
primer pairs – amplifying from upstream of the 5’ homology arm to within the tag, and from 
within the tag to downstream of the 3’ homology arm – also gave no products. 
From these PCR results we concluded the experiment had not worked and neither of the 
mice carried endogenous fluorescent tags. 
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3.3.2.2 Tagging Shroom2 
Another gene of interest within the research group is SHROOM2, a gene on the X 
chromosome which has also been linked to CRC risk. As with C11orf53 and C11orf93, the 
antibodies available for SHROOM2 have issues of non-specificity that limit our ability to 
visualise the protein. I therefore also designed a CRISPR/Cas9 experiment to add an 
endogenous mCherry tag to Shroom2 in mice, and prepared the Shroom2-mCherry injection 
mix in parallel to the C11orf-tag injection mix. I used the same approach in designing primers 
for genotyping. 
In contrast to the C11orf-tag experiment, 25 pups were born following the initial Shroom2-
mCherry injection session. Genotyping suggested that five of these had mCherry inserted in 
the correct place and subsequent organoid culture shows the presence of red fluorescent 
signal (figure 3.9). 
 
Figure 3.9: Merged fluorescence and brightfield image of an organoid derived from the small 
intestine of a SHROOM2-mCherry mouse, showing red fluorescent signal. Image taken at 20X. 




To understand the function of C11orf53 and C11orf93, I examined the localisation of their 
proteins. Due to the absence of high-specificity antibodies to either protein to detect them 
directly in cells or tissue, I took alternative approaches to visualise them, using protein tags. 
C11ORF53-DDK co-localises with calnexin, which is consistent with previous data suggesting 
a connection to the ER. There are also many links between the ER and CRC, with ER stress 
affecting intestinal stemness, tumourigenesis, and inflammatory bowel disease (Drake et al., 
2015; Heijmans et al., 2013; Hosomi et al., 2015; Niederreiter et al., 2013). 
The nucleus is clearly defined within the calnexin staining as a region of no signal, but this is 
not the case for the DDK staining – there is little distinction between the nucleus and the 
surrounding ER. It is difficult to say if this means C11ORF53-DDK functions differently within 
the ER than the membrane protein calnexin, or that C11ORF53-DDK is present within the 
nucleus as well as the ER. It may also be peculiarity of the staining and bleedthrough with 
DAPI, although as there are no cells where the nucleus is stained and the ER is not, and the 
nuclei are not highlighted in the C11ORF93-DDK cells, I do not believe this is the case. 
C11ORF93-DDK forms distinct foci, which appear within the bounds of the ER on 2D imaging 
but are not necessarily located within the ER in the 3D cell. It has been suggested that the 
foci resemble γ-tubulin, which is associated with centrioles and the basal bodies that anchor 
cilia, but subsequent co-staining shows the proteins do not co-localise. It would be 
interesting to do more exploration into what these foci are by investigating other potential 
co-localising proteins, but I chose to prioritise developing and characterising the mouse 
model, results from which could then be used to guide such study in a more targeted manner. 
As these immunofluorescence results were obtained using overexpression vectors, there are 
several caveats and they should not be accepted unconditionally. The proteins are not being 
expressed at endogenous levels or under endogenous control; the ORF does not include the 
UTRs, and the C11ORF93 plasmid does not contain the complete cDNA sequence of the 
longer two transcripts; there is a Myc-DDK tag on the C-terminus; and the cells are under 
stress from the transfection and forced overexpression. Additionally, as the tag is not 
fluorescent, I had to use antibodies to visualise it. While the anti-DDK antibody looks highly 




It is encouraging that I am not seeing the same pattern with C11ORF53-DDK and C11ORF93-
DDK, as it suggests the results seen are not purely an artefact of the plasmid, tag or antibody. 
However, as the plasmids carry tagged versions of two different proteins they may not show 
the same artefacts. The co-localisation of C11ORF53 and calnexin is supported by previous 
data from Claire Smillie suggesting a link between the C11orf genes and the ER, and while 
this does not rule out that the observed activity is being influenced by the artificial nature of 
the system, it does give supporting evidence that we can have confidence in it. 
Given the limitations of an artificial overexpression system, endogenous tags would be highly 
useful. It is unfortunate that so far we have not successfully produced a mouse line with 
fluorescently tagged proteins, due to the very low survival of embryos that received the 
injection of the CRISPR mix. 
We did not carry out any experiments to determine the cause of the developmental block 
that was observed in the injected embryos. However, the Shroom2-mCherry mouse line was 
successfully generated in tandem to the failed C11orf-tag lines. We can exclude the physical 
microinjection, due to the survival of both the Shroom2-mCherry line and other procedures 
carried out by the transgenic service during this period. Within the injection mixes from the 
two experiments, the Cas9 mRNA was aliquoted from the same batch, the gRNAs were 
purchased at the same time, and the repair templates were prepared in parallel. We can 
therefore assume the chemical composition between the two experiments is comparable, 
with the exception that as two proteins were being targeted in the C11orf-tag experiment 
there was a higher concentration of nucleic acids than in the Shroom2 experiment. 
It is therefore likely that the developmental block observed in the C11orf-tag embryos is a 
genetic effect caused by the action of Cas9, rather than a chemical effect of the injection mix. 
The aim of this experiment was not to alter the function of the genes, but simply to add C-
terminal fluorescent tags. It is possible that there were more substantial effects on C11orf53 
and C11orf93 than intended. However, we can compare these results to the use of CRISPR to 
create a knockout mouse line (see chapter 5). Such massive developmental defects have not 
been observed in that complete knockout line, either during its creation or in subsequent 
generations, which suggests that in addition to any disruption that may have occurred to the 
targeted genes, the gRNAs used here have significant off-target effects. 
As localisation of proteins can give key insights into their function, continued study to obtain 
more data into C11ORF53 and C11ORF93 localisation would be of great use in understanding 
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their role in CRC. Further use of the DDK-tagged plasmids, a new CRISPR experiment to add 
fluorescent tags using redesigned gRNAs, or trying to raise different antibodies to the 
proteins are all potential avenues for future work.  
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Chapter 4: Investigation of Gene Function through mRNA 
Localisation          
4.1 Introduction 
To investigate the function of the C11orf genes, and so hopefully elucidate some aspect of 
their cellular role, I examined the localisation of their mRNA within the intestine. For 
C11orf92, with no known protein, this is the only gene product that can be studied. C11orf53 
and C11orf93 do produce proteins, but with all tested antibodies showing too much non-
specific binding to be used in localisation studies, and no success with endogenous tags, 
mRNA was the only option available for viewing patterns of gene activity within colonic 
tissue. 
mRNA is not interchangeable with protein, as levels of one do not necessarily reflect levels 
of the other, and the location of a protein itself within the individual cells can be significant. 
However, mRNA localisation is both a useful tool in its own right and a particularly valuable 
source of data when protein-based information is difficult to obtain. Within a complex organ 
such as the intestine, there are many cell types of different function, and these can be 
identified by their transcription profile (Grün et al., 2015). Any information we can gather 
into which cell types express our genes of interest can aid our understanding of how 
alteration in their expression can lead to CRC. 
The expression patterns of the three genes were assessed using RNAscope on formalin-fixed 
paraffin-embedded (FFPE) colonic tissue from human CRC patients, wild type (WT) mice and 
ApcMin/+ mice. The ApcMin/+ mouse line (Adenomatous polyposis coliMultiple intestinal neoplasia/+) 
carries a mutation which makes them highly susceptible to the spontaneous formation of 
intestinal adenomas, and is used as a model of human familial adenomatous polyposis (FAP) 
(Su et al., 1992). The mouse tissue was freshly harvested and fixed in 10% neutral buffered 
formalin (NBF) by myself and Vidya Rajasekaran, and processed and paraffin-embedded by 
the University of Edinburgh Division of Pathology at the Western General Hospital. Our Swiss 
roll technique of intestinal tissue preparation allows the entirety of both small and large 
intestine from a mouse to be treated and viewed on a single slide, so I was able to collect 
data along the whole length of the intestine. Human tissue was obtained from ten patients 
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who were undergoing surgery at Western General Hospital and consented to their tissue 




4.2 Utilisation of RNAscope to detect transcripts 
4.2.1 Methods 
RNAscope is an in situ hybridisation technique to visualise mRNA molecules, utilising a 
“double Z” probe pair design (figure 4.1). Both probes within a pair must bind exactly 
adjacent to provide the foundation for subsequent amplification, giving the technique high 
specificity. A pool of approximately 20 probe pairs is designed across the transcript and a 
signal can be detected as long as any three pairs correctly bind, giving high sensitivity even if 
some regions of the sequence have degraded or are inaccessible due to bound proteins. 
Following the multiple amplification steps, a single mRNA molecule can be visualised as a dot 
using a light microscope. 
As the technique can be applied to FFPE tissue, the mRNA can be visualised and quantified 
within the tissue context. This offers a huge advantage over other quantitative techniques 
such as qRT-PCR analysis, which require destroying the tissue to extract the mRNA. In 
addition to expression patterns within regions of tissue, it is possible to accurately distinguish 
tissue types and quantify the expression within each individually, such as between crypt 
epithelium, lymphoid tissue, and underlying muscularis (figure 4.2). By comparison, in mRNA 
extraction techniques, while an effort can be made to only process stripped mucosa, it is far 
more difficult to be confident in having a pure cell population. 
RNAscope was carried out on FFPE sections of human, WT mouse and ApcMin/+ mouse tissue. 
Following the in situ hybridisation, slides were scanned using the NanoZoomer slide scanner 
from Hamamatsu, which allows the entire slide to be captured in one large high-resolution 
file, and the tissue examined. While there are options for automating dot counting, such as 
by Definiens or Image J, we did not have much success applying these to our images as we 
had great difficulty setting the parameters to achieve the correct sensitivity. This was further 
complicated by the way that probe pools for different genes can give dots of subtly different 
appearance; for example, C11orf92 dots tend to be larger and have less defined edges than 
C11orf93 dots, which are quite small and sharp. Additionally, the NanoZoomer obtains its 
large images as a series of smaller tiles, and the extent to which each of these is in focus can 
vary across a slide. 
I therefore carried out manual counting on all of my slides. While I will not be 100% accurate 
in my signal identification, by having a clear definition of what I consider a dot I was able to 
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have internal consistency. This was verified by taking a subset of human patient normal 
mucosa and recounting all of their crypts for each gene several months after the initial count 
(figure 4.3). I was also able to be very precise in my delineation of the tissue regions of 
interest, to only count the desired cell types. 
Across the tissues – human, WT mouse and ApcMin/+ mouse – I counted the amount of signal 
for each C11orf gene in the intestinal crypts. I only counted properly sectioned crypts, 
meaning those where the whole length of the crypt was clearly visible (figure 4.4). Crypts 
were selected at a magnification where I could determine if a crypt was sectioned correctly 
but not visualise any RNAscope signal, to avoid bias in my crypt selection, before then using 
a higher magnification to perform the counts. To be able to quantify the distribution of 
transcripts within crypts, I split each crypt into thirds. This was not based on any biological 




Figure 4.1: Schematic of RNAscope workflow. Fixed cells or tissue sections are permeabilised and probes are hybridised to mRNA. Both probes in the 
“double Z” pair must bind exactly next to each other to provide the base for amplification. A series of amplification steps allows a high amount of label 




Figure 4.2: Section of fixed Swiss-rolled mouse large intestine, stained with haematoxylin and 
eosin (H&E). It is possible to distinguish the mucosal epithelium, the underlying muscularis 




Figure 4.3: Comparison of initial count and recount for individual crypts within three human 
patients. I performed RNAscope on 10 human colon tissue samples for C11orf53, C11orf92 
and C11orf93, and counted the signal for each gene in each colonic crypt. Crypts were 
numbered so that each datapoint could be attached to a specific crypt on the slides. Three 
patients were randomly selected several months later and I recounted all of the RNAscope 
signal for each gene without reference to my original counts.  I then compared the first and 
second counts. R2 values are included for each gene, showing internal consistency in my 
identification and counting of RNAscope signals. The data shown is the total pooled results 
from across all three recounted patients.  
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Figure 4.4: A section of WT mouse large intestine probed for C11orf93, showing (a) a properly 
sectioned crypt suitable for counting, and (b-d) improperly sectioned crypts that would not 





4.2.2.1 Expression patterns in normal intestinal mucosa 
C11orf53 has the most distinct pattern of expression, occurring in compact clusters of 
transcripts with very little signal in between (figure 4.5a). C11orf92 and C11orf93 have more 
diffuse expression of individual dots (figure 4.5b, 4.5c). All three genes show highest 
expression towards the base of the crypt (figure 4.6). These patterns are consistent across 
human, WT mouse and Apcmin/+ mouse large intestine tissue. C11orf93 has the highest 
expression in all three sample types, but in mice C11orf53 and C11orf92 have similar levels 
of expression, while in humans C11orf92 is much higher than C11orf53. C11orf53 is also more 
basal in humans than in mice, but C11orf93 is less basal. 
While I did not have any human small intestine tissue, I did analyse the crypts and the villi in 
WT and ApcMin/+mouse small intestine, split into proximal and distal (figure 4.7a). As with the 
division of the crypts and villi into tertiles, this separation is based on a physical split rather 
than any biological marker; during collection and processing it is necessary to cut the small 
intestine into two lengths. In both proximal small intestine (PSI) and distal small intestine 
(DSI) C11orf53 has particularly high expression in the villi, while C11orf93 has the highest 
expression in the crypts. Comparing WT and ApcMin/+, C11orf53 is significantly lower in PSI 
crypts and villi and DSI crypts on the ApcMin/+ background compared with WT. C11orf92 is 
significantly lower in ApcMin/+ PSI crypts but significantly higher in DSI crypts. C11orf93 is 
significantly higher in all of the ApcMin/+ SI crypts and villi, but not in the large intestine (LI) 
crypts. 
I also compared the distribution of transcripts in the crypt and villi tertiles between WT and 
ApcMin/+ (figure 4.7b). The region with the most difference is PSI crypts, where all three genes 
have significant changes in distribution: C11orf53 has a reduction in expression in the top of 
the crypt and an increase in the middle, while C11orf92 has a reduction in the base with 
increase in the middle and C11orf93 has reduction in the base with increase in both the 
middle and top thirds. There are also significant differences with C11orf53 in the PSI villi and 
C11orf92 in the DSI crypts, in both cases with lower expression in the base tertile. 
In addition to the crypts themselves, I counted the signal in the underlying muscularis and in 
patches of lymphoid tissue in the mice (figure 4.8). In the muscularis, which was measured in 
500µm strips, C11orf93 has the highest expression and C11orf53 has the lowest expression. 
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However, C11orf93 is significantly lower on the ApcMin/+ background compared to WT, while 
C11orf53 is significantly higher. C11orf92 has much higher expression than the other two 
genes in lymphoid tissue, which was measured in 3000µm2 regions. C11orf53 and C11orf92 
genes show significantly higher lymphoid expression in ApcMin/+ mice compared to WT. 
The human patients had previously been genotyped for rs3802842 and rs7130173. For both 
SNPs, patients who are homozygous for the risk alleles show significantly lower expression 
than those homozygous for the non-risk allele (figure 4.9a, 4.9b), as would be expected from 
the previous expression analysis (Smillie, 2015). 
As well as the overall lower expression, risk alleles of the SNPs are associated with altered 
distribution of transcripts (figure 4.9c, 4.9d). All three genes have significantly higher 
proportions of their expression in the base third of the crypt in patients with the risk alleles. 
C11orf53 and C11orf93 have significantly lower proportions in the top third, while C11orf92 
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Figure 4.6: Mean expression of C11orf53, C11orf92 and C11orf93 as detected by RNAscope 
in LI crypts in human (n=10, mean 16.5 crypts per patient per gene), WT mouse (n=3, mean 
19.1 crypts per animal per gene) and ApcMin/+ mouse (n=3, mean 19.1 crypts per animal per 
gene), normalised to crypt length. (a) Mean total expression per LI crypt. Bars represent the 
mean of all crypts, with the mean for each human or mouse shown as an individual data 
point. (b) Mean percentage of expression in each LI crypt tertile.   
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Figure 4.7a: Mean total 
expression of C11orf53, 
C11orf92 and C11orf93 in 
WT and ApcMin/+ mice, as 
detected by RNAscope. 
n=3 animals per genotype, 
with mean 16.7 PSI crypts, 
3 PSI villi, 16.7 DSI crypts, 
3 DSI villi and 19.1 LI crypts 
per animal per gene. 
Expression normalised to 
length of crypt/villi. Bars 
represent the mean of all 
crypts/villi, with the mean 
for each animal shown as 
an individual data point. 
Data was a mix of normally 
and not-normally 
distributed according Shapiro-Wilk normality test, and so was compared using two-tailed Mann Whitney U test or student’s t test as appropriate. 
Significant differences are indicated by stars. 
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Figure 4.7b: Mean 
percentage of 
expression of C11orf53, 
C11orf92 and C11orf93 
in each crypt or villus 
tertile in WT and 
ApcMin/+ mice, as 
detected by RNAscope. 
n=3 animals per 
genotype, with mean 
16.7 PSI crypts, 3 PSI 
villi, 16.7 DSI crypts, 3 
DSI villi and 19.1 LI 
crypts per animal per 




normality test, and so 
was compared using two-tailed Mann Whitney U test or student’s t test as appropriate. Significant differences are indicated by stars. 
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Figure 4.8: Mean expression of C11orf52, C11orf92 and C11orf93 in WT and ApcMin/+ mice as 
detected by RNAscope per (a) 500μm large intestine muscularis propria, n=3 animals per 
genotype, mean 10 sections of muscularis propria per animal; (b) 3000μm2 large intestine 
lymphoid tissue, n=3 animals per genotype, mean 2.7 sections of lymphoid tissue per animal. 
Bars represent the mean of all sections, with the mean for each animal shown as an individual 
data point. Data was a mix of normally and not-normally distributed according to Shapiro-
Wilk normality test, and so was compared using two-tailed Mann-Whitney U test or student’s 
t test as appropriate. Significant differences are indicated by stars.   
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Figure 4.9: Differences in expression between SNP genotypes as detected by RNAscope. (a) 
Mean total signal per LI crypt by risk alleles of tagging SNP rs3802842. For 0 risk alleles, n=5, 
with mean 15.3 crypts per patient per gene. For 2 risk alleles, n=4, with mean 18.1 crypts per 
patient per gene. (b) Mean total signal per LI crypt by risk alleles of probable causal SNP 
rs7130173. For 0 risk alleles, n=5, with mean 15.3 crypts per patient per gene. For 2 risk 
alleles, n=5, with mean 17.9 crypts per patient per gene. (c) Mean RNAscope signal 
distribution between LI crypt tertiles by risk alleles of rs3802842, using same data as (a). (d) 
Mean RNAscope signal distribution between LI crypt tertiles by risk alleles of rs7130173, 
using same data as (b). Bars represent the mean of all sections, with the mean for each 
patient shown as an individual data point. Data was a mix of normally and not-normally 
distributed according to Shapiro-Wilk normality test, and so was compared using two-tailed 





4.2.2.2 Expression patterns in intestinal polyps and tumours 
The crypts analysed in the ApcMin/+ mice and human patients were all from normal mucosa, 
despite the presence of growths in their intestines. In the humans, the normal mucosa was 
sourced from a separate site than that of the tumour, and in the mice I made sure to leave a 
“buffer” of ~5 crypts either side of the visible edges of polyps. 
However, I examined the mouse polyps separately. The architecture is greatly disrupted so 
crypts are no longer useful structures for counting. Instead, I split the polyps into strips of set 
dimensions, 200x50µm, starting at the base of the epithelium and progressing into the polyp 
(figure 4.10). There is no pattern of expression either increasing or decreasing with polyp 
depth. There is also much variation between different polyps. Basic expression patterns seen 
in normal mucosa are maintained in polyps: C11orf93 has the highest expression and 
C11orf53 the lowest, and C11orf53 occurs in clusters while C11orf92 and C11orf93 are 
diffuse. 
This conservation of transcript distribution is also seen in human tumours. Patients that have 
low expression in normal mucosa have minimal expression in tumours, even lower than in 
normal mucosa, while those with high expression in normal mucosa have similar or higher 




Figure 4.10: (a) ApcMin/+ polyp 
that has been probed for 
C11orf93 and split into 
sections 200x50µm, beginning 
with the base of the crypts at 
the submucosa and extending 
into the polyp. Image taken at 
333X. (b) Position of the 
sections within the whole 
polyp. Image taken at 72X. (c) 
Mean expression of C11orf 
genes in each strip of polyp, as 
shown in (a) and (b), with 
increasing distance from the 
base of the crypts. There is no 
pattern of increase or 
decrease in gene expression 
with increased distance into 
the polyp. Data shown is from 




4.2.2.3 Comparison with qRT-PCR and HT12 microarray results 
When the human patients were undergoing surgery and tissue collection, in addition to the 
normal mucosa sections that were processed into FFPE blocks, mRNA was also extracted 
from fresh tissue. Expression analysis was carried out by Claire Smillie and Li-Yin Ooi (Ooi, 
2016; Smillie, 2015).  Patients were classified as either “high expressors” or “low expressors” 
based on qRT-PCR results. Illumina HT12 microarrays were also run on the patients. My ten 
patient samples comprised five high expressors and five low expressors, selected for me by 
another member of the group who could see their expressor status, while I was blinded to 
this information. Following RNAscope data collection on these patients, I then tried to 
identify the two groups of five. I was able to correctly assign eight of the ten patients (figure 
4.11).  
All ten patients had qRT-PCR results and eight also had HT12 microarray results. Once I was 
unblinded and given access to this data, I plotted each patient’s mean RNAscope score 
against their qRT-PCR score, and HT12 microarray score if available (figure 4.12).  
The correlation between RNAscope and these other RNA-based techniques is not very high. 
One reason for this weak correlation may be the nature of the probes for each technique 
(figure 4.13). RNAscope uses a pool of ~20 probe pairs across a wide region of the transcript, 
and only requires three to bind to give a signal. This is to ensure a signal can still be obtained 
even if sections of the molecule are degraded or concealed by bound proteins. qRT-PCR and 
HT12 microarrays use a single probe, or pair of probes, so if this section of sequence is 
damaged no product can be generated. The extent to which this may occur will vary between 
samples and genes, giving the lower correlation. 
Another reason might be due to cell types present in the source of the expression data. As 
RNAscope is performed on fixed tissue and the signal assessed within the tissue context, it is 
possible to be very exacting in only counting transcripts within the mucosal layer, and 
excluding anything in the muscularis or other tissue type. The RNA used for qRT-PCR and 
HT12 analyses was extracted from stripped mucosa, and was shown to be enriched for 
epithelial markers, but the samples will still not have been a completely pure mucosal 
population. 
C11orf53 has particularly poor correlation between RNAscope and qRT-PCR. It is possible 
that, because the signal clusters, I undercount higher expression due to not being able to 
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fully distinguish transcripts when they are at high density. C11orf53 has the highest 
correlation between HT12 microarray and RNAscope, but this is primarily driven by a single 




Figure 4.11: Mean RNAscope 
expression of each C11orf gene 
per LI crypt in 10 patients. Bars 
represent the mean of all 
crypts, with each crypt shown 
as an individual data point. 
Letter underneath the CR 
number indicates whether 
they were designated a high 
(H) or low (L) expressor, based 
on their qRT-PCR results. 
Asterisks mark patients I was 
not able to correctly identify as 
such from their RNAscope 
results. Misidentification of 
patient CR75 was primarily due 
to their C11orf92 expression, 
as their results for C11orf53 and C11orf93 are consistent with other low expressors. Patient CR204 also has C11orf92 expression that appears out of 
proportion with their C11orf93 result and their classification of being a high expressor; as there is little variation between C11orf53 expression between 
high and low expressors, this patient’s classification of high for the locus as a whole may be being driven purely by their high C11orf93 expression
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Figure 4.12: (a) Mean RNAscope signal for C11orf53, C11orf92 and C11orf93 per large 
intestine crypt for 10 patients plotted against their qRT-PCR value for each gene, which was 
generated from RNA extracted from stripped mucosal tissue. Trendlines and R2 values are 
included. (b) Mean RNAscope signal for C11orf53, C11orf92 and C11orf93 per large intestine 
crypt for 8 patients plotted against their Illumina HT12 microarray value for each gene, which 
was generated from RNA extracted from stripped mucosal tissue. Trendlines and R2 values 




Figure 4.13: Schematics of the known transcripts of C11orf53, C11orf92 and C11orf93, in 
blue, showing the locations of qRT-PCR and  HT12 probes in grey, and RNAscope probes in 
pink. While the qRT-PCR and HT12 probes detect only small regions of the mRNA, the 
RNAscope system of a pool of up to 20 probe pairs allows coverage of a much larger 
proportion of the transcript, so giving greater sensitivity in circumstances where the mRNA 




.4.2.2.4 Co-expression between C11orf genes and other markers 
As C11orf92 and C11orf93 have similar expression patterns in their distribution within the 
crypt, we checked to see if they are being co-expressed. Serial sections were cut from WT 
mouse tissue blocks and I probed alternate sections for the two genes. I then found crypts 
that were well orientated on both slides and overlaid the signal from one probe onto the 
other (figure 4.14). These overlays do not suggest the two genes are only expressed together. 
The stem cells in the intestine are located in the base of the crypts and Lgr5 is used as a key 
marker of these stem cells (Barker et al., 2007). As the C11orf genes show the highest 
expression in base of the crypt, I carried out 2-plex RNAscope on WT mouse tissue to see 
how much co-expression there is between these genes and Lgr5 (figure 4.15). While the 
genes are not exclusively expressed – there are cells that are both C11orf+ and Lgr5+ - there 
are also cells that only express one of the two. 
It is possible to couple RNAscope to an antibody-based technique, either 
immunohistochemistry or immunofluorescence. Although 2-plex RNAscope was the best 
option for Lgr5, as the antibodies available for Lgr5 are not very specific, this would be very 
useful for other markers in further investigation into which cell types do or do not express 
the C11orf genes. Unfortunately so far we have been unsuccessful at carrying this out in our 
lab – combining the pre-treatment conditions for the technique has so far resulted in either 
under-treated tissue in which the antibodies cannot access the antigens, or over-treated 




Figure 4.14: Serial sections of WT mouse LI, probed for (a) C11orf92 and (b) C11orf93. (c) The 
location of the C11orf92 signal, represented by blue circles, is overlaid onto the image of 
C11orf93 signal, seen as pink dots. The two genes show clearly different expression patterns 




Figure 4.15: Wild type mouse 
large intestine that has been 
treated with duplex 
RNAscope to visualise 
expression patterns between 
multiple genes on the same 
tissue section. Lgr5, a marker 
for intestinal stem cells, is 
detected with pink probe. (a) 
C11orf53, (b) C11orf92 and (c) 
C11orf93 are detected with 
teal probe. Signal has been 
circled to aid visualisation. 




Figure 4.16: Examples of our attempts to combine RNAscope with immunohistochemistry 
(IHC), staining for β-catenin. (a) The tissue was pre-treated using the only the conditions for 
RNAscope, proceeding directly from RNAscope amplification to antibody incubations. The 
tissue has been undertreated for IHC and the antibodies cannot access antigens, giving no 
staining. (b) The tissue was pre-treated for RNAscope, and further pre-treatment for IHC was 
performed between RNAscope amplification and antibody incubation. The tissue has been 
overtreated, destroying structural definition. RNAscope must be performed before IHC as 
RNA is less likely to survive IHC than proteins are to survive RNAscope, in part because 





The use of in situ RNA hybridisation has allowed us to examine the expression patterns of the 
C11orf genes, despite the lack of useable antibodies. This provides a range of new 
information on their activity, some of which lends support to previous conclusions and some 
of which allows novel ideas to be developed. 
It is clear, from looking at all of the expression data gathered from across these tissues, that 
C11orf53, C11orf92 and C11orf93 each have their own distinct expression pattern. This 
further supports the view that this locus is in fact three separate genes, rather than a single 
open reading frame called FLJ45803, as was once thought. 
It is also clear that these genes show consistent patterns across human and mouse. The genes 
have different degrees of conservation between the two species – C11orf53 is 83% 
conserved, C11orf92 is 50% conserved and C11orf93 is 65% conserved. As we have made 
extensive use of mouse models in the study of these genes, it is reassuring to have this 
confirmation that their behaviour, beyond the gene sequences, is conserved between 
species. It is also interesting to note that the gene with the lowest sequence conservation, 
C11orf92, has the highest similarity in transcript level and distribution between human and 
mouse. 
C11orf53’s pattern of expression strongly suggests it is being expressed in a specific cell type. 
There is little overlap between C11orf53+ cells and Lgr5+ cells, but some cells expressing both 
C11orf53 and Lgr5 have been observed, indicating that C11orf53 is primarily expressed in 
differentiated cells rather than stem cells, but it is not exclusive to differentiated cells. 
Likewise, they are in the wrong place to be Paneth cells, also found in the base with the stem 
cells (Sato et al., 2011). They lack the distinctive “goblet” shape which gives goblet cells their 
name, caused by apical accumulation of secretory granules (Specian and Oliver, 1991). Other 
possible cell types include tuft cells and enteroendocrine cells. Being secretory, both these 
cell types must have extensive endoplasmic reticulum activity to process all the peptides to 
be secreted. 
The overexpression immunofluorescence data showed that C11ORF53-DDK co-localises with 
calnexin, an endoplasmic reticulum protein (see chapter 3 for immunofluorescence data); 
furthermore, the pattern of C11orf53 transcripts within the cells does itself somewhat 
resemble the endoplasmic reticulum. It is therefore reasonable to suggest that C11orf53+ 
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cells are some form of secretory cell, although determining which one, or ones, will require 
more investigation into co-expression with type-specific markers such as Dclk1 for tuft cells 
(Gerbe et al., 2012) and Cldn4 for enteroendocrine cells (Nagatake et al., 2014). 
By contrast, C11orf92 and C11orf93 do not appear to be cell type-specific, being expressed 
across a higher number of cells along the length of the crypts. While the Lgr5 2-plex shows 
that these genes are not solely expressed in the stem cells, they do show higher expression 
in the region of the crypt where the stem cells are found, and this proportion increases both 
in ApcMin/+ mice compared to WT mice, and in humans with more risk alleles of the identified 
risk SNPs rs3802842 and rs7130173, despite the accompanying overall reduction in 
expression level. This may suggest that, although they do have functions elsewhere in the 
colonic tissue, it is their activity in the stem cell region that gives their link to cancer initiation. 
Since these genes are thought to be tumour suppressors, it might be anticipated that they 
would show reduced expression in the ApcMin/+ model of tumourigenesis compared to WT, 
but there is no consistent pattern of this. C11orf53 is lower throughout the intestines, but 
C11orf93 is higher in the SI and C11orf92 is higher in both DSI and LI. 
This is unexpected, but not concerning. All of the eQTL data suggesting these genes are 
tumour suppressors was based on the LI, and they have not been implicated in the risk of any 
other types of cancer, including small intestinal, so we should not expect them to act as 
tumour suppressors in the SI. Additionally, the original GWAS and subsequent expression 
analysis were performed on patients with sporadic cancers, rather than FAP, which is the 
type of CRC the ApcMin/+ mouse models. It has been shown that the tagging SNP rs3802842 
does not affect colonic polyposis in FAP patients as it does in non-FAP patients (Cheng et al., 
2015). This could be because the effect of the Apc mutation is so powerful it overwhelms the 
impact of lower-effect risk genes, but it could also be because these genes do not have the 
same tumour suppressor activity in the context of FAP and significant Apc disruption. 
Whether or not it implies a loss of tumour suppressor function on the ApcMin/+ background, 
the many statistically significant differences between WT and ApcMin/+ mice, with regard to 
both transcript level and transcript distribution, suggests some level of interaction between 
the Wnt pathway in which Apc acts (Sansom et al., 2004) and the as-yet-unknown C11orf 
pathway. As the Wnt pathway, and Apc in particular, have strong established involvement 




Chapter 5: Creation and Characterisation of Knockout Mouse 
Models           
5.1 Introduction 
Mouse models have long been established as a key tool to study biological systems. Their 
similarities to humans, on a genetic and physiological level, make them good representations 
of the human system. Of course, we must always remember they are models and do not 
completely represent human biology; in addition to the interspecies differences, the highly 
homogenous genetic background and closely regulated environments of laboratory mice are 
not representative of human populations. Nevertheless, mouse models have contributed to 
many important insights. 
They are of particular use in GI research, as their digestive systems are far more similar to 
ours than other common models such as C. elegans, Drosophila or zebrafish. With respect to 
the 11q23.1 locus, only placental mammals have orthologues of all three genes, which of 
course limits the models that can be used. Additionally, as mice are an established CRC 
model, there are many research tools available, such as well-characterised colon-specific 
carcinogens and CRC-susceptible genetic backgrounds. While larger animal models can be a 
closer match in terms of their digestives systems, mice also have the benefit of their size and 
lifespan making them a more economical model than pigs or primates. 
The equivalent of the 11q23.1 locus in mice contains orthologues of all three genes, with 
sequence conservation ranging 56-82%. As shown by my RNAscope results in chapter 4, the 
pattern of gene expression within colorectal tissue is consistent between human and mouse. 
I therefore created a knockout mouse model to provide information on the C11orf genes’ 
functions by observing the effect of their loss on a complete organism. I used CRISPR/Cas9 to 
generate a 20kb deletion spanning the 3’ end of C11orf53, all of C11orf92 and the 5’ end of 
C11orf93. I focused on studying this triple deletion, but future work on models with only a 
single gene knockout is planned. 
I investigated the model’s CRC risk both by allowing the mice to age, and by using genetic 
and chemical means of tumour induction. We also used various techniques to assess the 
mice, including blood counts, intestinal expression analysis, and immunohistochemistry (IHC) 
on intestinal tissue. Additional data came from observations on the breeding and survival of 
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the line. Since this is a novel model and the function of the genes is unknown, we took a 
broad approach to studying the animals, such as using a basic panel of intestinal markers for 
IHC. As we gather more data and improve our understanding of the genes’ functions, we can 




5.2 Generation of the C11orf mouse models 
5.2.1 Methods 
I used the CRISPR/Cas9 system to create mutations in C57BL/6J mouse embryos. This strain 
was chosen because the group’s existing mouse models were also C57BL/6J and we wanted 
a consistent genetic background for any future crosses between lines. An injection mix of 
gRNAs and Cas9 mRNA was injected into embryos by Emma Allen at the transgenic service. 
No repair template was used, as I did not aim to create specific mutations using homology-
directed repair, but to induce random indels via non-homologous end joining. 
As it was not known to what extent, if at all, each of the three genes of the locus is 
contributing to CRC risk, we decided to begin by disrupting all three. Due to the close 
proximity of the genes we could not rely on recombination to generate a compound mutant 
from separately-created lines. I therefore included a gRNA for each gene in a single injection 
mix, with the aim of inducing an indel into each gene. We also hoped that, since CRISPR is 
not 100% efficient, I would also generate single and double gene knockout mutations 
alongside the triple gene knockout. If the triple gene knockout displayed an altered 
phenotype we could then proceed with analysing individual gene knockouts. 
I designed gRNAs to target exonic regions of C11orf53 and C11orf93 approximately one third 
into the coding sequence (figure 5.1a), with the intention that this was far enough into the 
gene that it would not be skipped by a late alternative start site, but with enough sequence 
remaining that a frameshift mutation would have a significant impact. I also ensured the 
exons targeted were common to all transcripts. For C11orf92, this restricted the target region 
to a single small exon which forms the entirety of one transcript, but which is within a larger 
exonic region in the other transcript. gRNA sequences were designed using the online CRISPR 
design tool from the Zhang lab at MIT (www.crispr.mit.edu (Hsu et al., 2013)). 
I designed genotyping primers approximately 400bp either side of the each gRNA target site, 
to allow sequencing across any indels while being far enough away to avoid disruption of the 




Figure 5.1: The region of mouse chromosome 9 containing the orthologues of C11orf53, C11orf92 and C11orf93. (a) The sites targeted by gRNAs to 
generate knockouts by CRISPR are highlighted with green arrows. Positions of genotyping primers are illustrated with grey arrows (not to scale). (b) The 
C11orf-/- mouse line has a deletion covering 20kb, represented in green. Use of the outer two primers gives a product of 800bp when the deletion is 




Following the microinjection session and subsequent transfer of embryos into pseudo-
pregnant females, 22 pups were born, of which 20 survived to 16 days for genotyping. I 
performed PCR using the three genotyping primer pairs. Only 11 of the mice had a product 
for all three genes, with four giving two products, three giving one product, and two mice 
having no PCR products for any primer pair. I used additional primers within GAPDH to 
confirm the DNA extractions had been successful. 
I was able to complete genotyping of the mice by recombining primer pairs. The size of the 
products indicated large sections of sequence, spanning the distance between gRNA target 
sites, had been removed (figure 5.1b); this was confirmed by sequencing. Mutation results 
are summarised in table 5.1. While C11orf53 and C11orf92 show similar mutation 
frequencies, C11orf93 was less frequently altered. This may mean that disruptions of this 
gene are less tolerated than the other two genes. Alternatively, it may be that the gRNA for 
this gene was not as efficient as the other two gRNAs, although the score assigned to each 
gRNA sequence by the Zhang lab online tool ranked the C11orf93 gRNA above the C11orf92 
gRNA. As C11orf92 is believed to be non-coding, it is much more difficult to predict if a small 
indel will have any impact on gene function, compared to the induction of a premature stop 
codon or a frameshift in a protein-coding gene; this is why the proportion of disruptive 
mutations in lower for this gene. 
I chose three independent mutations to take forward and study. All three had 20kb of 
sequence lost, splicing exon 5 of C11orf53 onto exon 4 of C11orf93 and completely removing 
C11orf92, and as such totally disrupting all three genes. The other mutations were 
cryopreserved. In addition to sequencing, mRNA-seq expression analysis (discussed below) 
shows complete loss of transcripts for the three deleted genes in the homozygous knockout, 
with an intermediate level of expression in the heterozygote (figure 5.2a-5.2c). The exception 
is C11orf93 in the proximal small intestine, which shows unaltered expression. As the 
downstream section of this gene is still present, spliced to the upstream section of C11orf53, 
it is possible that the splice gene is still being transcribed, particularly since C11orf53 
ordinarily has high expression in this tissue. There is not a corresponding peak for C11orf53 




CRISPR carries with it the potential for off-target effects. An additional 5’ G was included in 
the gRNAs to reduce these (Cho et al., 2014), but this does not guarantee their absence. We 
have not carried out whole genome sequencing to confirm that there are no such mutations. 
However, the three independent triple knockout lines all exhibit the same phenotype, and 
the phenotype continues to segregate with the C11orf mutation after six generations. I am 
therefore confident that the observed phenotype is due to the loss of the target locus. mRNA-
seq expression analysis of the closest gene, Pou2af1, around 30kb away, shows no loss of 
expression and so the deletion is contained to the region of interest (figure 5.2d). 
I subsequently re-derived a line carrying an 11bp deletion in C11orf53, which creates a 
premature stop codon after 20 amino acids, to examine the loss of C11orf53 alone. This line 
is still in its early stages so only some data is available for this mutation. None of the mice 
resulting from my CRISPR experiment carried a lone C11orf93 mutation, but a knockout line 
has been generated by the International Mouse Phenotyping Consortium (IMPC). Due to a 
husbandry error we have not as yet been able to establish the line in our unit for our own 
study but where applicable reference will be made to publically available IMPC data, which 




Gene Mutations Disruptive mutations 
C11orf53 32/40 29/32 
C11orf92 31/40 21/31 
C11orf93 11/40 10/11 
Table 5.1: Frequency of mutations of each gene in the mice resulting from the initial CRISPR 
injection, based on 40 copies of each gene across 20 pups, and the number of those 
mutations that can be reasonably expected to disrupt the gene by introducing a frameshift 
mutation or an early stop codon. 
Figure 5.2: Normalised counts of mRNA-seq expression data across proximal small intestine, 
distal small intestine, proximal large intestine, distal large intestine, and the rectum/anus for 
(a) C11orf53, (b) C11orf92, (c) C11orf93 and (d) Pou2af1, the next nearest gene to the deleted 
locus. The C11orf-/- mice show large reduction in their expression of C11orf53, C11orf92 and 
C11orf93 compared to C11orf+/+, with an intermediate reduction in C11orf+/-. Pou2af1 
expression is largely unchanged between the three genotypes.  
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Figure 5.3: All traits measured in the C11orf93 knockout line generated by the IMPC, with the 




5.3 Maintenance of the lines 
5.3.1 Methods 
Mice were housed in individually ventilated cages (IVCs) with group sizes and enrichment 
according to Home Office regulations. The cage room was kept at 21-23°C with a 12-hours-
on, 12-hours-off light cycle all year. The unit has a pathogen health status rating of 4. Mice 
were given the RM3 diet (Special Diets Services) in pellet form, a high nutrient diet containing 
fatty acids, with constant access to both food and water. Pups were earclipped for 





Male C11orf-/- mice are infertile. This was demonstrated by caging two C11orf-/- males with 
three females each, all animals being of breeding age, for three months with no pups 
resulting. The IMPC lists infertility in male C11orf93 homozygous knockouts. No fertility 
issues have been observed in females of any genotype. 
Genotype frequencies in the C11orf knockout line do not fit what would be expected from 
Medelian ratios. In the pups resulting from C11orf+/- x C11orf+/- pairings, there is a significant 
decrease in the incidence of homozygote mutants, implying a developmental issue resulting 
from being C11orf null that reduces viability (table 5.2a). There is also a significant increase 
in heterozygote incidence, suggesting some form of heterozygote advantage. C11orf+/+ x 
C11orf+/- matings show an increase in heterozygote incidence from expected, although it is 
not significant (table 5.2b). C11orf+/- x C11orf-/- matings show a significant decrease in 
homozygote incidence (table 5.2c). 
By comparison, the C11orf53 mutant line do not show deviations from the expected 
genotype frequencies (table 5.2d). IMPC data shows the genotype ratios in the C11orf93 line 
are as expected. No differences in sex distribution have been observed in any genotypes. 
As part of our tumour induction studies, discussed below, I crossed the C11orf knockout line 
onto the ApcMin background. This mouse strain carries a homozygous-lethal nonsense 
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mutation in the Wnt antagonist Apc, causing constitutive activation of the Wnt signalling 
pathway and leading to spontaneous intestinal adenoma formation. Crossing onto this 
background can be used to accelerate tumourigenesis (Su et al., 1992). The differences 
between the expected and observed ratios of genotypes becomes more pronounced when 
at least one parent carries the ApcMin mutation, compared to both parents being Apc wild 
type (table 5.3). While the C11orf-/- and ApcMin/+ mutations are not entirely incompatible – I 
have had one C11orf-/- ApcMin/+ mouse – these results do suggest an interaction between the 
two pathways that reduces viability beyond the two mutations alone. 
To investigate at what point the homozygotes are being lost, I collected embryos at E14.5 
from C11orf+/- Apc+/+ females mated with C11orf+/- ApcMin/+ males. Embryos were fixed and 
whole mounted, with the yolk sacs being used for genotyping. There was no significant 
deviation in genotype frequencies from expected (table 5.4). All embryos were still alive at 
the point of collection. Histology does not show any developmental defects in any of the 
embryos and there was no difference in size between the genotypes. 
As embryos at E14.5 are too big to be reabsorbed, all homozygotes still present after this 
point are being born, but we do not know if they are alive at birth. The litter size, as counted 
by the technicians, does not change, meaning all pups present when the litter is first counted 
are still alive when genotyping samples are taken at day 14; however, there can be several 
hours between a litter being born and being counted during which a mother can eat pups. 
Recording the cages with a night-vision camera could be used to determine if the pups are 





5.2a) C11orf+/- x C11orf+/- matings – 261 pups 
Genotype 
Expected Observed 
Ratio Number Ratio Number 
C11orf+/+ 1 65.25 1 67 
C11orf+/- 2 130.5 2.46 165**** 
C11orf-/- 1 65.25 0.43 29**** 
5.2b) C11orf+/+ x C11orf+/- matings – 28 pups 
Genotype 
Expected Observed 
Ratio Number Ratio Number 
C11orf+/+ 1 14 1 11 
C11orf+/- 1 14 1.55 17 
5.2c) C11orf+/- x C11orf-/- matings – 15 pups 
Genotype 
Expected Observed 
Ratio Number Ratio Number 
C11orf+/- 1 7.5 1 12* 
C11orf-/- 1 7.5 0.25 3* 
5.2d) C11orf53+/- x C11orf53+/- matings – 25 pups 
Genotype 
Expected Observed 
Ratio Number Ratio Number 
C11orf53+/+ 1 6.25 1 7 
C11orf53+/- 2 12.5 1.71 12 
C11orf53-/- 1 6.25 0.86 6 
Table 5.2: Expected and observed frequencies of pups resulting from matings between a) two 
C11orf heterozygous knockouts, b) C11orf wild type with C11orf heterozygous knockout, c) 
C11orf heterozygous knockout with C11orf homozygous knockout, and d) two C11orf53 
heterozygous knockouts. Significant deviations from expected, according to chi squared 
testing, have been marked. Table 5.2a contains both Apc+/+ and ApcMin/+ mice; this data is split 
in table 5.3a and 5.3b. Tables 5.2b, 5.2c and 5.2d contain only Apc+/+ mice.  
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5.3a) C11orf+/-Apc+/+ x C11orf+/-Apc+/+ matings – 184 pups 
Genotype 
Expected Observed 
Ratio Number Ratio Number 
C11orf+/+ 1 46 1 49 
C11orf+/- 2 92 2.2 108* 
C11orf-/- 1 46 0.55 27** 
5.3b) C11orf+/-ApcMin/+ x C11orf+/-Apc+/+ or Min/+ matings – 77 pups 
Genotype 
Expected Observed 
Ratio Number Ratio Number 
C11orf+/+ 1 19.25 1 18 
C11orf+/- 2 38.5 3.17 57**** 
C11orf-/- 1 19.25 0.11 2**** 
Table 5.3: Expected and observed frequencies of pups resulting from matings between two 
C11orf heterozygous knockouts, as given in table 5.2a, divided between matings where (a) 
both parents were Apc+/+ and (b) at least one parent was ApcMin/+. Significant deviations from 
expected, according to chi squared testing, have been marked. 
 
 
5.4) C11orf+/-Apc+/+ x C11orf+/-ApcMin/+ matings – 20 embryos 
Genotype 
Expected Observed 
Ratio Number Ratio Number 
C11orf+/+ 1 5 1 4 
C11orf+/- 2 10 3.25 13 
C11orf-/- 1 5 0.57 3 
Table 5.4: Expected and observed frequencies of embryos collected at E14.5 resulting from 
matings between two C11orf heterozygous knockouts where the mother was Apc+/+ and the 




In addition to their reduced incidence at birth, the C11orf-/- mice display a striking failure to 
thrive, with greatly reduced survival by adulthood. All homozygous knockout mice survive to 
20 days of age, but by day 31 only 52% are still alive (figure 5.4). Those mice that die typically 
exhibit a runt phenotype. Those that do survive past one month old display no health 
problems past one year old, although on average they are smaller than their littermates 
(figure 5.5). Heterozygous knockouts do not show any survival problems. In comparison, no 
survival problems have been observed in the C11orf53 mutant line or are listed in the IMPC 
C11orf93 knockout line data, although the C11orf93 knockout mice do show significantly 
reduced body weight. 
The timing of this extreme drop in survival is highly interesting, as the mice are weaned at 21 
days. Although pups may begin to eat some solid food before this point, at 21 days they are 
removed from their mother to new cages, marking a complete transition to purely solid food 
with no milk. Access to soft mash in addition to hard pellets after weaning did not aid survival. 
There is no pattern of survival correlating to litter size, to maternal age, to maternal 
genotype, or whether it was the mother’s first litter. 
As the deaths appeared to be triggered by weaning, we tried delaying weaning from 21 days 
to 28 days. This did not improve survival, which actually decreased for this cohort to 20%. 
There was higher proportion of animals that were found partially eaten or missing entirely, 
compared with the 21 day cohort which were mostly found intact. It may be that some of the 
28 day group, while lagging behind their littermates in terms of size, would not have died 
naturally, but were instead killed by their mothers. Alternatively, it may simply be due to the 
low numbers of animals in this group. Only three litters, containing five homozygous 
knockouts, were weaned late, as once the worsened survival was observed the protocol was 
ended and all litters returned to 21 day weaning. 
The combination of reduced frequency and poor survival has severely limited the number of 
C11orf-/- mice that have been available to use. Much of the subsequent data in this chapter 




Figure 5.4: Survival curve 
for the C11orf knockout 
colony. C11orf+/+ and 
C11orf+/- mice have 100% 
survival (the wild type line 
being directly under the 
heterozygous line, and so 
not visible), while C11orf-/- 
mice have greatly reduced 
survival at both 21 day and 
28 day weaning. No 
differences were observed 
in C11orf+/+ or C11orf+/- 
mice between 21 day and 
28 day weaning and so 



















C11orf+/+ (all, n=78) C11orf+/- (all, n=194)
C11orf-/- (21 day weaning, n=27) C11orf-/- (28 day weaning, n=5)
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Figure 5.5a: Weights of C11orf+/+, C11orf+/- and C11orf-/- mice at various age points, coloured 





Figure 5.5: (b) Photograph of four-week old females, showing size difference between 
C11orf-/- (left) and C11orf+/- (right). Photo taken by Vidya Rajasekaran. (c) Photograph of 





5.4 Tumour induction 
5.4.1 Methods 
5.4.1.1 Aging 
I aged the mice beyond one year old to allow any potential age-induced phenotypes to 
develop. Mice were monitored for signs of general and intestinal discomfort, including 
lethargy, hunched gait, rectal prolapse, blood around the anus, and pale extremities (an 
indication of anaemia). I collected intestines, caecum, stomach, liver, kidneys, spleen, heart 
and lungs, which were fixed in 10% NBF and paraffin embedded. 
 
5.4.1.2 Chemical induction 
1,2-dimethylhydrazine (1,2-DMH) is a potent alkylating agent which, when administered by 
subcutaneous injection, induces colonic tumours in mice and rats by causing GA transitions 
(Fiala, 1977; Thumherr et al., 1973), with approximately two thirds of tumours having 
mutations in the K-ras proto-oncogene (Jacoby et al., 1991). 
10 week old females were given subcutaneous injections of 40mg 1,2-DMH/kg body weight. 
The DMH was diluted in EDTA and we included mice injected with EDTA only as controls. We 
culled the mice after one week and harvested tissue. I collected intestines, caecum, stomach, 
liver, kidneys, spleen, heart and lungs, which were fixed in 10% NBF and paraffin embedded. 
 
5.4.1.3 Susceptible genetic background 
The ApcMin mouse line, as previously discussed, is a model of familial adenomatous polyposis. 
As it has a very reliable development of intestinal polyps, it is frequently used to assess the 
effects of other potential CRC risk factors which alone may not be sufficient to induce CRC 
within the time constraints of a mouse model, but which can amplify the ApcMin/+ phenotype. 
I crossed the C11orf knockout line with the ApcMin line. As described above, the incidence of 
C11orf-/- mice was extremely low on the ApcMin background (table 5.4) and only one C11orf-/- 
ApcMin/+ mouse was produced. 
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Mice were monitored for symptoms of discomfort, as in the aging cohort, and culled 
accordingly; the ApcMin/+ phenotype is fatal if left to develop fully, but this was not permitted 
to happen and mice were culled when they began showing signs of distress. I collected 
intestines, caecum, stomach, liver, kidneys, spleen, heart and lungs, which were fixed in 10% 
NBF and paraffin embedded. Between fixation and embedding the intestines were stained 
with methylene blue, a dye which enters the crypts of the intestines. When the tissue is 
subsequently destained in ethanol, the dye remains in aberrant crypt foci, accentuating 




Two male homozygous knockouts were culled at 14 months of age, as they had pale 
extremities. This is a sign of anaemia, and can indicate the presence of growths in the 
intestines restricting nutrient absorption. However, no sign of any growths was present when 
I examined the tissue, with all organs appearing normal (figure 5.6-5.12). I also collected 
blood for full blood counts, which did show anaemia with low red blood cells, and low white 
blood cells (see below for full blood analysis). One female homozygous knockout has reached 
15 months of age without pale extremities. 
Heterozygotes were aged to 18 months without exhibiting any symptoms of health issues, 
and histological examination does not reveal the development of any phenotype with age. 
In total 11 male and eight female wild types, 27 male and 26 female heterozygotes, and three 




Figure 5.6: H&E sections of proximal small intestine collected at 3 weeks and 60 weeks of age, from C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was 




Figure 5.7: H&E sections of distal small intestine collected at 3 weeks and 60 weeks of age, from C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was 




Figure 5.8: H&E sections of large intestine collected at 3 weeks and 60 weeks of age, from C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was washed in 




Figure 5.9: H&E sections of stomach collected at 3 weeks and 60 weeks of age, from C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was washed in PBS 




Figure 5.10: H&E sections of caecum collected at 3 weeks and 60 weeks of age, from C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was washed in PBS 




Figure 5.11: H&E sections of spleen collected at 3 weeks and 60 weeks of age, from C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was washed in PBS and 
fixed for 24 hours in 10% NBF at room temperature before being processed and paraffin embedded. Due to the small size of C11orf-/- mice, the spleen 
was not identified at 3 weeks. Images taken at 200X. 
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5.4.2.2 Chemical induction 
We saw no tumour development in mice of any C11orf genotype. While one week is not a 
long period of time, 40mg/kg is a high dose of 1,2-DMH and one week has been sufficient to 
induce a large growth in another of our mouse models when given 40mg/kg 1,2-DMH. There 
are multiple alternative regimes for DMH-induction, some of which we would have 
performed had we had the available mice, such as weekly injections of 20mg/kg 1,2-DMH for 
five weeks with tissue collection five weeks after the final injection, or 15mg/kg injections 
weekly injections for 12 weeks. 
A further experiment which I was unable to do due to limitations of animals and time, but 
which would be a highly interesting future experiment, is to combine 1,2-DMH or its 
metabolite azoxymethane (AOM) with dextran sulphate sodium (DSS). When given in 
drinking water, DSS induces chronic inflammation, a key risk factor in CRC development 
(Kulaylat and Dayton, 2010). A study comparing the susceptibility of two mice strains to 
colitis-associated CRC, through the use of a single AOM injection followed by intermittent 
DSS administration, detected a CA-CRC susceptibility locus on mouse chromosome 9 (Van 
Der Kraak et al., 2010). While the locus, Css4, is very large at 41Mb, it does cover C11orf53, 
C11orf92 and C11orf93; Css4 is syntenic to regions on human chromosomes 11 and 15, 
including 11q23. We would therefore have liked to repeat the experiment performed in this 
study, in which a 10mg/kg AOM injection was followed by three 4-day periods of 3% DSS in 
drinking water, beginning one week after the AOM injection and with 17 days between DSS 
periods, and tissue was collected a various timepoints up to 18 weeks after the AOM 
injection. 
 
5.4.2.3 Susceptible genetic background 
There is a slight trend for heterozygous knockouts to have more SI and LI polyps than wild 
type mice, but it is not significant (figure 5.12a, 5.12b). There was no difference in the mean 
age at which the mice were culled (figure 5.12c). The single homozygote knockout had more 
LI polyps than the averages for both wild types and heterozygous knockouts, but this was still 
within the observed range for both other genotypes. This was also the youngest mouse to be 
culled, at 76 days; only four heterozygotes and one wild type were culled under 100 days. 
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ApcMin/+ mice exhibit splenomegaly, due to high splenic haematopoiesis which is thought to 
be a response to impeded differentiation of haematopoietic tissues (You et al., 2006). ApcMin/+ 
mice have lost the quiescent haematopoietic stem cell population in bone marrow (Lane et 
al., 2010) and Wnt signalling has been shown to regulate haematopoiesis (Luis et al., 2011). 
Due to this extramedullary haematopoiesis ApcMin/+ mice are not anaemic despite the 
disruption in their bone marrow (You et al., 2006). I measured the length and width of spleens 
removed from C11orf+/+ and C11orf+/- ApcMin/+ mice when they were culled for ApcMin/+ 
phenotype. While the C11orf+/- mice still had enlarged spleens compared to ApcWT mice, they 




Figure 5.12: Phenotypes of C11orf mice on the ApcMin/+ background. Bars represent the mean, 
with each animal shown as an individual datapoint. (a) Polyp counts in small intestine and (b) 
polyp counts in large intestine; (c) the age at which mice were culled due to ApcMin/+ 
phenotype; (d) the size of their spleens at death. Data was not normally distributed according 
to Shapiro-Wilk normality test, and so was compared using two-tailed Mann-Whitney U test. 




5.5 Immunohistochemical analysis 
5.5.1 Methods 
We utilised immunohistochemistry (IHC) to visualise various proteins of interest in FFPE 
intestinal tissue from mice in the C11orf knockout line. IHC was performed by Vidya 
Rajasekaran, Marion Bacou and Calum Robertson on tissue from three-week old and 11-week 
old female mice, staining with antibodies raised against Ki-67, β-catenin, cytokeratin-7 and 
Clca1 and using DAB to visualise. Tissue staining was also carried out by the Pathology 
Department using periodic acid Schiff (PAS) and alcian blue for mucins. Images presented are 
representative of the wider tissue. 
5.5.2 Results 
Ki67 is expressed in proliferating cells, being present in S, G2 and M phases but absent in G0, 
with variable expression in G1 (Gerdes et al., 1984). In healthy intestine, Ki-67 should only be 
present in the proliferating cells in the base of crypts. This is what is observed in the tissue of 
C11orf+/+, C11orf+/- and C11orf-/- mice, indicating there is no aberrant cell proliferation taking 
place outside the stem cell niche (figure 5.13). 
β-catenin is a transcription factor which stimulates transcription of Wnt-responsive genes 
(Cong et al., 2003). It is present at low levels in the cytoplasm until Wnt signalling is activated, 
which inhibits β-catenin degradation, allowing it to accumulate and translocate into the 
nucleus (figure 1.4); high β-catenin levels in the nucleus is associated with poor prognosis in 
CRC (Chen et al., 2013b). In all C11orf genotypes, β-catenin is localised to the cytoplasm 
rather than the nuclei (figure 5.14). 
Accumulation of nuclear β-catenin causes epithelial cells to lose cell-cell adhesion and cell 
polarity, and enter a dedifferentiated state (Mariadason et al., 2001; Naishiro et al., 2001). 
This epithelial-mesenchymal transition (EMT)-like change allows cancer cells to migrate and 
invade and so is key to progression (Brabletz et al., 2005). Cytokeratin-7, also called keratin-
7 or sarcolectin, is a type II keratin expressed in epithelial cells and can therefore be used to 
detect regions where EMT has taken place (Ramaekers et al., 1990). No such loss of staining 
is observed in the C11orf knockouts (figure 5.15). Conversely, there appears to be stronger 




To detect mucins, the primary components of mucus, we used PAS and alcian blue staining. 
PAS detects neutral, acid-simple non-sulphated and acid-complex sulphated mucins, while 
alcian blue detects acid-simple non-sulphated and acid-complex mesenchymal mucins 
(Pernick, 2005). Both stains show a reduction in the knockout mice indicting a reduction in 
mucins (figure 5.16, 5.17). 
Following the mucin staining results, we used an antibody for the goblet cell marker Clca1. 
Clca1 is a chloride ion channel regulator secreted at high levels in intestinal mucus to 
promote mucus expansion and aid correct mucus structure (Nyström et al., 2018). It is 
downregulated in CRC (Bustin et al., 2001; Yang et al., 2013). There is reduced staining 
between C11orf+/+ and C11orf+/- mice, with a further reduction in C11orf-/- (figure 5.18). This 




Figure 5.13: FFPE sections of intestinal tissue stained for proliferation marker Ki-67. Staining is only present in the base of the crypts, where the stem 
cell niche is located. Tissue is from three-week old C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was washed in PBS and fixed for 24 hours in 10% NBF 




Figure 5.14: FFPE sections of intestinal tissue stained for transcription factor β-catenin. Staining is present in the cytoplasm of the cells but not in the 
nuclei. Tissue is from three-week old C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was washed in PBS and fixed for 24 hours in 10% NBF at room 




Figure 5.15: FFPE sections of intestinal tissue stained for epithelial marker cytokeratin-7. Tissue is from three-week old C11orf+/+, C11orf+/- and C11orf-/- 





Figure 5.16: FFPE sections of intestinal tissue stained with periodic acid Schiff to detect neutral, acid-simple non-sulphated and acid-complex sulphated 
mucins. Tissue is from three-week old C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was washed in PBS and fixed for 24 hours in 10% NBF at room 




Figure 5.17: FFPE sections of intestinal tissue stained with alcian blue to detect acid-simple non-sulphated and acid-complex mesenchymal mucins. 
Tissue is from three-week old C11orf+/+, C11orf+/- and C11orf-/- mice. Tissue was washed in PBS and fixed for 24 hours in 10% NBF at room temperature 




Figure 5.18: FFPE sections of intestinal tissue stained for goblet cell marker Clca1. Tissue is from three-week old C11orf+/+, C11orf+/- and C11orf-/- mice. 





5.6 Genome-wide mRNA expression within intestinal tissue 
5.6.1 Methods 
I harvested and cleaned intestinal tissue from freshly-culled seven-week old female mice. I 
split the intestine into proximal small intestine (PSI), distal small intestine (DSI), proximal 
large intestine (PLI), distal large intestine (DLI) and the rectum/anus (R/A). I extracted mRNA 
using phenol-choroform extraction. This mRNA was sequenced by polyA selection using a 
NextSeq machine at 25 million paired-end reads by the Wellcome Trust Clinical Research 
Facility. The sequencing data was subsequently aligned and normalised by Alison Meynert, 
and differential expression analysis was performed by Graeme Grimes, both from the IGMM 
Bioinformatics Analysis Core. In addition to the lists of significantly altered genes, I used the 
normalised counts to look at the expression patterns of individual genes of interest. 
Due to the low numbers of C11orf-/- mice available for study, the following results are based 
on only a single mouse per genotype. For preliminary analysis purposes the PSI and DSI 
results were pooled into SI, and the PLI, DLI and R/A results were pooled into LI, although 
they are not true replicates. Further work is being carried out by Vidya Rajasekaran and 
Marion Bacou to gather data from more animals, including males. 
 
5.6.2 Results 
5.6.2.1 Comparisons between genotypes and tissues 
Differential expression analysis calculated the fold change in expression between each 
genotype pair – C11orf-/- vs C11orf+/+, C11orf-/- vs C11orf+/- and C11orf+/- vs C11orf+/+ – within 
the SI and the LI. The genes were ranked by adjusted p-value (table 5.5-5.10). 
I then compared the lists of significantly altered genes in the SI and LI for each genotype 
comparison (figure 5.19). In all genotype pairs, there are more genes unique to each tissue 
than shared between SI and LI. This is not surprising, as there are many differences between 
SI and LI, such as a thicker mucus layer in the LI and higher density of immune cells in the SI 
(Bowcutt et al., 2014). Additionally, the 11q23.1 locus is only associated with LI cancers and 
not SI cancers, so we would expect to see some differences between the two in the knockout 
model. All genes that are significantly altered in both SI and LI are either upregulated in both 
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or downregulated in both, so while the magnitude of the genes’ activity is variable between 
SI and LI, they do not have opposing roles in the two different tissues. 
I also compared the lists of significantly altered genes in each genotype comparison for the 
SI and the LI (figure 5.20). In both tissues the C11orf-/- vs C11orf+/+ comparison contained 
more significant genes than either of the other two genotype pairs. From these venn 
diagrams, and using the direction of fold change for each gene, there are 40 genes in the SI 
and 14 in the LI where C11orf+/- is intermediate to the other two genotypes, meaning 
expression varies with the dosage of the C11orf genes. Nine genes in the SI and 11 in the LI 
show similar expression for C11orf-/- and C11orf+/-, so both copies of the C11orf genes are 
required to maintain expression levels of these genes. Seven genes in the SI and nine in the 
LI have similar expression for C11orf+/- and C11orf+/+, so only one copy of the C11orf genes 
needs to be present to maintain expression levels. 
There are 11 genes in the SI and nine in the LI where C11orf+/- has a more pronounced fold 
change than C11orf-/-. Eight genes in the SI and seven in the LI have similar expression for 
C11orf-/- and C11orf+/+ but not for C11orf+/-, and there are 16 genes in the SI and 15 in the LI 
where the fold changes for C11orf-/- and C11orf+/- compared to C11orf+/+ are in opposite 
directions. These genes may be involved in the heterozygous advantage observed in the 





Table 5.5: (a) Upregulated and (b) downregulated genes in C11orf-/- SI compared to C11orf+/+ 
SI. Only results with adjusted p-value lower than 0.05 are included; only the top 20 results 
are shown if more than that were significant, with full results in appendix 2. 






ENSMUSG00000096580 Igkv1-132 4.000504 1.16E-09 3.88E-06 
ENSMUSG00000038393 Txnip 0.771696 4.24E-07 0.000504 
ENSMUSG00000096206 Gm22317 4.295699 4.26E-07 0.000504 
ENSMUSG00000093815 Gm26444 4.295699 4.26E-07 0.000504 
ENSMUSG00000096214 Gm22634 4.296132 4.24E-07 0.000504 
ENSMUSG00000095969 Rnu1a1 4.296132 4.24E-07 0.000504 
ENSMUSG00000094826 Gm23804 4.296132 4.24E-07 0.000504 
ENSMUSG00000096659 Gm25679 4.296132 4.24E-07 0.000504 
ENSMUSG00000096205 Gm22068 4.296132 4.24E-07 0.000504 
ENSMUSG00000064856 Gm23444 4.105354 6.38E-07 0.000558 
ENSMUSG00000094050 Gm23472 4.105354 6.38E-07 0.000558 
ENSMUSG00000099250 Gm26191 4.237009 5.97E-07 0.000558 
ENSMUSG00000099021 Gm22405 4.237033 5.97E-07 0.000558 
ENSMUSG00000076258 Gm23935 4.194404 7.30E-07 0.000565 
ENSMUSG00000076281 Gm24270 4.194456 7.30E-07 0.000565 
ENSMUSG00000087943 Gm24245 4.194627 7.29E-07 0.000565 
ENSMUSG00000088088 Rmrp 4.175727 8.86E-07 0.00066 
ENSMUSG00000065767 Gm23849 3.9081 4.34E-06 0.002647 
ENSMUSG00000064702 Gm24950 3.9081 4.34E-06 0.002647 
ENSMUSG00000065944 Rnu2-10 3.9081 4.34E-06 0.002647 






ENSMUSG00000044694 2010007H06Rik -5.10397 4.71E-21 9.47E-17 
ENSMUSG00000076665 Ighv7-1 -4.97152 2.50E-13 2.52E-09 
ENSMUSG00000076646 Ighv2-6-8 -5.80358 6.84E-13 4.59E-09 
ENSMUSG00000106025 Gm42940 -2.36275 6.48E-11 3.26E-07 
ENSMUSG00000096452 Ighv1-77 -3.98198 3.26E-10 1.31E-06 
ENSMUSG00000076671 Ighv13-1 -3.87739 1.29E-07 0.000325 
ENSMUSG00000093955 Ighv1-34 -3.81985 1.28E-07 0.000325 
ENSMUSG00000054641 Mmrn1 -3.60255 1.80E-07 0.000401 
ENSMUSG00000052631 Sh2d6 -3.89891 5.79E-07 0.000558 
ENSMUSG00000076523 Igkv15-103 -3.03602 5.65E-07 0.000558 
ENSMUSG00000094491 Igkv1-133 -3.88721 1.30E-06 0.000937 
ENSMUSG00000021867 Tmem254b -1.17836 3.58E-06 0.002485 
ENSMUSG00000094951 Ighv5-6 -2.8445 2.01E-05 0.009886 
ENSMUSG00000094940 Ighv1-84 -2.49211 6.99E-05 0.028689 
ENSMUSG00000036027 1810046K07Rik -3.16194 7.62E-05 0.029506 




Table 5.6: (a) Upregulated and (b) downregulated genes in C11orf-/- LI compared to C11orf+/+ 
LI. Only results with adjusted p-value lower than 0.05 are included; only the top 20 results 
are shown if more than that were significant, with full results in appendix 2. 






ENSMUSG00000076688 Ighv15-2 4.804936 1.05E-10 4.84E-07 
ENSMUSG00000096638 Ighv2-9 4.299691 1.13E-09 4.46E-06 
ENSMUSG00000094322 Ighv9-4 3.288061 8.00E-08 0.00017 
ENSMUSG00000094319 Igkv4-54 4.141772 1.81E-07 0.000345 
ENSMUSG00000089911 Hiat1 0.788464 1.32E-06 0.001915 
ENSMUSG00000038393 Txnip 0.545223 1.20E-05 0.013232 
ENSMUSG00000043911 Olfr922 3.706281 1.29E-05 0.013232 
ENSMUSG00000098021 Gm9522 2.695 1.46E-05 0.014386 
ENSMUSG00000095571 Ighv5-17 2.395451 2.11E-05 0.020101 
ENSMUSG00000047632 Fgfbp3 0.872673 2.49E-05 0.022176 
ENSMUSG00000078377 Gm4294 3.310395 3.60E-05 0.029175 






ENSMUSG00000054641 Mmrn1 -7.03663 7.63E-35 2.10E-30 
ENSMUSG00000106025 Gm42940 -2.97723 1.74E-29 2.40E-25 
ENSMUSG00000044694 2010007H06Rik -5.11863 1.13E-27 1.04E-23 
ENSMUSG00000076523 Igkv15-103 -3.73619 1.02E-12 7.00E-09 
ENSMUSG00000096452 Ighv1-77 -4.35894 4.75E-11 2.62E-07 
ENSMUSG00000034330 Plcg2 -0.96762 1.94E-09 6.70E-06 
ENSMUSG00000073125 Xlr3b -2.96502 6.05E-09 1.85E-05 
ENSMUSG00000095442 Ighv1-4 -3.04911 6.90E-09 1.90E-05 
ENSMUSG00000051079 Rgs13 -4.17152 1.25E-08 3.14E-05 
ENSMUSG00000094561 Ighv1-22 -3.06901 6.22E-08 0.000143 
ENSMUSG00000009246 Trpm5 -3.52297 1.88E-07 0.000345 
ENSMUSG00000021867 Tmem254b -1.0399 3.19E-07 0.000549 
ENSMUSG00000020901 Pik3r5 -1.70761 5.79E-07 0.00094 
ENSMUSG00000094940 Ighv1-84 -2.76271 8.96E-07 0.001373 
ENSMUSG00000094345 Igkv14-126 -3.35858 1.64E-06 0.002259 
ENSMUSG00000076598 Igkv3-7 -2.51215 2.31E-06 0.00303 
ENSMUSG00000076671 Ighv13-1 -3.00713 7.40E-06 0.00928 
ENSMUSG00000025889 Snca -3.1989 9.56E-06 0.011459 
ENSMUSG00000019429 Ffar3 -2.45661 1.29E-05 0.013232 




Table 5.7: (a) Upregulated and (b) downregulated genes in C11orf-/- SI compared to C11orf+/- 
SI. Only results with adjusted p-value lower than 0.05 are included; only the top 20 results 
are shown if more than that were significant, with full results in appendix 2. 






ENSMUST00000214998 March5-205 4.145081 6.62E-10 4.12E-06 
ENSMUSG00000086377 4930529C04Rik 4.169928 3.85E-07 0.001062 
ENSMUSG00000064856 Gm23444 4.104652 6.51E-07 0.001471 
ENSMUSG00000094050 Gm23472 4.104652 6.51E-07 0.001471 
ENSMUSG00000030223 Ptpro 1.499331 4.16E-06 0.006904 
ENSMUSG00000076652 Ighv7-3 2.885547 7.27E-06 0.009037 
ENSMUSG00000076525 Igkv1-99 3.561475 7.81E-06 0.009245 
ENSMUSG00000020659 Cbll1 0.759941 1.84E-05 0.01908 
ENSMUSG00000084128 Esrp2 0.416835 3.42E-05 0.03036 
ENSMUSG00000079343 C1s2 3.520282 3.41E-05 0.03036 
ENSMUSG00000101166 Gm28496 3.423767 3.84E-05 0.032915 
ENSMUSG00000103889 RP23-347F2.2 2.947448 4.18E-05 0.03468 
ENSMUSG00000006191 Cdkal1 0.894438 4.44E-05 0.035587 
ENSMUSG00000104768 Gm38412 2.533581 5.10E-05 0.039593 






ENSMUSG00000076547 Igkv4-70 -4.29404 8.14E-15 2.02E-10 
ENSMUSG00000044694 2010007H06Rik -3.89452 9.89E-13 1.23E-08 
ENSMUSG00000095633 Igkv4-58 -4.28741 6.30E-12 5.22E-08 
ENSMUSG00000054641 Mmrn1 -4.1298 2.19E-09 1.09E-05 
ENSMUSG00000094087 Ighv1-61 -4.21319 3.79E-09 1.57E-05 
ENSMUSG00000035299 Mid1 -1.76366 5.92E-09 2.10E-05 
ENSMUSG00000095338 Igkv3-9 -4.19323 5.55E-08 0.000172 
ENSMUSG00000096577 Ighv1-71 -3.97242 7.48E-07 0.001549 
ENSMUSG00000076534 Igkv12-89 -3.42182 3.40E-06 0.006498 
ENSMUSG00000017734 Dbndd2 -0.69298 3.74E-06 0.006635 
ENSMUSG00000076598 Igkv3-7 -2.15777 4.93E-06 0.007659 
ENSMUSG00000034871 Fam151a -3.74887 5.47E-06 0.007989 
ENSMUSG00000096670 Ighv2-6 -3.02718 5.78E-06 0.007989 
ENSMUSG00000076594 Igkv6-13 -2.80214 6.98E-06 0.009037 
ENSMUSG00000096844 Igkv6-14 -2.45214 1.13E-05 0.012772 
ENSMUSG00000095285 Ighv5-9 -2.8867 1.52E-05 0.01641 
ENSMUSG00000094262 Igkv4-62 -3.53369 2.30E-05 0.022838 
ENSMUST00000202978 Men1-224 -2.8061 2.53E-05 0.024234 




Table 5.8: (a) Upregulated and (b) downregulated genes in C11orf-/- LI compared to C11orf+/- 
LI. Only results with adjusted p-value lower than 0.05 are included; only the top 20 results 
are shown if more than that were significant, with full results in appendix 2. 






ENSMUSG00000076665 Ighv7-1 4.468703 1.29E-13 6.74E-10 
ENSMUSG00000094322 Ighv9-4 4.004452 6.88E-11 2.26E-07 
ENSMUSG00000094319 Igkv4-54 4.843086 1.39E-09 3.09E-06 
ENSMUSG00000096638 Ighv2-9 3.106664 7.13E-06 0.009343 
ENSMUSG00000047632 Fgfbp3 0.878853 9.83E-06 0.011721 
ENSMUSG00000094502 Ighv1-69 2.806439 1.77E-05 0.020179 
ENSMUSG00000038393 Txnip 0.503153 5.32E-05 0.048925 
ENSMUSG00000064352 mt-Ts1 2.073457 5.50E-05 0.048925 
ENSMUSG00000048489 8430408G22Rik 2.121217 5.72E-05 0.048925 






ENSMUSG00000054641 Mmrn1 -7.91474 1.00E-43 2.63E-39 
ENSMUSG00000103254 Ighv1-15 -4.31451 7.89E-16 6.90E-12 
ENSMUSG00000035299 Mid1 -1.99057 7.90E-16 6.90E-12 
ENSMUSG00000044694 2010007H06Rik -3.75426 1.97E-15 1.29E-11 
ENSMUSG00000096461 Igkv14-130 -4.86508 1.02E-11 3.82E-08 
ENSMUSG00000076547 Igkv4-70 -3.23436 1.01E-11 3.82E-08 
ENSMUSG00000094087 Ighv1-61 -4.19307 1.09E-10 3.19E-07 
ENSMUSG00000095633 Igkv4-58 -3.33389 1.41E-09 3.09E-06 
ENSMUSG00000076598 Igkv3-7 -3.15956 1.29E-09 3.09E-06 
ENSMUSG00000095335 Igkv3-5 -3.78311 6.59E-09 1.33E-05 
ENSMUSG00000025889 Snca -3.86558 4.83E-08 9.05E-05 
ENSMUSG00000093894 Ighv1-53 -2.75943 1.85E-07 0.000324 
ENSMUSG00000095338 Igkv3-9 -3.78214 2.68E-07 0.000439 
ENSMUSG00000076538 Igkv13-84 -3.65861 4.93E-07 0.00076 
ENSMUSG00000096715 Igkv3-4 -3.48415 9.69E-07 0.001412 
ENSMUSG00000041859 Mcm3 -0.81427 6.49E-06 0.008952 
ENSMUSG00000096078 Ighv1-62-2 -3.26719 8.47E-06 0.010578 
ENSMUSG00000087263 Gm15726 -1.82762 2.49E-05 0.027221 
ENSMUSG00000095285 Ighv5-9 -2.44515 3.47E-05 0.036394 




Table 5.9: (a) Upregulated and (b) downregulated genes in C11orf+/- SI compared to C11orf+/+ 
SI. Only results with adjusted p-value lower than 0.05 are included; only the top 20 results 
are shown if more than that were significant, with full results in appendix 2. 






ENSMUSG00000096670 Ighv2-6 5.834975 2.06E-17 2.50E-13 
ENSMUSG00000076594 Igkv6-13 5.259002 7.94E-17 6.40E-13 
ENSMUSG00000076547 Igkv4-70 4.451957 3.67E-16 2.22E-12 
ENSMUSG00000035299 Mid1 1.702836 1.47E-08 3.55E-05 
ENSMUSG00000094087 Ighv1-61 3.789115 7.52E-08 0.000151 
ENSMUSG00000076534 Igkv12-89 3.946155 8.13E-08 0.000151 
ENSMUSG00000095335 Igkv3-5 3.780899 2.58E-07 0.000446 
ENSMUSG00000076670 Ighv3-5 3.942184 4.77E-07 0.000769 
ENSMUSG00000095633 Igkv4-58 3.059841 5.20E-07 0.000787 
ENSMUSG00000094262 Igkv4-62 4.10988 1.12E-06 0.00159 
ENSMUSG00000076548 Igkv4-69 3.901295 2.23E-06 0.002993 
ENSMUSG00000102524 Ighv1-2 3.586638 1.18E-05 0.013019 






ENSMUSG00000076665 Ighv7-1 -6.06438 4.53E-19 1.10E-14 
ENSMUSG00000076646 Ighv2-6-8 -6.06414 3.62E-14 1.75E-10 
ENSMUSG00000106025 Gm42940 -2.25281 1.89E-11 7.63E-08 
ENSMUST00000214998 March5-205 -4.25946 1.48E-10 5.10E-07 
ENSMUSG00000094491 Igkv1-133 -5.15148 1.70E-10 5.15E-07 
ENSMUSG00000093955 Ighv1-34 -4.28828 2.80E-09 7.53E-06 
ENSMUSG00000095771 Igkv14-111 -3.0836 4.04E-08 8.88E-05 
ENSMUSG00000096452 Ighv1-77 -2.89367 2.86E-06 0.003495 
ENSMUSG00000076523 Igkv15-103 -2.83776 2.89E-06 0.003495 
ENSMUSG00000076671 Ighv13-1 -3.34672 4.26E-06 0.004905 
ENSMUSG00000076571 Igkv5-37 -3.28667 1.89E-05 0.019904 
ENSMUSG00000025316 Banp -0.75399 2.09E-05 0.021025 
ENSMUSG00000076680 Ighv6-6 -3.19045 3.22E-05 0.031114 
ENSMUSG00000094930 Igkv6-25 -2.64835 3.73E-05 0.034737 
ENSMUSG00000094951 Ighv5-6 -2.70976 4.54E-05 0.040705 




Table 5.10: (a) Upregulated and (b) downregulated genes in C11orf+/- LI compared to C11orf+/+ 
LI. Only results with adjusted p-value lower than 0.05 are included; only the top 20 results 
are shown if more than that were significant, with full results in appendix 2. 






ENSMUSG00000035299 Mid1 2.168241 2.28E-18 1.58E-14 
ENSMUSG00000076547 Igkv4-70 4.49414 6.87E-18 3.57E-14 
ENSMUSG00000095335 Igkv3-5 5.168307 6.82E-15 2.83E-11 
ENSMUSG00000095633 Igkv4-58 4.003953 6.74E-12 2.34E-08 
ENSMUSG00000103254 Ighv1-15 3.181438 2.50E-09 5.78E-06 
ENSMUSG00000094051 Ighv1-36 3.544269 6.43E-08 0.000112 
ENSMUSG00000094087 Ighv1-61 3.49377 7.64E-08 0.000122 
ENSMUSG00000089911 Hiat1 0.863741 1.17E-07 0.000165 
ENSMUSG00000078377 Gm4294 4.237886 1.19E-07 0.000165 
ENSMUSG00000096577 Ighv1-71 3.355272 6.93E-06 0.006267 
ENSMUSG00000094117 Igkv3-12 2.58294 1.46E-05 0.012626 
ENSMUSG00000037386 Rims2 1.568707 3.72E-05 0.029767 






ENSMUSG00000106025 Gm42940 -3.06997 2.18E-30 4.53E-26 
ENSMUSG00000076665 Ighv7-1 -5.77113 1.08E-21 1.12E-17 
ENSMUSG00000021867 Tmem254b -1.31436 1.32E-10 3.92E-07 
ENSMUSG00000094345 Igkv14-126 -4.30699 1.42E-09 3.69E-06 
ENSMUSG00000095442 Ighv1-4 -3.00972 1.19E-08 2.47E-05 
ENSMUSG00000076523 Igkv15-103 -2.82879 6.33E-08 0.000112 
ENSMUSG00000076680 Ighv6-6 -3.49247 4.66E-07 0.000605 
ENSMUSG00000096921 Gm26822 -3.70606 7.67E-07 0.000938 
ENSMUSG00000094561 Ighv1-22 -2.68888 2.07E-06 0.002388 
ENSMUSG00000096452 Ighv1-77 -2.7362 3.22E-06 0.003528 
ENSMUSG00000072676 Tmem254a -1.32681 4.03E-06 0.004187 
ENSMUSG00000094491 Igkv1-133 -3.45514 4.40E-06 0.004359 
ENSMUSG00000076646 Ighv2-6-8 -3.41646 6.57E-06 0.006211 
ENSMUSG00000033439 Trmt13 -0.9466 2.03E-05 0.016862 




Figure 5.19: Overlap of the genes that were 
significantly altered (p < 0.05) in mRNA-seq 
analysis between genotypes, showing how 
many genes were significantly altered in SI, 
LI or both. Venn diagrams show the overlap 
between tissues when comparing (a) 
homozygous knockout and wild type, (b) 
homozygous knockout and heterozygous 
knockout, and (c) heterozygous knockout 
and wild type. 
Figure 5.20: Overlap of the genes that were significantly altered (p < 0.05) in mRNA-seq 
analysis between tissues, showing how many genes were significantly altered in one, two or 





Figure 5.21: Different expression patterns seen in the mRNA-seq data, with the normalised 
counts in each genotype (C11orf+/+, C11orf+/- and C11orf-/-) shown for each tissue analysed 
(proximal small intestine, distal small intestine, proximal large intestine, distal large intestine, 
and rectum/anus). All of these genes were significantly differentially expressed at the 
adjusted p-value < 0.05 threshold. (a) Example of a gene that is downregulated in both 
heterozygous and homozygous knockouts. (b) Example of a gene that is upregulated in 
homozygous knockouts but not heterozygous knockouts. (c) Example of a gene showing 
partial downregulation in heterozygous knockouts and total downregulation in homozygous 
knockouts. (d) Example of a gene that is upregulated in heterozygous knockouts and 




5.6.2.2 Gene ontology enrichment analysis 
I used the online GOrilla tool (www.cbl-gorilla.cs.technion.ac.il, (Eden et al., 2007, 2009)) to 
run gene ontology (GO) enrichment analysis on the resulting lists of upregulated and 
downregulated genes for each genotype comparison in SI and LI, with the gene lists being 
ranked by adjusted p-value (tables 5.11-5.22). 
Many of the enriched GO terms are immune-related, such as immunoglobin complex, 
complement activation, phagocytosis and B-cell receptor signalling. There is no clear pattern 
of what is upregulated and what is downregulated, with immune-related terms being 
common in both, and some individual terms being listed as both upregulated and 
downregulated in the same comparison. Many of the significantly altered genes, both 
upregulated and downregulated, were immunoglobin chains, and this is presumably the 
major factor in the strong immune association, although there are also some other immune-
related genes. These include Rgs13, a regulator of G protein signalling with roles in mast cell 
and germinal centre B lymphocyte responses (Bansal et al., 2008; Shi et al., 2002), and Sh2d7, 
a paralogue of Sh2d2a, which is a T cell regulator linked to arthritis (Smerdel et al., 2004). 
Cellular component terms are largely membrane-bound, including the nucleus, endoplasmic 




Table 5.11: Gene ontology enrichment analysis of genes upregulated in C11orf-/- SI compared 
to C11orf+/+ SI. Only results with FDR q-value lower than 0.05 are included; only the top 15 
results are shown if more than that were significant, with full results in appendix 3. 
5.11a) Cellular process 
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5.11b) Molecular function 


















































































5.11c) Cellular component 
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Table 5.12: Gene ontology enrichment analysis of genes downregulated in C11orf-/- SI 
compared to C11orf+/+ SI. Only results with FDR q-value lower than 0.05 are included; only 
the top 15 results are shown if more than that were significant, with full results in appendix 
3. 
5.12a) Cellular process 
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5.12b) Molecular function 




















































































































5.12c) Cellular component 
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Table 5.13: Gene ontology enrichment analysis of genes upregulated in C11orf-/- LI compared 
to C11orf+/+ LI. Only results with FDR q-value lower than 0.05 are included; only the top 15 
results are shown if more than that were significant, with full results in appendix 3. 
5.13a) Cellular process 





Enrichment (N, B, n, b) 
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5.13b) Molecular function 


































5.13c) Cellular component 
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Table 5.14: Gene ontology enrichment analysis of genes downregulated in C11orf-/- LI 
compared to C11orf+/+ LI. Only results with FDR q-value lower than 0.05 are included; only 
the top 15 results are shown if more than that were significant, with full results in appendix 
3. 
5.14a) Cellular process 
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5.14b) Molecular function 
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25 7.57 (9699,83,695,45) 
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5.14c) Cellular component 
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27 6.57 (9699,78,946,50) 
GO:0009897 
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Table 5.15: Gene ontology enrichment analysis of genes upregulated in C11orf-/- SI compared 
to C11orf+/- SI. Only results with FDR q-value lower than 0.05 are included; only the top 15 
results are shown if more than that were significant, with full results in appendix 3. 
5.15a) Cellular process 
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5.15b) Molecular function 
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5.15c) Cellular component 
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Table 5.16: Gene ontology enrichment analysis of genes downregulated in C11orf-/- SI 
compared to C11orf+/- SI. Only results with FDR q-value lower than 0.05 are included; only 
the top 15 results are shown if more than that were significant, with full results in appendix 
3. 
5.16a) Cellular process 
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5.16b) Molecular function 



















07 8.36 (10086,89,244,18) 
GO:0004930 










5.16c) Cellular component 





























































































Table 5.17: Gene ontology enrichment analysis of genes upregulated in C11orf-/- LI compared 
to C11orf+/- LI. Only results with FDR q-value lower than 0.05 are included; only the top 15 
results are shown if more than that were significant, with full results in appendix 3. 
5.17a) Cellular process 
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5.17b) Molecular function 

































































































5.17c) Cellular component 
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Table 5.18: Gene ontology enrichment analysis of genes downregulated in C11orf-/- LI 
compared to C11orf+/- LI. Only results with FDR q-value lower than 0.05 are included; only the 
top 15 results are shown if more than that were significant, with full results in appendix 3. 
5.18a) Cellular process 
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5.18b) Molecular function 



























































































































5.18c) Cellular component 
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Table 5.19: Gene ontology enrichment analysis of genes upregulated in C11orf+/- SI compared 
to C11orf+/+ SI. Only results with FDR q-value lower than 0.05 are included; only the top 15 
results are shown if more than that were significant, with full results in appendix 3. 
5.19a) Cellular process 
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5.19b) Molecular function 

















































5.19c) Cellular component 
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Table 5.20: Gene ontology enrichment analysis of genes downregulated in C11orf+/- SI 
compared to C11orf+/+ SI. Only results with FDR q-value lower than 0.05 are included; only 
the top 15 results are shown if more than that were significant, with full results in appendix 
3. 
5.20a) Cellular process 
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5.20b) Molecular function 



























































5.20c) Cellular component 
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Table 5.21: Gene ontology enrichment analysis of genes upregulated in C11orf+/- LI compared 
to C11orf+/+ LI. Only results with FDR q-value lower than 0.05 are included; only the top 15 
results are shown if more than that were significant, with full results in appendix 3. 
5.21a) Cellular process 
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5.21b) Molecular function 
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5.21c) Cellular component 
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Table 5.22: Gene ontology enrichment analysis of genes downregulated in C11orf+/- LI 
compared to C11orf+/+ LI. Only results with FDR q-value lower than 0.05 are included; only 
the top 15 results are shown if more than that were significant, with full results in appendix 
3. 
5.22a) Cellular process 
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5.22b) Molecular function 












20 14.63 (10641,70,291,28) 
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02 5.77 (10641,922,18,9) 
5.22c) Cellular component 
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5.6.2.3 Wnt signalling pathway 
I looked at several key genes from the Wnt signalling pathway, as it is highly significant in 
CRC. Additionally, the altered expression levels of the C11orf genes between WT and ApcMin/+ 
tissue seen with the RNAscope (figure 4.7) indicates an interaction between the Wnt and 
C11orf pathways. This pathway is extensive with many associated genes; as it was not 
practical to assess every one, I have chosen a subset of important proteins, or representative 
members of important families, to illustrate overall changes in the Wnt pathway. 
There are 19 known members of the Wnt family of secreted ligands in the mouse (Nusse, 
2018). Wnt3 is expressed in the colon from Paneth cells and is elevated in CRC tumours (Farin 
et al., 2012; Voloshanenko et al., 2013). Wnt3 shows no difference in expression between 
the C11orf homozygous knockouts and WT, and although there does appear to be a reduction 
in the heterozygotes, it was not significant (figure 5.22a). 
There are 13 known members of the Frizzled family of receptors in the mouse (Nusse, 2018). 
Of these, Fzd7 is the one predominantly expressed in CRC cell lines and may be a CRC 
therapeutic target (Ueno et al., 2008; Vincan et al., 2007). There is no difference in Fzd7 
expression between genotypes (figure 5.22b). 
β-catenin, discussed above, is a key transcription factor which stimulates expression of Wnt-
responsive genes. There is no difference in Ctnnb1 expression between genotypes (figure 
5.22c). This is in line with the β-catenin IHC staining (see figure 5.14). 
As previously described, Apc is frequently mutated in CRC (Brannon et al., 2014). Apc forms 
part of the complex which targets β-catenin for degradation and is inhibited when Wnt 
signalling is activated, allowing β-catenin accumulation (Munemitsu et al., 1995). There does 
appear to be a reduction in Apc expression in both heterozygous and homozygous C11orf 
knockouts in the DLI but not in any other tissue section, and this was not a significant change 
– although the DLI data was pooled with PLI and R/A data for the differential analysis, which 
may have masked any change in only one section of the LI (figure 5.22d). 
In addition to its function as a transcription factor in the Wnt signalling pathway, β-catenin 
also plays a role in cell adhesion junctions, where it binds to E-cadherin (Drees et al., 2005). 
E-cadherin and Apc compete for β-catenin (Hülsken et al., 1994) and loss of E-cadherin 
promotes growth, invasion and drug resistance in CRC (Chen et al., 2012). There is no 
difference in Cdh1 expression between genotypes (figure 5.22e).  
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Figure 5.22: mRNA-seq expression data for Wnt signalling pathway components (a) Wnt3, (b) 
Fzd7, (c) Ctnnb1, (d) Apc and (e) Cdh1. Normalised counts for each genotype (C11orf+/+, 
C11orf+/- and C11orf-/-) shown for each tissue analysed (proximal small intestine, distal small 




5.6.2.4 Goblet cell markers 
Following the IHC results showing reduced mucin and Clca1 staining, I looked at the 
expression of Muc2, Clca1, Fcgbp, Agr2 and Zg16, which are all key markers for goblet cell 
activity (Birchenough et al., 2015). 
Muc2 is a mucin that forms the basis of intestinal mucus, the protective layer shielding the 
intestinal epithelium from damage, both by acting as a lubricant to aid the passage of 
material, and by providing a barrier against microbes. Deficiency in Muc2 has been shown to 
cause colitis (Van der Sluis et al., 2006) and CRC (Velcich et al., 2002). There is no difference 
in Muc2 expression between genotypes (figure 5.23a). 
Despite the IHC results showing reduced staining of Clca1, the chloride ion channel regulator, 
there is no difference in Clca1 expression between genotypes (figure 5.23b). 
Fcgbp is a glycoprotein which binds Muc2 to aid in stabilisation of the mucus layer through 
crosslinking; it also binds to the Fc part of IgG antibodies (Johansson et al., 2009). Fcgbp has 
been shown to regulate EMT in gallbladder cancer (Xiong et al., 2014). There appears to be a 
reduction in Fcgbp expression in heterozygous and homozygous C11orf mutants in the DLI 
(figure 5.23c). The gene is not a significant hit but the effect may be lost due to pooling of 
the DLI data with the PLI and R/A data, where there is no difference in expression. 
Agr2 is a protein disulphide isomerase present in the ER to aid in the folding of secreted 
proteins; goblet cells have extensive ER due to the high levels of proteins secreted and Agr2 
is essential for correct Muc2 production (Park et al., 2009; Zhao et al., 2010). Agr2 has been 
linked to IBD and CRC (Kim et al., 2011; Zheng et al., 2006). There is no difference in Agr2 
expression between genotypes (figure 5.23d). 
Zg16 is a lectin-like component of mucus which binds Gram-positive bacteria to reduce their 
interaction with the intestinal wall (Bergström et al., 2016). Loss is associated with increased 
stemness and CRC development (Hasnain et al., 2013). There appears to be an increase in 
Zg16 expression in heterozygous C11orf knockouts in the DLI, but Zg16 was not listed as 




Figure 5.23: mRNA-seq expression data for goblet cell markers (a) Muc2, (b) Clca1, (c) Fcgbp, 
(d) Agr2 and (e) Zg16. Normalised counts for each genotype (C11orf+/+, C11orf+/- and 
C11orf-/-) shown for each tissue analysed (proximal small intestine, distal small intestine, 




5.6.2.5 Tuft cell markers 
As discussed in chapter 4, there are secretory cell types beyond goblet cells. I therefore 
looked at the tuft cell markers Dclk1, Trpm5, Gnat3, Chat and Gfi1b (Von Moltke et al., 2016). 
Dclk1 is a kinase which binds microtubules and is involved in directed cargo transport (Lipka 
et al., 2016). In addition to being a tuft cell marker it can be used to distinguish normal stem 
cells (Dclk1-negative) from tumour stem cells (Dclk1-positive) in the intestine (Nakanishi et 
al., 2013). Dclk1-expressing cells are also required for intestinal regeneration and may 
function in maintaining the stem cell niche (Middelhoff et al., 2017) There is a reduction in 
Dclk1 expression between C11orf WT and C11orf heterozygous knockouts, with a further 
reduction in the homozygous knockouts, although it was not a significantly altered gene 
(figure 5.24a). 
Trpm5 is a cation channel activated by Ca2+ that is important in taste transduction (Liu and 
Liman, 2003). As with Dclk1, Trpm5 shows reduced expression in both the heterozygous and 
homozygous C11orf knockouts, with a greater effect in the homozygotes (figure 5.24b). 
Trpm5 is also a significant hit in the differential expression analysis between C11orf-/- and 
C11orf+/+ in the LI, with a log2 fold change of -3.52 and adjusted p-value 3.45E-4. 
Another tuft cell marker with a role in taste is Gnat3, a subunit of the G protein gustducin; 
loss of Gnat3 causes male sterility (Mosinger et al., 2013). C11orf homozygous knockouts 
show total loss of Gnat3 expression, with a partial loss in heterozygotes in the DSI, PLI and 
DLI (figure 5.24c). It was not significant in the differential analysis, possibly because these 
samples were pooled with PSI and R/A samples, where the WT also has minimal expression 
so the fold change is very low. This may be involved in the infertility seen in the C11orf-/- 
males. 
Choline acetyltransferase synthesises the neurotransmitter acetylcholine in cholinergic 
neurons. Acetylcholine is released by human CRC cells and mediates cell proliferation 
stimulation (Cheng et al., 2008). While Chat was not considered significantly altered, it does 
show reduction in proportion with C11orf reduction (figure 5.24d). 
Gfi1b is a zinc-finger protein that is a key regulator of haematopoiesis, specifically being 
essential for megakaryocytic and erythroid development, with Gfi1b null mice dying during 
embryonic development due to lack of erythrocytes (Saleque et al., 2002). It is overexpressed 
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in leukaemia (Vassen et al., 2009). C11orf-/- and C11orf+/- mice show lower Gfi1b expression 
than C11orf+/+, although it was not a significant hit (figure 5.24e). 
Figure 5.24: mRNA-seq expression data for tuft cell markers (a) Dclk1, (b) Trpm5, (c) Gnat3, 
(d) Chat and (e) Gfi1b. Normalised counts for each genotype (C11orf+/+, C11orf+/- and  
C11orf-/-) shown for each tissue analysed (proximal small intestine, distal small intestine, 
proximal large intestine, distal large intestine, and rectum/anus).  
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5.6.2.6 Enteroendocrine cell markers 
In addition to goblet cells and tuft cells, enteroendocrine cells are also a secretory cell type 
found in the intestine. Cldn4, Chga, Ffar1 and Ffar4 are enteroendocrine cell markers 
(Nagatake et al., 2014). 
Claudin-4 is an integral membrane protein which is a component of tight junction strands 
and has been associated with multiple cancers, including breast, ovarian, prostate and 
pancreatic (Morin, 2005). There is no clear pattern of change in Cldn4 expression between 
genotypes (figure 5.25a). 
Chromogranin A plays roles in secretory granule biogenesis and calcium homeostasis, in 
addition to being the precursor to a number of other secretory peptides (D’amico et al., 
2014). There is no difference in Chga expression between genotypes (figure 5.25b). 
Free fatty acid receptors 1 and 4, also known as GPR40 and GPR120, are nutrient sensors 
involved in energy homeostasis regulation via secretion of hormones such as insulin, GLP-1 
and CCK (Kaemmerer et al., 2010). There is no difference in either Ffar1 or Ffar4 expression 




Figure 5.25: mRNA-seq expression data for enteroendocrine cell markers (a) Cldn4, (b) Chga, 
(c) Ffar1 and (d) Ffar4. Normalised counts for each genotype (C11orf+/+, C11orf+/- and 
C11orf-/-) shown for each tissue analysed (proximal small intestine, distal small intestine, 




5.7 Haematological analysis 
5.7.1 Methods 
I collected fresh blood via cardiac puncture from mice culled by CO2 asphyxiation, which was 
stored on ice with EDTA anticoagulant. Full blood counts were performed by the University 
of Edinburgh Easter Bush Pathology Laboratory. Initial blood samples were all from 14-month 
old males (three wild type, three heterozygous knockouts and two homozygous knockouts), 
with further samples taken from two-month old males (one per genotype). 
 
5.7.2 Results 
The blood counts at 14 months of age show many significant differences in the blood of 
C11orf-/- mice compared to C11orf+/- and C11orf+/+ mice. The homozygotes have greatly 
reduced total white blood cells (WBCs), with almost a seven-fold reduction from the 
heterozygotes (figure 5.26a). The differential counts of the WBC subtypes show the relative 
proportions are broadly conserved, although heterozygous and homozygous knockouts show 
decreased neutrophils and increased lymphocytes compared to wild types (figure 5.26b). 
C11of-/- mice also have severely decreased red blood cells (RBCs) and somewhat lower mean 
corpuscular haemoglobin concentration, giving greatly reduced overall haemoglobin (figure 
5.27). Their packed cell volume is low, but there is much variation in their mean corpuscular 
volume, with elevated red blood cell distribution width. Preliminary results from 7-week old 
males suggest the homozygotes are already deviating from the wild type at this age, although 
thus far the data is based on only a single mouse per genotype. Blood counts taken by the 
IMPC do not show any significant differences in the C11orf93 knockout line compared to WT. 
However, IMPC blood tests are only performed at 16 weeks; our data shows that the  
C11orf-/- blood phenotype becomes more pronounced with age, so while at 16 weeks there 
may not be enough of a difference to be significant, the C11orf93 knockout line may show a 
phenotype at a later age. 
During general tissue collection from the colony I also observed that approximately one third 
of both homozygous and heterozygous knockouts had large blood clots present on their lungs 
when I opened the chest cavity, which were not found in wild type animals. Histological 
examination showed that the blood did not originate from the lungs, which appeared 
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healthy, and the blood was simply adhering to the surface of the lungs as it clotted (figure 
5.28). This is only seen when the mice are culled by cervical dislocation, and not in those 
culled by CO2 asphyxiation. Animals that are culled by asphyxiation and then undergo cervical 
dislocation immediately after death have this blood present at similar rates (table 5.23). 
 
Figure 5.26: Analysis of blood samples 
taken from males. Bars represent the 
mean, with each animal displayed as an 
individual datapoint. (a) Total white 
blood cells; (b) proportion of white 
blood cell subtypes. Data was not 
normally distributed according to 
Shapiro-Wilk normality test, and so 
was compared using two-tailed Mann-
Whitney U test. Significant results are 
indicated by stars.  
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Figure 5.27: Analysis of blood samples taken from males. Bars represent the mean, with each 
animal displayed as an individual datapoint. (a) Total red blood cell count; (b) mean 
corpuscular haemoglobin concentration; (c) total haemoglobin concentration; (d) packed cell 
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volume, which is predominantly comprised of RBCs; (e) mean corpuscular volume; (f) red 
blood cell distribution width, indicating the variation in RBC width. Data was not normally 
distributed according to Shapiro-Wilk normality test, and so was compared using two-tailed 
Mann-Whitney U test. Significant results are indicated by stars. 
Figure 5.28: H&E of a lung and chest blood clot from a heterozygous knockout mouse, 
characteristic of the blood in the chest cavity observed in the colony at necropsy. The blood 
clot was adhered onto the lung at removal but no blood is present within the lung itself and 
the clot detached cleanly following fixation, indicating that the blood did not originate from 
the lungs. 
Cull method Blood present in thoracic cavity 
Cervical dislocation (n=55) 31% 
CO2 asphyxiation (n=11) 0% 
CO2 asphyxiation + cervical dislocation (n=9) 33% 
Table 5.23: Cause of death of animals carrying either one or two C11orf null mutations, and 




I have successfully created a knockout mouse model of the locus containing C11orf53, 
C11orf92 and C11orf93, as confirmed by sequencing and expression data. The animals show 
a clear phenotype of developmental issues, alongside altered intestinal homeostasis, 
haematopoietic system dysfunction and expression analysis indicating an immune system 
disruption. 
The most striking phenotype in the triple gene knockout line is the reduction in homozygote 
frequency at birth and homozygote survival following weaning, both of which show some 
developmental problems in the young animals that do not affect adult animals if they survive 
to maturity. Those animals that survive to one month then display no other health problems 
until the anaemia observed beyond 14 months of age and otherwise appear normal. The 
exception is that homozygotes that survive tend to be smaller throughout life, so are unable 
to make up for this lack of growth in youth. 
The survival rate being 52% among homozygous knockout mice implies a range of severity, 
with variation between mice as to how strong the phenotype is. This may also be why there 
is a reduction in the genotype incidence but not a complete loss. Behavioural differences are 
also likely to be involved, with some individual mice feeding more than others do. 
The timing of the deaths of the juvenile animals occurring around weaning seems highly 
suggestive that there is a gastrointestinal cause. Since the drop in survival did not fully track 
with delayed weaning, shifting by two days rather than seven, this suggests it is not purely 
due to the change in diet; however, we would expect the pups to naturally increase their 
consumption of solid food as they age and decrease milk consumption even if they still have 
access to it. We cannot control for this behaviour and force the pups to only consume milk 
until 28 days. Furthermore, as this is their natural weaning age, there are many physiological 
changes that occur in their gastrointestinal system during this period. These include villi and 
crypt density decreasing after three weeks, with villi and crypt width increasing but few new 
villi and crypts being formed (Cheng and Bjerknes, 1985); expression of the brushborder 
enzymes sucrose-isomaltase and lactase-phlorizin hydrolase undergoing significant changes 
during the suckling-weaning transition around day 17 (Traber, 1999); and multiple claudin 
regulators of tight junction selectivity showing increased expression from day 14 to day 28 
(Holmes et al., 2006). 
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Neither the low knockout frequency nor the low knockout survival observed in the triple 
C11orf knockout model have been observed in the single C11orf53 or C11orf93 knockout 
lines. Until we establish a C11orf92 knockout, we cannot know whether they are purely due 
to the loss of C11orf92, or if the effects of each gene loss stack into a more extreme 
phenotype than is present in any single knockout. If it is the second case, that would imply 
the genes function in related pathways and provide some degree of redundancy to each 
other, so creating synthetic lethality. I think it is interesting to note that C11orf92 is the only 
gene out of the three that is unique to placental mammals (see figure 1.9), and so if there 
were to be a single gene with a key role related to gestation and suckling, it would seem a 
good candidate. 
As the aim of this project was to understand not only the function of the genes but also how 
they were therefore involved in CRC, I was particularly interested in how the knockout mouse 
model might differ in its development of CRC. However, I was unable to induce a clear CRC 
phenotype in my model. No growth developed with age, although the animals had to be 
culled at 14 months old when they began developing anaemia. Due to the highly reduced 
frequency of C11orf-/- mice on the ApcMin/+ background I have only had one C11orf-/- ApcMin/+ 
animal, who does appear to have a more extreme phenotype of higher LI polyps and shorter 
lifespan, but this in only one animal and the LI polyps are still within the observed range of 
the other genotypes. In both the aging study and use of the susceptible genetic background, 
while I cannot say there is an increased CRC incidence, other features of the model have 
prevented my being able to fully explore this. 
There is also a survivor bias inherent in the tumour induction studies. The 52% survival at 
weaning implies a range of severity; as tumour induction takes place in adult mice, it 
therefore requires selection for those animals with the milder phenotype as the more 
severely affected animals do not survive to the point at which these studies take place. If a 
way to improve survival at weaning can be found to allow a higher proportion of the more 
severely affected mice to reach adulthood, the results in the tumour induction experiments 
may then change. 
Villin is an actin-bundling protein expressed in brushborder epithelial cells within the 
intestines, and its promoter region can therefore be used to specifically express transgenes 
within the intestinal epithelium (Pinto et al., 1999). Combining the Villin promoter with Cre 
recombinase allows generation of tissue-specific knockouts of genes flanked by LoxP sites 
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that are restricted to the intestines (El Marjou et al., 2004). This system has been used to 
generate an alternate Apc model, in which somatic mutations of Apc are induced in the adult 
intestines, leaving normal Apc function in the rest of the body intact (Hinoi et al., 2007). By 
crossing the C11orf knockout line onto the Apcfl/+/Villin-Cre background instead of the 
ApcMin/+ background, we can avoid the systemic embryonic interaction between the mutation 
that so greatly reduces C11orf-/- frequency on the ApcMin/+ background. 
The Villin-Cre system could also be applied to the C11orf genes themselves. Restricting the 
deletion to the intestinal epithelium may reduce the systemic phenotypes seen, such as the 
reduced frequency at birth and widespread immune system disruption, to give more 
surviving animals with which to explore an intestinal phenotype. Other possibilities to 
improve survival include using a heated chamber to raise cage temperature to 25-28°C, and 
changing the diet to an even higher nutrient content – although, as diet can have a significant 
effect on intestinal phenotypes, caution would be required if comparing data across different 
diets. 
Alongside the tumour studies, I carried out more general assessment of the C11orf knockout 
line. The blood counts show a reduction in all measured lineages of blood cells, meaning the 
disruption is at the early stages of haematopoiesis. This corresponds with the reduced spleen 
size seen on the ApcMin/+ background. ApcMin/+ mice have altered bone marrow 
haematopoiesis and so perform extramedullary haematopoiesis, which causes 
splenomegaly. When there is a C11orf mutation, this compensatory mechanism is not as 
effective, and while their spleens are still enlarged, it is to a lesser degree. 
The blood counts give a clue as to the cause of the blood clots seen in the chest cavity. 
Cervical dislocation can break blood vessels in the neck, hence not being a recommended 
technique when blood is to be collected. The observed blood in the chest cavity may be due 
to increased vascular fragility, which could cause more breakage and so allow more blood 
out of the neck. Alternatively, it may be due to reduced blood clotting, which would give the 
blood more time to leak into the chest, rather than clotting in the neck at the site of breakage. 
As the blood counts show a reduction across blood cell lineages, this would support a lack of 
platelets and so reduction in clotting. 
There is strong evidence of immune system disruption in the knockout mice, as alongside the 
reduction in WBCs there are many immune-related GO terms that are enriched in the 
differential expression analysis, albeit that this is a preliminary analysis. However, this 
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corresponds with the link between this locus and CA-CRC. The immune system has a key 
regulatory role in tissue homeostasis, and disruption of interactions can cause inflammation, 
which enhances cancer predisposition (De Visser et al., 2006). This interaction is well-
established in the large intestine, with IBD being a major risk factor for CRC (Kulaylat and 
Dayton, 2010; Lutgens et al., 2008). 
We have not seen the mice being more susceptible to infection, but they are isolated from 
many diseases: they are kept in IVCs which filter the air, and although the facility they are 
housed in is considered “dirty” this is still a relative term, and dirty for a scientific animal unit 
is still quite clean. A future experiment of interest would be to measure their susceptibility 
to infection following exposure. If colitis plays a role in these genes’ involvement with CRC, 
infection may also be another method to induce CRC via inflammation, in addition to 
chemical induction using DSS. 
PAS and alcian blue staining shows reduced mucin staining within the intestines of the C11orf 
knockout mice, indicating some dysfunction of the goblet or other secretory cells. 
Additionally, the Clca1 staining also shows reduction in the mutant mice. The correlates with 
the RNAscope localisation of mRNA, which indicated that C11orf53 was being expressed in a 
specific cell type. These cells were not in the right position within the intestinal crypts to be 
stem cells or Paneth cells, and so it seemed likely that they were a secretory cell type, as 
these form the majority of specialised cells in the intestinal epithelium.  
The protein staining of reduced mucins and reduced Clca1 contrasts with the expression 
analysis, which does not show alteration in any key goblet cell markers, including core mucin 
Muc2 and Clca1 itself. One explanation to reconcile these two pieces of data is that tissue 
staining detects protein, while mRNA-seq detects mRNA. It may be that the goblet cells are 
still transcribing mucus genes at the same rate but the proteins are not being translated as 
highly, or are being degraded faster. Goblet cells have extensive ER and quality control 
systems to ensure the mucus proteins are correctly folded, and any that are not are either 
retained until they are corrected or are degraded, rather than being secreted. A disruption 
to protein folding could result in lower protein without reducing mRNA, although markers of 
ER stress are also unchanged in the expression data. This also fits with the expression data 
showing reduction across tuft cell markers; goblet cells and tuft cells could be independently 
affected by the mutation, but as they are both secretory cell types a disruption of this system 
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would affect both. It is unclear why goblet cells are only affected at the protein level but tuft 
cells show a reduction at the mRNA level. 
The knockout mouse model created here displays a wide-ranging phenotype, and there is 
still much to be done to identify and understand its various features. I deleted three genes, 
as all are linked to CRC risk, but that does not mean they all act in the same pathway. The 
mutation could affect multiple systems and a single explanation for all the data may not be 
possible. Utilisation of the single gene KO models may help to distinguish between the 




Chapter 6: Derivation and Utilisation of Ex Vivo Systems from 
Mouse Tissue          
6.1 Introduction 
Animal models provide an invaluable research tool, allowing us to assess the effect of an 
alteration of one element on the entire body and all its systems. However, their complexity 
can make it challenging to quantify individual features, and there can be practical difficulties 
– to measure cell proliferation within the intestinal epithelium of a live mouse involves both 
logistical and ethical issues as to how to carry out such an experiment. 
One method for monitoring proliferation within an animal is through use of 
bromodeoxyuridine (BrDU), which incorporates into DNA in place of thymine (Nowakowski 
et al., 1989) and so can be used to measure the extent of DNA synthesis between BrDU 
administration and tissue staining (Drucker et al., 1996). However, BrDU has been shown to 
have negative side effects, including inducing premature senescence (Michishita et al., 1999) 
and inhibiting cancer cell proliferation (Levkoff et al., 2008); the extent of these depends on 
the time period between exposure and tissue collection. Lineage tracing can be carried out 
using fluorescent proteins under Cre-Lox control to label stem cells and visualise all daughter 
cells (Schepers et al., 2012; Snippert et al., 2010). 
Another alternative is to use animal models as the source of material to establish ex vivo 
systems. This allows additional means of analysis alongside the whole animal, while 
preserving a consistent mutation and genetic background across a study. I used mice from 
the C11orf-/- colony to derive primary cell lines, which I then used in proliferation and 
migration assays. I also worked with Anna Maria Ochocka-Fox to culture intestinal organoids. 
These three-dimensional tissue cultures replicate the intestinal crypt structure and cell types; 





6.2 Fibroblast cell lines from mouse ear tissue 
6.2.1 Methods 
6.2.1.1 Establishment of fibroblast cell cultures 
In order to measure the effect of C11orf loss on cell activity, I derived primary cell lines from 
C11orf+/+, C11orf+/- and C11orf-/- mice, using collagenase-D-pronase digestion of the tissue 
followed by filtering out individual cells (Khan and Gasser, 2016). An alternative would have 
been to generate the mutation in an established cell line, such as a human CRC cell line, but 
we wanted the consistency of identical mutations in the animal, organoid and cell models. 
My cell lines were fibroblast cells derived from ear tissue harvested immediately post-
mortem, due to their relative ease of derivation and maintenance, but they are neither 
intestinal nor epithelial and this should be considered when assessing results. 
 
6.2.1.2 Cell activity assays 
I used assays to investigate some key features of cell activity that are altered in cancer cells, 
specifically proliferation and migration. 
I measured cell proliferation using an SRB colorimetric assay, in which plates are fixed at set 
time points and protein stained by SRB dye. The amount of bound dye is quantified by optical 
plate reader. I plated C11orf+/+, C11orf+/- and C11orf-/- cells at equal starting density and fixed 
plates every 24 hours until 96 hours. 
I used two kinds of migration assay, both of which involve cells closing a gap in the cell 
monolayer. Cells were serum-starved to keep cell growth to a minimum and ensure migration 
was being measured rather than proliferation. I photographed the cells at different time 
points and used the Measure tool in ImageJ to quantify the remaining area, which was then 
calculated as a proportion of the original area. Using a script to define the gap was 
unsuccessful, so the area was defined manually. 
The first migration assay I carried out was the scratch assay (figure 6.1a). I cultured C11orf+/+, 
C11orf+/- and C11orf-/- cells in 6-well plates to 90% confluency, at which point I switched them 
to low-serum media. The next day, at 100% confluency, I scratched a line down the centre of 
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each well using a P200 pipette tip. The cells were washed to remove any loose cells and 
imaged at 1 hour, 24 hours and 48 hours post scratch. 
An issue with the scratch assay is that the action of scratching the cell layer can damage the 
cells at either edge of the gap, meaning the assay may be measuring the response to damage 
as well as migration. I therefore also performed a migration assay using chamber inserts, 
which adhere to the base of 24 well plates (figure 6.1b). Cells are plated in small chambers; 
when the insert is removed, the cells are in two defined patches with a gap in between, and 
no damaged cells at the edges. As with the scratch assay, I changed the media to low-serum 
24 hours before removing the insert. For this assay we used a live imaging system to 
photograph the cells every 30 minutes hours for 65 hours, although gap closure analysis was 





Figure 6.1: (a) Schematic of the scratch migration assay, showing a confluent cell layer being scratched 
with a pipette tip; cells migrate into the gap left by the scratch and this is photographed and measured. 
(b) Schematic of the chamber insert migration assay, showing cells growing in adhered chambers 
which are then removed to leave two distinct patches of cells; cells migrate into the gap between the 





I successfully derived primary mouse fibroblast lines from ear tissue harvested from 
C11orf+/+, C11orf+/- and C11orf-/- mice (figure 6.2). These cell lines were used in assays for 
proliferation and migration. No visual differences in morphology were observed between the 
different genotypes. Cells of different genotypes were extracted and maintained in parallel. 
I did not immortalise the lines, but only used young cells (passage 4-8) in assays to avoid any 
effects of aging cells. While I did not use any method of quantification, I observed the cell 
growth slowed after passage 13. 
I carried out the SRB assay twice, each time with 12 replicates per cell line. I also included 
blank media to subtract background, and an additional outer ring of blank media as an 
evaporation buffer, as the “edge effect” of 96 well plates can alter cell growth in the out 
wells. I observed no differences in proliferation rate between C11orf+/+, C11orf+/- and  
C11orf-/- cells (figure 6.3). 
I performed the scratch assay once (figure 6.4a, 6.4b); each cell line was seeded in two wells, 
and the scratch in each well was photographed in three places. There is no clear pattern 
observable in the results (figure 6.5a). At 24 hours there is a significant difference between 
C11orf+/- and C11orf-/- cells (p=0.0244) but this is lost by 48 hours, when all cell lines have 
almost closed the scratch. 
I also ran the chamber insert assay once (figure 6.4c, 6.4d, 6.5b). The cells did not move in a 
single direction, hence the fluctuations in the proportion of gap remaining as cells retreat 
backwards. As in the other migration assay, there is no clear indication that one of the 
genotypes exhibits faster or slower migration. 
Unlike in the scratch assay, in the chamber insert assay the gap closure plateaus around 20 
hours with a substantial amount of the gap remaining. This may be due to the live imaging 
we used. Instead of spending the majority of the experiment in an incubator, as the scratched 
cells did, these cells were in an imaging system for the entire duration. While we did set the 
temperature and CO2 to match the incubator (37°C, 5% CO2), the humidity could not be 
replicated due to the microscope electrical components and we observed the media level 
seemed to drop with evaporation. As the plate could not be removed mid-experiment we 
could not replace this media, and this may have taken a toll on the cells. I attempted to repeat 
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the assay twice but both times the cells did not show any migration and died before the end 
of the experiment; this may also have been due to the conditions within the imaging system. 
 
Figure 6.2: Brightfield images 
of C11orf+/+, C11orf+/- and 
C11orf-/- primary mouse 
fibroblasts. Fibroblasts were 
extracted from whole mouse 
ear tissue and cultured 
without being immortalised. 





Figure 6.3: SRB proliferation assay on non-immortalised primary mouse fibroblasts at passage 
7. Cell lines were plated in 96 well plates at equal density and proliferation was measured 
every 24 hours by binding of SRB dye, read at 565nm. Experiment contained 24 replicates 
per cell line. 
Figure 6.4: Brightfield images of wild type mouse fibroblasts during migration assays: the 
scratch assay, (a) 1 hour and (b) 48 hours post scratch; the chamber assay, (c) 1 hour and (d) 






















Figure 6.5: Migration assays on primary mouse fibroblasts. (a) The scratch migration assay, 
performed by scratching a gap into the cell layer, using mouse fibroblasts at passage 4 with 
six replicates per cell line. (b) The chamber migration assay, performed by culturing cells with 
an insert to prevent growth within a region, the insert then being removed to leave a gap, 




6.3 Organoids from mouse intestinal tissue 
6.3.1 Methods 
Organoids are three-dimensional tissue cultures that are grown in a supportive matrix. Unlike 
a monolayer of cells in a dish, organoids recapitulate some of the structures found in mature 
organs, complete with multiple cell types. In the case of intestinal organoids, these “mini 
guts” consist of complete crypts around a central lumen-like region. Stem cells are isolated 
from whole tissue and used to generate the organoids; the stem cell niche in the base of the 
crypts is maintained in mature organoids (Sato et al., 2009). While organoids are more 
complex than a cell monolayer, they are still an inherently incomplete model, missing the 
wider context of vasculature and the immune system. This must be remembered when 
considering results. 
Anna Maria Ochocka-Fox derived organoids from freshly harvested proximal small intestine 
(SI) and large intestine (LI) tissue from C11orf+/+ and C11orf-/- male mice at three weeks and 
seven weeks old. These were cultured in matrigel with media supplemented with noggin, 
epidermal growth factor (EGF) and R-spondin, which are required for successful culturing of 
intestinal organoids (Sato et al., 2009). 
 
6.3.2 Results 
Wild type intestinal organoids show a budding phenotype, caused by Paneth cells secreting 
the growth factor Wnt, which induces proliferation in nearby cells and leads to bud formation 
(Sato et al., 2011) (figure 6.6a). As organoids are cultured under non-homeostatic conditions, 
they show exponential growth and continuous budding, which provides a means by which to 
measure the activity of the organoid population (Farin et al., 2012). When these Wnt 
gradients are lost, such as through culture with high levels of supplementary Wnt, or if the 
organoids have a disruption in the Wnt pathway as in ApcMin/+ tissue, the organoids do not 
bud but have a round, cystic shape (Sato et al., 2011) (figure 6.6b). The ratio of budding:cystic 
organoids can therefore be used as a measure to compare two organoid populations. 
Eight days after Anna Maria Ochocka-Fox derived organoids from fresh mouse tissue (figure 
6.7), I counted the number of budding and the number of cystic organoids per well and took 
the mean of the percentage budding in each well. The two biological replicates were 
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combined; although the mice used were at different ages (three weeks and seven weeks) the 
wild type and homozygous mice were age matched. There was a significant difference in the 
both the SI and LI, with fewer C11orf-/- organoids showing the budding phenotype than the 
C11orf+/+ organoids (figure 6.8). This difference – approximately a 25% reduction in both 
tissues – suggest an altered intestinal homeostasis phenotype and that there is a disruption 
somewhere in the normal function of the Wnt signalling pathway in the C11orf-/- mice. 
 
 
Figure 6.6: Brightfield images of small intestinal organoids grown from Apc+/+ and ApcMin/+ 
mice, photographed on day 8 of culture. (a) Wild type intestinal tissue exhibits the budding 
phenotype as the organoids recapitulate the crypt structures present in vivo. (b) When the 
Wnt signalling pathway is disrupted, as in ApcMin/+ tissue, the budding phenotype is lost to 
the round cystic phenotype as the lack of Wnt gradients prevents buds from forming. The 
extent to which an intestinal organoid culture buds can therefore be an indication of how 




Figure 6.7: Brightfield images of SI and LI organoids grown from C11orf+/+ and C11orf-/- mice, 
photographed on day 8 of culture. By this day in culture, the budding phenotype is being 
exhibited by the C11orf+/+ organoids, and to a lesser extent in the C11orf-/- organoids. 
Figure 6.8: Percent of intestinal organoids per well showing the budding phenotype on day 8 
of culture. Bars represent the mean, with each well shown as an individual datapoint. 
Organoids were cultured from SI and LI tissues from C11orf+/+ and C1orf-/- mice. Data was not 
normally distributed according to Shapiro-Wilk normality test, and so was compared using 




By using the C11orf-/- mouse colony as a source of material to set up ex vivo systems, I have 
been able to quantify aspects of cell activity in a way that would have been highly complex 
in a living animal. Extracted cell lines have been used to measure cell proliferation and 
migration, while cultured organoids have given insights into the activity of the Wnt pathway 
in intestinal tissue. The expression analysis of C11orf53, C11orf92 and C11orf93 following the 
GWAS showed that the CRC risk genotype is associated with reduced expression of the three 
genes, implying they are tumour suppressor genes (Smillie, 2015). I focused on key tumour 
suppressor mechanisms of proliferation and migration. 
The C11orf-/- organoids show a significant decrease in budding compared to C11orf+/+ 
organoids, both in those derived from the SI and the LI. The size of the effect is far less than 
that seen in ApcMin/+ organoids, but the risk conferred by the C11orf locus is also far smaller 
than that of the Apc gene.  
As the development of buds in organoids has been shown to be due to Wnt gradients, the 
change in budding observed in the LI organoids indicates some alteration of this Wnt 
signalling in the C11orf-/- mice. This can be through direct activation of the pathway, such as 
loss of the Wnt antagonist APC (Sato et al., 2011). Aberrant activation of the Wnt pathway 
has been found in over 90% of human CRC (Cancer Genome Atlas, 2012). This pathway 
modulates cell proliferation, and it would be expected that an over-activation of the pathway 
would result in increased cell proliferation. 
However, C11orf-/- fibroblasts did not show any alteration in proliferation rates compared to 
C11orf+/+ and C11orf+/- cells. The cells used were fibroblasts extracted from ear tissue, so this 
does not necessarily mean intestinal epithelial cells do not show a difference, but the 
fibroblast data do agree with human CRC cell line findings that proliferation is not affected 
by either C11orf siRNA knockdown (Smillie, 2015) or C11orf overexpression (see chapter 3). 
These results together suggest the C11orf genes do not function as tumour suppressors 
through regulation of proliferation rates. 
An alternative mechanism behind differences in organoid budding is a change in the degree 
of differentiation of the crypt cells. Since it is the Paneth cells that secrete Wnt to the 
surrounding cells, a shift in the population from Paneth cells to stem cells reduces the amount 
of Wnt that can be produced (Schuijers et al., 2015). The Wnt signalling pathway is also itself 
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involved in differentiation (Ogaki et al., 2013). As we have not found any evidence of the 
C11orf genes affecting cell proliferation, it may therefore be more likely that the C11orf-/- 
organoids have an increased degree of stemness. 
A further inconsistency comes from preliminary expression data from mouse whole intestinal 
tissue, which does not indicate that Wnt signalling has been affected, with no significant 
differences in expression of key Wnt pathway components such as Wnt3, Apc, Ctnnb1, Cdh1 
or Fzd7 between C11orf genotypes (see chapter 5 for expression analysis). This does not rule 
out a disruption in the activity or response to some element of the pathway, beyond their 
expression levels. We must also consider that pathways may not respond in the same way in 
fibroblasts, in organoid ex-vivo systems, or in complete animals. 
I also investigated cell migration, as another common mechanism for tumour suppressors is 
inhibition of metastasis, and Wnt signalling has been shown to promote cell migration (Vlad-
Fiegen et al., 2012). I did not find differences in the migration activity of C11orf-/- fibroblasts, 
but the conditions of these assays – closing a gap in a monolayer – has limited similarity to 
the physiological movement of a cancer. A true invasion assay, where cells must penetrate 
into a collagen matrix, would be a more relevant future experiment. 
There are other elements of metastasis that could be investigated, such as angiogenesis. It is 
worth noting, though, that metastasis affects cancer survival rather than incidence, and while 
there have been many studies linking the tagging SNP rs3802942 to CRC risk (Hofer et al., 
2017; Middeldorp et al., 2009; Tanikawa et al., 2018; Tanskanen et al., 2018; Tenesa et al., 
2008; Xiong et al., 2010), rs3802842 has not been found to be associated with CRC survival 
(Phipps et al., 2012; Smith et al., 2015; Theodoratou et al., 2018). 
Tumour suppressor genes also have roles in induction of apoptosis and DNA damage repair. 
The C11orf fibroblast lines could be used in assays for these features, such as the comet assay 
for DNA damage repair (Collins, 2004) or the Annexin V-Affinity assay for apoptosis (Engeland 
et al., 1996), to assess if the C11orf genes act through these mechanisms. 
While there are still questions as to the mechanism, the organoids give quantitative data that 
there are intestinal differences between C11orf+/+ and C11orf-/- mice. These changes can likely 
be traced back in some way to the Wnt signalling pathway, which is highly mutated in CRC, 
although as yet we do not know where in the activation, secretion or response to Wnt the 
disruption is occurring. 
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The preliminary expression data indicates several key components of the Wnt signalling 
pathway are being expressed at the correct levels. Further investigation into the activity of 
the pathway could include assessing the binding and stabilisation of proteins, such as β-
catenin to TCF, through mass spectroscopy or pull down assays (Lowry et al., 2005). The 
response of the system to upstream elements could be tested by knocking down or 
overexpressing those proteins and measuring the response, such as in increase in β-catenin 
phosphorylation in response to Wnt overexpression (Van Noort et al., 2002).  
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Chapter 7: Discussion         
7.1 The function of 11q23.1 and its role in CRC 
The aim of this project was to investigate C11orf53, C11orf92 and C11orf93, three genes in 
the 11q23.1 locus, which have been associated with CRC risk. I undertook this using 
visualisation techniques for both protein and mRNA, creation of a knockout mouse model, 
and derivation of ex vivo systems from that mouse model. 
The markedly reduced survival rate of the C11orf-/- mice in the week following weaning, in 
addition to the disparity between expected and observed ratios of genotypes in this colony, 
are strong evidence that this locus, while largely uncharacterised, has an important function 
within the mouse. The timing of the survival drop being in the week following natural 
weaning would also suggest that the cause may be associated with the gastrointestinal 
system, concurring with this locus’ link to colorectal cancer. Additionally, the distinct 
expression patterns observed with RNAscope are confirmation that this locus contains three 
separate genes that, at least to some extent, have individual activity. 
It is clear from the data collected from the knockout mouse model that loss of C11orf53, 
C11orf92 and C11orf93 has a significant effect on the immune system. This is exhibited in the 
greatly reduced white blood cell counts measured in the aged C11orf-/- mice, and in the 
genome-wide expression analysis within intestinal tissue. There is widespread alteration in 
the expression of immune-related genes in the mutant mice, which can be seen in the high 
number of immunoglobin genes, among other immune-related genes, that occur in the lists 
of significantly altered genes between genotypes. This is confirmed by gene ontology analysis 
of these lists, which reports many immune-related gene ontology terms as being significantly 
enriched. A further link between 11q23.1 and the immune system comes from the locus’ 
position within a wider region that modifies CA-CRC susceptibility (Van Der Kraak et al., 
2010). 
The immune system has a key role in the initiation and development of cancer, both in 
prevention and promotion, through mechanisms including modulation of angiogenesis, 
mediation of tumour cell lysis, and suppression of antitumour immune responses (De Visser 
et al., 2006). Within the intestines, inflammation is a significant risk factor for CRC, with IBD 
increasing risk of CRC by up to 70% and being the third highest risk factor for CRC behind the 
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hereditary conditions FAP and Lynch syndrome (Kulaylat and Dayton, 2010; Lutgens et al., 
2013). 
An essential part of the immune system within the intestines is the production of mucus, 
which reduces inflammation and infection by easing passage of digestive material and 
limiting intestinal epithelium contact with digestive material and microorganisms. Mucus 
components are secreted by goblet cells and there are many interactions between goblet 
cells and other elements of the immune system. During infectious colitis, goblet cells produce 
resistin-like molecule-β which recruits CD4+ T cells (Bergstrom et al., 2015), while deficiency 
in γδ-T cells results in altered goblet cells and mucin expression (Kober et al., 2014). Tissue 
staining on mouse intestinal tissue shows that C11orf-/- mice have a reduction in production 
of various mucus components, and so this element of the immune system, in addition to the 
WBCs and immunoglobins, is also affected by loss of the 11q23.1 locus. 
Due to the large volume of proteins being secreted, goblet cells have high ER activity, and 
disruption of normal ER function disrupts the production of the mucus layer (Zhao et al., 
2010). As the mucus prevents inflammation, ER stress and aberrant mucus assembly is 
therefore associated with inflammation and colitis (Heazlewood et al., 2008; Johansson et 
al., 2014) and ER stress is a risk factor for IBD (Hosomi et al., 2015; Kaser et al., 2008). ER 
stress protein XBP1 has also been linked to intestinal tumourigenesis (Niederreiter et al., 
2013). 
Claire Smillie has previously found evidence that C11ORF53, and to a lesser extent C11ORF93, 
localises to the ER, in addition to gene ontology analysis on sets of genes with correlating 
expression to the C11orf genes in which ER-associated terms were frequently found to be 
enriched (Smillie, 2015). I replicated the localisation of C11ORF53 and C11ORF93 to the ER in 
my own use of overexpression plasmids carrying DDK-tagged proteins. Furthermore, in my 
RNAscope work C11orf53 appears to be primarily expressed in a specific cell type, having a 
tightly clustered distribution rather than the diffuse pattern of C11orf92 and C11orf93. As 
within the intestinal tissue, many of the specialised cell types are secretory, this may be 
further evidence of a function within secretory cells. While the immunohistochemical data 
of reduced mucus staining is contrasted by the expression data, which does not indicate an 
alteration in key goblet markers including core mucin Muc2, the expression data does show 
reduction in several markers of tuft cells, another secretory cell type. 
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There is also data that the C11orf pathway in some way interacts with the Wnt signalling 
pathway. The ApcMin/+ background, which has aberrantly activated Wnt signalling, exhibits 
both lower expression of the C11orf genes and reduced frequency of C11orf-/- mice. The 
reduced budding of the C11orf-/- organoids can be linked back to an alteration in Wnt 
signalling, as it is this pathway which governs the proliferation of intestinal cells and so the 
budding of intestinal organoids (Sato et al., 2011). Wnt growth factors are secreted by Paneth 
cells which are found in the base of the intestinal crypts, alongside the stem cells. RNAscope 
visualisation revealed that C11orf92 and C11orf93, in particular, have their highest 
expression in the base of the crypts. 
The blood analysis shows a reduction across all measured blood cell lineages, with both RBCs 
and multiple types of WBC having low numbers and so indicating a malfunction at the stem 
cell level. The Wnt signalling is involved in induction and maintenance of haematopoietic 
stem cells (Reya et al., 2003; Tran et al., 2010) and ApcMin/+ mice have disrupted 
haematopoiesis (Lane et al., 2010; You et al., 2006), and so this phenotype may likewise be 
attributable to changes in the Wnt signalling pathway. 
As they are secreted proteins, members of the Wnt family pass through the ER, where they 
are retained by proteins such as GRP78 to regulate Wnt signalling (Burrus and McMahon, 
1995; Zoltewicz et al., 2009). It has been shown that ER stress and the unfolded protein 
response alter the stemness of intestinal cells (Heijmans et al., 2013; Niederreiter et al., 2013) 
and the haematopoietic stem cell pool (Van Galen et al., 2014), both of which are maintained 
by Wnt signalling (Pinto et al., 2003; Reya et al., 2003). 
Given the data from both localisation studies and expression analysis that links the C11orf 
locus to the ER, I propose that disruption of these genes has an effect on the secretory system 
of cells, which results in reduced mucin production. Wnt signalling is a highly complex 
pathway and there are many points at which it may interact with C11orf. However, the 
proposed secretory/ER association provides a potential mechanism that underlies both the 
Wnt and immune data, rather than two separate affected systems, and I therefore suggest 
that secretion of Wnt has been affected by loss of the C11orf genes in the same way as 
secretion of mucus components.  
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7.2 Future work 
This project has made some progress in characterising the roles of C11orf53, C11orf92 and 
C11orf93, but there are still many unanswered questions. In this section, I will discuss some 
potential routes for further work, as research in the 11q23.1 locus continues. 
Improved knowledge of the localisation of the C11orf gene products within the cell and tissue 
contexts will be key in understanding the genes’ mechanism of action. In the continued 
absence of specific antibodies, there should be further attempts to add endogenous tags to 
C11ORF53 and C11ORF93, as this will allow both improved visualisation and pull-down or 
mass spectrometry assays to determine binding partners. Additionally, by using duplex 
RNAscope or improving the coupling of RNAscope to IHC, C11orf53 expression should be 
compared to a panel of markers to determine which cell type is producing the distinctive 
expression pattern observed, such as Dclk1 for tuft cells (Gerbe et al., 2012). 
The low numbers of knockout mice available has meant much of my data is based on a small 
number of replicates, or single animals. A priority for further study is therefore to repeat 
these experiments, such as the differential expression analysis, to generate more robust data 
that will allow higher confidence in the conclusions drawn. In particular, once there are 
replicates of the mRNA-seq data, a far higher level of analysis can take place, including 
considering each region of the intestines individually rather than having to pool all data into 
simply small intestine and large intestine. This deeper exploration would be valuable as CRC 
incidence is not consistent throughout the length of the large intestine. In the case of 
11q23.1, the risk SNP rs3802842 confers a higher risk of rectal cancer than of colonic cancer 
(Tenesa et al., 2008).  
Obtaining more mice for analysis would be greatly aided by finding a way to improve the 
survival of the homozygote knockouts, as the alternative is breeding a great many animals 
with surplus wild types and heterozygotes. This could be done by trying a higher-nutrient diet 
or increasing the temperature of the cages. Additionally, as the systemic knockout is clearly 
difficult to cope with at young ages, conditional knockouts in which the mutation is restricted 
to the intestinal epithelium or induced after one month of age would reduce the severity of 
the phenotype and so produce more animals which reach maturity. 
A reduced severity knockout model may have higher incidence on the ApcMin/+ background, 
allowing better exploration of the effect of C11orf loss on a CRC susceptibility background, 
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including polyp number and lifespan. Alternatively, the existing C11orf knockout line could 
be crossed onto a different susceptible line such as the Apcfl/fl/Villin-Cre background, to 
reduce the Apc phenotype severity rather than the C11orf severity. 
There is also scope for more work with chemical tumour induction. In addition to the one 
week, 40mg/kg regime I used, there are multiple other protocols with varying dose and time 
combinations, and these could be tested on the C11orf line. We are also keen to introduce 
colitis via DSS consumption to the tumour induction studies, in line with the finding that these 
genes are within a locus which modifies mouse susceptibility to CA-CRC (Van Der Kraak et al., 
2010). 
The single knockout models of C11orf53 and C11orf93 still require much characterisation, 
C11orf53 in particular. Thus far, these lines have not displayed the reduced homozygote 
knockout incidence or survival of the triple gene knockout line; we have yet to test their CRC 
susceptibility status, or perform many of the other analyses such as blood counts or 
immunohistochemistry that we have done on the triple knockout line. This data will allow 
phenotype elements to be assigned to specific genes, if they are only present in one of the 
single gene knockout lines. Alternatively, if the same phenotype is present in multiple lines, 
it will imply the genes function at different points of a common pathway. If the triple gene 
knockout line has features not displayed by any single gene knockout line, this will indicate 
the genes have an element of redundancy, or function in related pathways and so compound 
knockouts produce additive effects. 
Full exploration of this will also require a C11orf92 knockout line. Of the 31 C11orf92 
mutations my CRISPR experiment produced, 21 are large deletions between target sites in 
multiple genes, and so are not restricted to C11orf92, with the remaining 10 mutations being 
small indels. Unlike C11orf53 and C11orf93, which are protein coding and so can be 
reasonably expected to be disrupted by a frameshift mutation, C11orf92 is noncoding, and 
so the effect of a small indel is much harder to predict. These lines would need to be 
examined via qRT-PCR or similar to confirm a reduction in C11orf92 expression, and it may 
be necessary to carry out further CRISPR, perhaps using multiple guides throughout the gene 
to generate large deletions within C11orf92, to produce a C11orf92 single knockout line with 
confidence. 
With regards to furthering specific results I have obtained, there are methods to investigate 
the physical properties of mucus following harvesting of mouse intestinal tissue, including 
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measurement of its thickness, having utilised a charcoal suspension to mark the surface, and 
measurement of its permeability through tracking the downward progress of fluorescent 
beads placed on the surface (Gustafsson et al., 2012). These assays can be used to quantify 
the mucus changes indicated by the tissue staining in the C11orf knockout mice. 
Additionally, the endoplasmic reticulum function can be investigated in more detail in 
knockout cell lines – either in my existing mouse fibroblast cells, in a new epithelial line that 
could be derived from the mouse colony, or in human knockout cell lines that could be 
generated using CRISPR or another gene editing technique. ER studies could include live 
imaging using systems such as ER-tracker dyes (Cole et al., 2000), quantification of ER stress 
using Thioflavin T (Beriault and Werstuck, 2013) or in vitro quantification of ER-associated 
degradation (Brodsky, 2010). 
The blood counts show pancytopenia, with reduction across all blood cell types. As these 
animals were closely watched and were necropsied, we know that it is not caused by an acute 
blood loss, and therefore is due to some form of stem cell injury. Blood smears should be 
carried out for visual assessment of the blood cells, as haematopoietic cell neoplasia of bone 
marrow or lymphocytic origin presents with abnormal cells in the blood (Darren Wood, 
2018). Preliminary examination of bone marrow H&Es have not revealed an obvious change, 
but they should be further studied, perhaps utilising additional tissue staining or collection 
of liquid bone marrow rather than fixed whole bones. 
Ultimately, while there are many avenues that remain to be explored with regard to these 
genes, there must be a balance struck between wide-ranging study to cover as much as 
possible, and a focussed investigation into their role in CRC risk. The future work of this lab 
will be directed towards the latter, as thus far the 11q23.1 locus has only been linked to CRC 
risk and so improved understanding of this mechanism offers the most potential for 
improving public health through advancing CRC prevention, detection and treatment. 
However, I believe that the wider effects of the 11q23.1 genes have proved to be highly 





Following a GWAS which identified 11q23.1 as a CRC risk locus, and subsequent expression 
analysis which implicated largely-uncharacterised genes C11orf53, C11orf92 and C11orf93, I 
have investigated these genes for insights into their function and role in CRC development. 
Localisation studies have shown that C11ORF53 may localise to the ER and be specifically 
expressed in a secretory cell type. Use of a knockout mouse has revealed a strong association 
with the immune system, which is altered in a knockout model with all three genes 
compromised. While CRC has not been induced, the animals still show an intestinal 
phenotype, including changes in mucus production within the intestines, in addition to 
disrupted haematopoiesis and low survival following weaning. Intestinal organoid culture has 
indicated altered Wnt signalling in the knockout. 
I propose that these genes play a role in the secretory system via the ER, and reduction of 
their activity affects proper secretion components both of intestinal mucus and of the Wnt 
signalling pathway, in turn producing the observed phenotypes in the mouse model and 
increasing CRC risk in humans. There is still much that needs to be done to fully understand 
this locus, but these results give a direction for future work, which will hopefully one day lead 
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